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ABSTRACT 
Sporadic cerebral amyloid angiopathy is a common small vessel disease that preferentially 
involves small cortical and leptomeningeal arteries due to progressive amyloid-β deposition 
in their walls. Cerebral amyloid angiopathy occurs frequently in elderly people, and is a 
common and important cause of symptomatic lobar intracerebral haemorrhage and 
cognitive impairment. There is currently a growing interest in cerebral amyloid angiopathy, 
at least partly thanks neuroimaging, which now allows an unprecedented ability to 
investigate the disease dynamics in vivo using MRI to reveal complex patterns of cerebral 
bleeding and ischaemia. The detection of CAA during life is becoming an increasingly 
important challenge, since approaches of prevention or treatment (disease-modification) 
are now emerging as realistic possibilities. Determining the most promising treatments 
requires development of reliable biomarkers, the goal of my research. The main objective 
of this PhD thesis is to provide new insights into potential clinical and applied clinical 
neuroimaging biomarkers in patients with cerebral amyloid angiopathy. This is accomplished 
by a portfolio of research studies investigating: (a) the clinical and radiological spectrum of 
transient focal neurological episodes as a potential clinical clue for cerebral amyloid 
angiopathy; (b) cortical superficial siderosis, a distinct pattern on bleeding in the brain, as 
both a diagnostic and a prognostic marker of cerebral amyloid angiopathy; (c) MRI-visible 
perivascular spaces topography, as a new marker of small vessel disease and cerebral 
amyloid angiopathy; (d) potential pathological, neuroimaging and genetic differences in 
patients with pathology-proven CAA with and without intracerebral haemorrhage and 
presents evidence for different disease phenotypes; (e) the evidence whether the presence 
and burden of cerebral microbleeds on MRI scans is associated with an increased risk of 
recurrent spontaneous ICH, and if this risk is different according to MRI-defined 
microangiopathy subtype, in a meta-analysis. 
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Sporadic cerebral small vessel disease: key definitions and 
current concepts 
Many of the modern advances and effective interventions in cerebrovascular disorders 
currently target only disease of large arteries. Until recently, small cerebral arteries have 
received little attention and clinicians have much less to offer for the prevention and 
treatment of small vessel disease.1 This is partly because small vessels are technically 
inaccessible, hard to study directly and hence the underlying mechanisms of small vessel 
disease remain relatively poorly understood.2 Yet, these diseases are considered to be 
among the most prevalent known neurologic processes and contribute substantially to 
stroke, cognitive impairment or other disabilities commonly seen in elderly persons (e.g. 
depression, motor and gait disturbances, urinary symptoms, functional impairment etc.).2-4 
In addition, small vessel disease can increase mortality.5, 6 
Although the term sporadic cerebral small vessel disease is used with various meanings 
in different contexts (e.g. clinical, neuroimaging, pathological etc.), in its most basic form it 
encompasses a group of age-related neuropathological processes affecting the small 
arteries, arterioles, capillaries, and rarely venules in the brain.1-3 Before defining these 
pathological processes, it is important to define what a small vessel is and specifically, “how 
small a small vessel is”. Interestingly, a survey performed among leading neuropathological 
centres, revealed that the definition of a small vessel is not consistent: less than 50% of the 
participants agreed on a size limit of less than 500 μm in transverse diameter or all vessels 
located deeper than in the cortex.7 Others have arbitrarily suggested a transverse diameter 
of ≤300 μm, predominantly referring to arterioles – likely illustrating that pathological 
processes of the arteriolar tree are more well know that those of other small vascular 
components (e.g. capillaries).2 The current definition of small vessels is more inclusive, 
referring to all vascular structures (ranging from around 5μm up to 2mm), small arteries, 
arterioles, capillaries, venules and small veins located in the brain parenchyma (i.e. 
intraparenchymal) or in the subarachnoid space (i.e. leptomeningeal).2 These small vessels 
can either: (a) penetrate the brain cortex superficially, supplying the gray matter with short 
branches of three lengths (reaching cortical layer III, V and the gray–white matter junction), 
and the subcortical white matter with longer branches; or (b) stem from arterial 
perforators deeper at the base of the brain and supplying the basal ganglia, thalami and 
brainstem structures.2 Specific small vessel pathologies can differentially affect these two 
systems as well as different range of vessels within each system (Figure 1.1). 
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Figure 1.1 The topography of sporadic cerebral small vessel disease. The small vessels of the brain can mainly 
be affected by two types of pathological process: (1) hypertensive arteriopathy – which typically affects small 
deep arterial perforators; or (2) cerebral amyloid angiopathy (CAA) – which preferentially affects the small 
arteries and arterioles of the cerebral cortex and gray–white-matter junction by the deposition of amyloid-β in 
the vessel walls. 
The overall rationale behind this definition of small vessels versus large vessels is 
twofold. First, this separation highlights that the pathological processes affecting small 
vessels in the brain are different from those that affect large vessels. It needs to be 
recognised that often this assumption is only partially true as small and large vessel disease 
processes can to a certain extent overlap and often co-exist in elderly individuals (e.g. 
hypertension-related atherosclerosis and arteriolosclerosis). In addition, the two subtypes 
of cerebrovascular disease can be driven by very similar risk factors, not the least of which 
is simply ageing. It is also important to keep in mind that large and small vessel systems 
form a continuum and therefore there is a cross-talk between aging large arteries and 
microvascular brain injury. For example, progressive age-associated increase in large artery 
stiffness exposes small vessels to higher pulse pressure which in turn can lead to 
progressive white matter rarefaction and cognitive impairment.8 Although subdividing 
cerebrovascular disease into micro-vascular (i.e. small vessel) macro-vascular (i.e. large 
vessel) components represent a gross oversimplification, this distinction serves the concept 
that not only the putative pathophysiology, but also the clinical consequences and the injury 
each group of diseases cause on the brain parenchyma are different. Approximately one 
third of symptomatic strokes are caused by diseases of small perforating arteries and 
arterioles of the brain, including lacunar stroke syndromes9 and most cases of spontaneous 
intracerebral haemorrhage (ICH) - perhaps the most severe and lethal type of stroke.1 
However, beyond its role in clinically overt acute stroke syndromes, small vessel disease 
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causes widespread microvascular damage (seen on neuroimaging or at autopsy) which is 
not symptomatic itself but has important cumulative effects on cognition. Hence, cerebral 
small vessel disease is one of the most important contributors to cognitive impairment in 
the elderly.10, 11 As people live longer, the burden of these diseases will rapidly grow over 
the coming years becoming an increasing healthcare challenge facing all societies 
worldwide.12 
There are two main sporadic forms of small vessel disease (Figure 1.1). The first one 
is sporadic cerebral amyloid angiopathy (CAA) (extensively covered in the next section of 
the Introduction), a chronic degenerative disease characterised with progressive deposition 
of amyloid-β in the media and adventitia of small arteries, arterioles and capillaries in the 
cerebral cortex, overlying leptomininges and grey–white matter junction.10, 11 In contrast to 
CAA which is relatively easy to define, the remaining sporadic small vessel disease is more 
difficult to define and name. To this end, the term “hypertensive arteriopathy” is widely 
used to describe a non-amyloid process often related to advanced age (but not clearly age-
driven), hypertension, diabetes mellitus and other common vascular risk factors, typically 
affecting the small perforating end-arteries of the deep grey nuclei and deep white matter.2 
It is characterised pathologically by lipohyalinosis, arteriolosclerosis or fibrinoid necrosis. 
This very common sporadic form of small vessel disease has been variously known as 
arteriolosclerosis, age-related or vascular risk-factor-related small vessel disease, or 
degenerative microangiopathy in the literature.2, 13, 14 The term “hypertensive arteriopathy” 
is not ideal (or even misleading) as it probably groups together a variety of sporadic small 
vessel disease pathologies not accounted by sporadic CAA, but not necessarily related 
specifically to hypertension.15 In other words, hypertension might not be a specific cause of 
these small vessel changes collectively called “hypertensive arteriopathy” (at least not in all 
cases), but can to a certain extent influence their evolution. Furthermore, there is not a 
consensus on the microscopic small vessel lesions best described under the term 
“hypertensive arteriopathy”, meaning that its severity might be difficult to evaluate in any 
given case. From a histopathologic perspective, hypertensive arteriopathy is mainly 
characterised by vessel wall thickening, narrowing of the lumen, loss of smooth muscle cells 
from the tunica media and deposits of an amorphous fibro-hyaline material. Other possible 
pathological features can include distal manifestations of atherosclerosis (microatheroma) 
and the presence of microaneurysms (i.e. elongated and dilated vessels).2 However, many 
researchers tend to subdivide hypertensive arteriopathy based on the most pronounced 
structural histopathological features found, e.g. atherosclerosis, arteriolosclerosis, 
lipohyalinosis, fibrinoid necrosis (the proposed acute from of lipohyalinosis), 
microaneurysms etc.2 These subtypes tend to predominantly affect different small vessel 
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sizes and can exist separately or in various combinations in any given case. Of these 
histopathological features, perhaps the one most strongly associated with hypertension-
related injury is fibrinoid necrosis, which is much more common in hypertensive patients’ 
brains than in those without hypertension,16-18 as well as in arterioles adjacent to deep 
ICH.17-21 Complicating matters further, the more effective treatments for hypertension in 
recent years is likely to have modified the specific pathological features, natural history and 
disease spectrum of hypertensive arteriopathy.15 Despite the limitations in definitions and 
given the lack of an alternative widely accepted term, for simplicity and consistency, the 
term “hypertensive arteriopathy” has been adopted in this thesis as one of convenience to 
avoid unnecessarily long and complex terms being repeated. Whatever term one prefers 
for this sporadic small vessel disease type, the microvascular changes associated with 
hypertensive arteriopathy presumably lead to both occlusion (including reduced vessel 
compliance and impaired vasoreactivity) and haemorrhage in the brain territories of the 
affected deep perforating arteries. Unsurprisingly, hypertensive arteriopathy has historically 
been associated with two types of cerebrovascular disease: lacunar infarcts22 and 
intracerebral haemorrhage.23 
Since small vessels (and hence the structural alterations of small vessel disease) 
cannot be easily visualised in vivo with the current neuroimaging techniques used in clinical 
practice, the brain parenchymal magnetic resonance imaging (MRI) lesions which they are 
thought to cause have been adopted as markers of small vessel damage.2 As a result, the 
term cerebral small vessel disease is frequently used indiscriminately to describe both the 
underlying small vessel pathologies and the neuroimaging correlates of their consequences 
on the brain parenchyma.2 Of note, these consequences are heterogeneous in nature 
including both ischaemic and haemorrhagic manifestations.2, 24 However, historically the 
term small vessel disease has been often (and still is) used misleadingly to describe only the 
ischaemic consequences on imaging.3 Despite this, sporadic small vessel disease is the 
leading cause of ICH, which in fact parallels the topography of the underlying microvascular 
pathology, so that spontaneous deep ICH (in the basal ganglia, thalami etc.) is 
predominantly caused by hypertensive arteriopathy, whereas lobar (cortical-subcortical) 
ICH is frequently caused by CAA. Lacunes and white matter hyperintensities (leukoaraiosis) 
are well known imaging markers of cerebral small vessel disease that have been extensively 
studied with MRI since the early 90s.25, 26 Advances in neuroimaging, now allows an 
unprecedented ability to investigate more complex dynamics (both haemorrhagic and non-
haemorrhagic) of small vessel disease in vivo: new imaging manifestations of small vessel 
disease include cerebral microbleeds,27 cortical superficial siderosis (cSS) and convexity 
subarachnoid haemorrhage,28 cerebral microinfarcts29 and perivascular spaces.30 
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A further concept to bear in mind when approaching neuroimaging markers of small 
vessel disease (and hence markers of pathologic consequences on the brain parenchyma), is 
that their pathogenic interpretation is not uniform, and given marker may be found in 
different types of small vessel disease.24 For example, in view of different topographical 
distribution of hypertensive arteriopathy and CAA, it is hypothesized that cerebral 
microbleeds have a preferential location depending on the underlying small vessel 
pathology: hypertensive arteriopathy is commonly associated with cerebral microbleeds in 
deep brain regions (e.g. basal ganglia, thalamus and brainstem), whereas CAA is 
characterised by cerebral microbleeds in a lobar distribution (cortical-subcortical).27 Hence, 
each marker or lesion on neuroimaging should not be taken in isolation. 
These advances in neuroimaging were recently illustrated in an international working 
group position paper from the Centres of Excellence in Neurodegeneration under the 
acronym STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1).31 This 
consensus paper presents a unified approach to small vessel disease at present as a 
neuroimaging-defined concept, which is changing rapidly paralleling the continued advances 
in neuroimaging techniques. Table 1.1 provides a glossary and definitions of the most 
commonly used research terms in the field of small vessel disease (a defined in the STRIVE 
consensus paper), including MRI modalities. 
In the next section of the introduction a closer look at CAA is provided, since this 
type of small vessel disease is the main focus of the research presented in this PhD thesis. 
Given that hypertension is theoretically treatable, whereas CAA is currently not, and 
considering that CAA is strongly associated with brain aging and is also directly linked to 
Alzheimer's disease, is not surprising that CAA is becoming the most common sporadic 
small vessel disease, at least in Western populations.32 This is partly illustrated by the 
changing profiles of spontaneous ICH in recent epidemiological studies, showing an increase 
in ICH incidence among patients aged 75 years or older, especially in relation to 
antithrombotic use.33, 34 Also, while the incidence of deep (probably hypertensive 
arteriopathy-related) ICH has fallen, the proportion of non-hypertensive lobar bleeds in 
those aged 75 years or over increased. It is likely that CAA is implicated in the majority of 
these lobar haemorrhages and might also account for the increased incidence of 
anticoagulation-associated ICH.28 
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Table 1.1 Research definitions of commonly used terms in the field of cerebral small vessel 
disease31 as well as basic structural MRI techniques.35 
Proposed definitions for neuroimaging features of small vessel disease 
 Recent small subcortical infarct: Neuroimaging evidence of recent infarction in the 
territory of one perforating arteriole, with imaging features or clinical symptoms consistent with 
a lesion occurring in the previous few weeks. 
 Lacune of presumed vascular origin: A round or ovoid, subcortical, fluid-filled cavity (signal 
similar to CSF) of between 3 mm and about 15 mm in diameter, consistent with a previous 
acute small subcortical infarct or haemorrhage in the territory of one perforating arteriole. 
 White matter hyperintensity of presumed vascular origin: Signal abnormality of variable 
size in the white matter that shows the following characteristics: hyperintensity on T2-weighted 
images such as fluid-attenuated inversion recovery, without cavitation (signal different from 
CSF). Lesions in the subcortical grey matter or brainstem are not included in this category 
unless explicitly stated. If deep grey matter and brainstem hyperintensities are also included, the 
collective term should be subcortical hyperintensities. 
 Perivascular spaces: Fluid-filled spaces that follow the typical course of a vessel as it goes 
through grey or white matter. The spaces have signal intensity similar to CSF on all sequences. 
Because they follow the course of penetrating vessels, they appear linear when imaged parallel 
to the course of the vessel, and round or ovoid, with a diameter generally smaller than 3 mm, 
when imaged perpendicular to the course of the vessel.  
 Cerebral microbleed: Small (generally 2–5 mm in diameter, but sometimes up to 10 mm) 
areas of signal void with associated blooming seen on T2*-weighted MRI or other sequences 
that are sensitive to susceptibility effects. 
 Brain atrophy: A lower brain volume that is not related to a specific macroscopic focal injury 
such as trauma or infarction. Thus, infarction is not included in this measure unless explicitly 
stated. 
 
The basic structural neuroimaging toolbox 
 Spin-echo sequences: conventional MRI pulse sequences in which both a 90° excitation pulse 
and a 180° refocusing pulse are used to generate an MR signal. The 180° refocusing pulse has 
the effect of reducing the susceptibility to magnetic field inhomogeneities, and thus leading to a 
reduced sensitivity to detect microbleeds, for example. 
 Fast spin-echo sequences: a type of spin-echo technique that uses a series of multiple rapid 
180° refocusing pulses and multiple echoes (echo train) and is in standard use for T2-weighted 
MRI because of the shortened scan duration. 
 T2*-weighted gradient-recalled echo sequence: an MRI pulse sequence that lacks a 180° 
refocusing (rephasing) pulse and is therefore more sensitive to magnetic susceptibility effects 
than are spin-echo or fast spin-echo techniques. 
 Magnetic susceptibility: a natural property of tissues, which reflects the magnetic response 
of a substance to an external magnetic field. The susceptibility differences between substances 
lead to local magnetic field inhomogeneities, resulting in faster T2* relaxation which leads to 
signal loss on MR sequences sensitive to T2* effects. The haemosiderin deposits within cerebral 
microbleeds are paramagnetic, and hence have a strong susceptibility effect, which increases 
local dephasing of spins allowing them to be more easily detected using sensitive MRI 
techniques. 
 Susceptibility effect: refers to the fast decay of the local MRI signal caused by the internal 
magnetisation of tissue that generates local inhomogeneity in the magnetic field. 
 Susceptibility-weighted imaging: a term applied to MRI data acquisition techniques that 
employ a high resolution 3D gradient-recalled echo sequence with a long echo time and 
generate additional contrast for magnetic susceptibility by use of phase imaging combined with 
magnitude data in an image post-processing step. 
 
  
 24 
Sporadic cerebral amyloid angiopathy: pathophysiology 
and clinical spectrum 
Sporadic cerebral amyloid angiopathy (CAA) is a common small vessel disease of the brain, 
characterised by the progressive deposition of amyloid–β protein in the walls of small-to-
medium sized arteries (up to about 2mm in diameter36), arterioles and capillaries in the 
cerebral cortex and overlying leptomininges.37, 38 CAA can also affect cerebellar vessels, but 
only rarely those in the brainstem or basal ganglia. Although known to pathologists for over 
a century,39, 40 CAA was not linked to clinical disease until as late as the 1960’s, when it was 
suggested to be a rare cause of intracerebral haemorrhage (ICH).41-43 In recent years, CAA 
has been “rediscovered” as a common and important cause of spontaneous ICH, which 
remains the most devastating form of stroke, with a fatality rate approaching 50% in 
contrast to improved outcomes from ischaemic stroke.44, 45 An increased understanding of 
CAA thus holds promise for improved prevention and treatment of ICH. 
The growing interest in CAA is at least partly thanks to two fields of research, which 
have been important in defining the expanding clinical-radiological phenotype and the 
underlying pathophysiology of the disease: (1) neuroimaging, which now allows an 
unprecedented ability to investigate CAA dynamics in vivo using MRI to reveal complex 
patterns of cerebral bleeding (including lobar microbleeds27) and ischaemia, and an 
increasing repertoire of specific amyloid-binding ligands;38, 46-50 and (2) transgenic mouse 
studies, which have allowed the experimental alteration of amyloid peptide expression and 
molecular structure, providing significant mechanistic insights. Despite these advances, CAA 
remains under-recognized by neurologists and stroke physicians, making a fresh look 
especially timely (see box for search strategy). 
The entity of CAA encompasses a number of highly diverse sporadic and genetic 
disorders that share the same pathological hallmark of amyloid-β fibril deposition in small 
leptomeningeal and cortical vessels. Here, we focus only on sporadic CAA. 
Search strategy and selection criteria 
References were identified through PubMed with the search terms: “cerebral amyloid angiopathy”; 
“microbleed(s) or microh(a)emorrhage(s) and cerebral amyloid angiopathy”; “intracerebral 
h(a)emorrhage”; and “vascular cognitive impairment” between January 1970 and August 2014. The 
references from identified articles and the authors’ own files were also searched for relevant 
publications. Only papers published in English were reviewed. The final reference list was chosen on 
the basis of relevance to the topics covered in this thesis. 
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Figure 1.2 The first published photograph of cerebral amyloid angiopathy (left panel), accompanied 
by the author’s illustration (right panel), from Fischer, 1910. Note the “fur-like” staining of the walls 
of the 3 small arteries. 
1.1 Historical perspectives on CAA: from a rare 
pathological curiosity to a common and devastating 
disease 
In 1907, Alois Alzheimer described the neuropathological findings in a 51- year-old woman 
with progressive dementia,51 observing scattered foci, within the cerebral cortex, “of a 
peculiar substance which can be recognized without stain and is, in fact, very resistant to staining.” 
In 1927, Divry discovered that these deposits were amyloid,52 now recognized to be a 
fibrillar protein with a powerful tendency to aggregate, and the main component of “senile 
plaques” that define Alzheimer’s disease. The CAA story began around the same time, in 
1909, at the Psychiatry Clinic at the University of Freiburg, Germany, with Gustav 
Oppenheim’s first histopathological report of foci of focal necrosis (“drusige Nekrosen”) in 
the brain next to abnormal capillary walls thickened by a translucent (“hyaline”) substance.39  
Soon afterwards, in 1910, Oskar Fischer confirmed occasional “fur-like” staining of 
small arteries in Alzheimer’s disease, and published the first known photograph of CAA 
(Figure 1.2). Building on these observations, the first systematic study of CAA, was 
published in 1938 by Scholz,40 who described a proteinaceous material (“Drusen”) in 
intracortical arteries, capillaries and the immediately adjacent brain tissue, that he termed 
“drusige Entartung der Arterien und Kapillaren’’.40 Other authors coined the term 
“angiopathie dyshorique” (dyshoric angiopathy)53, 54 (from the Greek word horos=border) 
implying that blood-derived amyloid might enter the brain (crossing the “blood-brain 
barrier”) leading to amyloid deposition around small vessels.54 
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Figure 1.3 The entrance of the University Psychiatric Clinic in Bel-Air at Geneve, where the 
University of Geneva brain collection was founded at the beginning of the 20th century. The panel 
on the right shows the brain of one of Stefanos Pantelakis original brains included in his study on 
congophilic angiopathy,55 along with the patients’ cognitive evaluation of executive skills (lower 
panel). 
However, in 1954, Stefanos Pantelakis, in the University Psychiatric Clinic in Bel-Air, 
Switzerland, demonstrated CAA was limited to the vascular wall, without adjacent 
parenchymal involvement (Figure 1.3), raising the alternative hypothesis that the amyloid 
may originate in the brain rather than the blood,55 consistent with modern concepts of 
amyloid pathophysiology. In his landmark paper, Pantelakis also described what are still 
considered the pathological hallmarks of CAA: (a) preferential involvement of small 
arterioles and capillaries of the leptomeninges, cerebral cortex, and cerebellar cortex; (b) a 
topographical distribution favouring posterior lobar brain regions (especially the occipital 
lobes); (c) the lack of involvement of white matter small vessels; (d) the association with 
increased age and dementia; (e) the lack of association with hypertension and 
arteriosclerosis (the other main small vessel disease, but which preferentially affects the 
basal ganglia and brainstem); and (f) the lack of any link with amyloidosis of other organs.55 
Since these early descriptions, understanding of the pathophysiological mechanisms in 
CAA has increased substantially. As it will become evident throughout this review, similar 
to the modern concept of cerebral small vessel disease, the term CAA now encompasses 
not only a specific cerebrovascular pathological trait and disorder, but also a clinical 
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syndrome (or syndromes) and brain parenchymal lesions seen on neuroimaging (including a 
set of imaging criteria). 
1.2 Epidemiology and risk factors 
Pathologically-defined CAA is common in the elderly.56-59 Population-based autopsy studies 
indicate a CAA prevalence of 20-40% in non-demented, and 50-60% in demented elderly 
populations.58, 60-63 Furthermore, CAA pathology may be severe in older individuals: in the 
Honolulu-Asia aging autopsy study (HAAS), severe CAA was found in 43% of demented and 
24% of non-demented elderly individuals (mean age at death: 85 years).62 In Alzheimer’s 
disease, CAA is almost invariable, being found at autopsy in more than 90% of cases.56, 64 
However, most of these patients have mild CAA; severe CAA is found in about 25% of 
Alzheimer’s disease brains.65 
Advancing age is the strongest known clinical risk factor for developing CAA.37 In a 
community-based sample of 100 individuals, the prevalence of cortical vascular amyloid-β 
deposition progressively increased from the 7th to the 9th decades,66 a pattern also 
observed in 784 consecutive autopsies, corrected for over-representation of Alzheimer’s 
disease.67 Moreover, patients with CAA-related ICH (suggesting advanced disease) in large 
autopsy series, were all older than 60 years (and most over age 70).42, 68, 69 CAA is seldom 
reported before the sixth decade of life; occasional patients presenting in their 50s have 
been described.70 
By contrast with hypertensive arteriopathy-the other main form of small vessel disease 
and cause of ICH,2 the risk of CAA is not accounted for by conventional cardiovascular risk 
factors other than age.37 Hypertension is not considered a risk factor for developing CAA, 
but may increase the risk of CAA-related ICH. Vinters37 – in a clinicopathological series of 
107 pathologically-proven CAA cases – found the prevalence of hypertension to be around 
32%, similar to community-dwelling elderly populations,71 while another pathological study 
reported that CAA patients with ICH were more frequently hypertensive (50%) than those 
without ICH (23%), suggesting that hypertension may contribute to CAA-related cerebral 
bleeding. 72 In a recent multicentre cohort of patients with spontaneous ICH, we found that 
the prevalence of hypertension in CAA-related ICH was 62% - significantly less than in non-
CAA-related ICH (85%).73 Whether hypertension in association with CAA confers a 
greater risk for ICH, compared to CAA alone is an important clinical question.74-76 
Apolipoprotein E (APOE) genotype is the only known genetic risk factor for sporadic 
CAA.77 APOE is a protein with crucial roles in lipoprotein complexes, which regulate lipid 
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metabolism by binding to cell-surface APOE receptors and proteins associated with lipid 
transfer and lipolysis.77 There are three major polymorphisms in the APOE gene, namely 
ε4, ε2 and ε3, resulting in a single amino-acid change78 which dramatically alters the 
functional properties of APOE isoforms.79 These alleles have a strong dose-dependent 
effect on the risk of developing CAA and its clinical severity. Thus, APOE ε4 in both post-
mortem and clinical series increases the risk of sporadic CAA-related lobar ICH; moreover, 
the number of ε4 alleles relate to clinical severity.77, 80-82 Individuals carrying the APOE ε2 
allele also have an increased risk of CAA-related lobar ICH.82, 83 Both of these risk alleles 
are also associated with a younger age of first ICH,84 greater likelihood of haematoma 
expansion, poorer clinical outcome,85, 86 and a higher risk of recurrence.87 Furthermore, the 
two allelic variants interact: patients with both APOE ε2 and ε4 alleles have the earliest 
disease onset and highest risk of early ICH recurrence.87, 88 The ε2 and ε4 alleles might 
promote CAA-related haemorrhage through distinct mechanisms: ε4 by promoting 
amyloid-β deposition; and ε2 by inducing structural changes in amyloid-laden vessels, 
making them prone to rupture.85, 86, 88-90 Other as yet unidentified genetic polymorphisms 
relating to amyloid metabolic pathways may also play a role in sporadic CAA, (for example 
presenilin-1, neprilysin and transforming growth factor beta-1),91-93 and are a topic of 
ongoing investigation. 
1.3 Neuropathology 
1.3.1 Morphological characteristics, natural history and 
severity grading 
CAA primarily involves neocortical and leptomeningeal arterioles, to a lesser extent 
capillaries and, very rarely, venules.38 In contrast to amyloid plaques found in Alzheimer’s 
disease - which are predominantly composed of the 42 amino-acid residue fragment 
(amyloid-β42) - the vascular amyloid in CAA is mostly composed of the more soluble, 40 
amino-acid fragment (amyloid-β40), suggesting different pathophysiological mechanisms for 
pathological deposition (see below).94-97 Cerebral vessels with moderate to severe CAA 
show an acellular wall thickening with a strongly eosinophilic smudgy appearance on 
haematoxylin-eosin stained sections.98 Congo-red staining, under polarized light, reveals 
amyloid deposits as “apple-green” birefringence (hence the term congophilic angiopathy)37, 99 
although immunological stains for amyloid-β are highly specific and now widely used. The 
development of CAA is progressive, with amyloid-β first appearing in the abluminal aspect   
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Figure 1.4 Histopathological features of cerebral amyloid angiopathy (CAA) (A1-A3) Morphological 
changes of the vessel walls of leptomeningeal arterioles as revealed by haematoxylin & eosin staining 
(H&E) and immunohistochemical detection of amyloid-β. In mild and moderate CAA only minimal 
structural changes can be detected: in A2 the arrowhead points to amyloid deposition in the vessel 
wall. However, in advanced CAA, there are significant structural alterations, the most extreme of 
which is vessel-within-vessel appearance, sometimes termed “double-barrelling” (detachment and 
delamination of the outer part of the tunica media; bracket in A3). (B1-B3) A similar pathologic 
range of CAA-related changes in leptomeningeal arterioles using immunohistochemical detection of 
amyloid-β. In mild CAA (B1) there is a patchy deposition amyloid in the vessels wall. Moderate CAA 
shows more dense amyloid deposition which spans the entire vessel wall (B2), while severe CAA, 
shows double-balled vessels and endothelial involvement (B3). (C1-C3) Pathological findings of CAA 
in cortical arterioles. C2 shows moderate CAA with pan-mural deposition of amyloid-β along with 
amyloid-β deposition in the surrounding brain parenchyma (arrowhead). In C3 a double-barrel 
vessels can be seen, although this is less common compared to leptomeningeal vessels. 
of the tunica media, surrounding smooth muscle cells, and in the adventitia (Figure 1.4).37 
At the initial stage the vessel wall structure is intact, but as the disease progresses, there is 
pan-mural amyloid accumulation, and loss of smooth muscle cells.38 In severe CAA, 
detachment and delamination of the outer part of the tunica media result in so-called 
“double barrel” appearance (Figure 1.4);38 fibrinoid necrosis and microaneurysm formation 
also occur in advanced disease. There may also be microbleeding with perivascular 
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deposition of erythrocytes and blood-breakdown products.98 Endothelial cells are usually 
preserved even in vessels severely affected by CAA.100 Occasionally amyloid-β is deposited 
in the surrounding brain parenchyma immediately adjacent to an affected vessel (sometimes 
called “dyshoric CAA”). 
CAA is also associated with cerebral ischaemic damage,56, 65, 101, 102 including cortical 
microinfarcts,103 and white matter pathology (demyelination and gliosis).43, 56, 96 Microinfarcts 
are predominantly lobar (cortical-subcortical), usually in patients with severe CAA. One 
possible mechanism for these ischaemic lesions is occlusion or reduced perfusion in 
amyloid-laden cortical vessels affected by CAA.  
The changes described above provide the basis of neuropathological scoring systems 
for CAA 72, 101, 104 each with strengths and limitations.105 No standardized consensus 
neuropathological criteria for rating CAA are available,106 but are desirable to allow 
comparison of CAA pathological studies between centres. A more detailed discussion of 
CAA severity grading can be found in a recent review by Attems and colleagues.38 
1.3.2 Pathological subtypes of sporadic CAA 
At least two distinct pathological subtypes of CAA have been described: CAA-type 1, 
characterised by amyloid-β in cortical capillaries (with or without involvement of other 
vessels)38; and CAA-type 2, where amyloid-β deposits are restricted to leptomeningeal and 
cortical arteries, arterioles and, rarely, veins.107 Amyloid-β deposition in the wall of 
capillaries (capillary CAA, also used to be termed “dyshoric angiopathy”) may cause luminal 
obstruction in the most severe stages.36 The APOE ε4 allele is most strongly associated 
with CAA-type 1, while APOE ε2 is more associated with CAA-type 2.107 CAA-type 1 
appears to be more closely associated with parenchymal amyloid deposition in Alzheimer’s 
disease.108 
1.4 Topographical distribution 
Sporadic CAA favours posterior cortical regions; the occipital lobe is most frequently 
affected, followed by the frontal, temporal and parietal lobes.37, 38 The occipital lobe is also 
most severely affected.109, 110 The cerebellum can be affected in advanced stages, while the 
basal ganglia, thalami, white matter and brainstem are typically spared.105 The distribution of 
CAA pathology shows a characteristic patchy pattern,37 so that foci of vessels severely 
 31 
affected by CAA may be adjacent to others with mild or absent amyloid-β deposition.37, 38 
The practical consequence of this is that cerebral biopsy may miss patchy CAA pathology. 
1.5 Pathophysiological pathways 
1.5.1 Amyloid-β production, clearance and accumulation 
Amyloid-β is generated by sequential cleavage of amyloid precursor protein (APP) by β- 
and γ-secretases. Mutations in the gene encoding the APP account for some rare (usually 
autosomal dominant) forms of CAA, including CAA-Dutch type.111 Familial non-amyloid-β 
forms of CAA include familial British dementia112, 113, familial Danish dementia114 and 
Icelandic cystatin C mutation.115 In general, hereditary forms of CAA have an earlier onset 
and more severe clinical manifestations than sporadic CAA.98, 116 Although exceptionally 
rare, familial CAAs have provided significant insights on how mutations in the coding region 
of the APP contribute to CAA pathogenesis: for example, the Iowa, Dutch, Italian, and 
Arctic mutations render amyloid-β highly toxic to vessel wall components,117-119 and more 
resistant to proteolytic degradation120 or clearance from the brain.121 
Factors that initiate or promote amyloid-β peptide deposition in the much more 
common sporadic CAA are not as well understood. Nevertheless, transgenic mouse 
models of cerebral amyloid deposition38 have provided the following insights (Figure 1.5): 
(a) the major source of human amyloid-β is neuronal;122, 123 (b) an increased ratio of 
amyloid-β40 : amyloid-β42 in the brain results in a shift from brain parenchyma to the 
vasculature (perhaps by increasing the solubility of amyloid-β and thus its diffusion into the 
vessel wall);124 and (c) vascular amyloid-β deposition largely results from impaired clearance 
of amyloid-β (rather than overproduction), especially along perivascular drainage 
pathways.38, 125, 126 Impairment of perivascular drainage pathways has emerged as a key 
mechanism in sporadic CAA:38, 127, 128 these efflux channels may be conceptualized as a 
cerebral “lymphatic system”, allowing interstitial fluid and solutes to drain out of the brain 
along basement membranes in the capillary walls, and between smooth muscle cells in the 
tunica media of small arteries (in the opposite direction to arterial blood flow) (Figure 
1.5).129 This transport system is thought to be driven by pulsations of the blood vessel 
wall.129, 130 As this and other clearance mechanisms fail in the ageing brain, or under other 
pathological conditions, amyloid-β is increasingly trapped and deposited in the walls of small 
arteries (Figure 1.5).129  
 
 32 
 
Figure 1.5 (A) Amyloid-β production, elimination and deposition in cerebral amyloid angiopathy 
(CAA). Converging evidence indicates that the major source of Aβ is neuronal. It is generated by 
sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretases, in proportion to 
neuronal activity. Aβ is eliminated from the brain by four major pathways: (a) proteolytic 
degradation by endopeptidases [such as neprilysin and insulin‑degrading enzyme (IDE)]; (b) receptor-
mediated clearance by cells in the brain parenchyma (microglia, astrocytes and to a lesser extent 
neurones; (c) active transport into the blood through the blood-brain barrier (BBB); (d) elimination 
along the perivascular pathways by which interstitial fluid drains from the brain.[86, 87] Specialized 
carriers (e.g. ApoE) and/or receptor transport mechanisms (e.g. the low-density lipoprotein receptor 
[LDLR] and LDLR‑related protein [LRP1]) are involved in all major cellular clearance pathways. 
Vascular deposition is facilitated by factors that increase the Aβ40:Aβ42 (while increased Aβ42 leads 
to oligomerisation and amyloid plaques) and impede perivascular passage. As the clearance 
mechanisms fail with age, Αβ is increasingly entrapped from the perivascular drainage pathways into 
the basement membranes of capillaries and arterioles of the brain leading to CAA. 
Evidence is emerging that cerebrovascular disease may impede the drainage along the 
perivascular pathways, contributing to CAA pathogenesis.127, 131 It has been suggested that 
amyloid-β deposition could further impair/block the perivascular drainage, leading to 
dilation of perivascular spaces (also known as Virchow-Robin spaces) not only within lobar 
regions, but also in the underlying white matter, that itself shows is unaffected by CAA.132, 
133 These enlarged perivascular spaces can reach several millimetres in diameter and may be 
visible on appropriate brain imaging; this requires further investigation as a potential useful 
neuroimaging marker of CAA.30, 133 
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Figure 1.6 APOE alleles have a differential effect on different molecular and cellular processes of 
Aβ production, elimination and deposition in a way that they either increase or decrease the risk of 
developing CAA (B). The roles of different ApoE alleles in various pathways in the brain which might 
contribute in the pathogenesis and pathogenicity of CAA are summarised in (B). 
As we have seen, APOE is a strong genetic risk factor for CAA, an effect mediated by 
its important role in amyloid-β metabolism, aggregation and clearance (Figure 1.6).77, 125, 126. 
APOE ε4 increases the amyloid-β40:amyloid-β42 ratio shifting amyloid deposition to the 
vessels instead of brain parenchyma,124 and may reduce the efficiency of efflux of amyloid-β 
along perivascular channels,38, 134 influencing CAA risk and age of onset.77, 135 APOE 
genotype may also interact with other small vessel disease changes: hypertensive 
arteriopathy, which leads to stiffening of the vessel wall, may reduce the pulsatile driving 
movements required for efficient perivascular drainage, and thus contribute to the risk of 
CAA.38 
1.5.2 From amyloid-β deposition to CAA pathogenesis  
Amyloid-β deposition has complex effects on vascular structure and function, which can 
result in brain injury.2, 136 Important morphological changes include: loss of smooth muscle 
cells;137 vessel wall thickening and lumen restriction;101 endothelial dysfunction; and a loss of 
compliance leading to brittle, fragile vessels prone to microaneurysm formation and 
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leakage.38 Acute trigger factors, for example sudden increases in blood pressure, or minor 
trauma (regularly encountered in clinical practice, but not to our knowledge formally 
studied), may cause the rupture of these abnormally weak, amyloid-laden vessels. Amyloid-
β deposition may also impair local regulation of cerebral blood flow,136 neurovascular unit 
function138 and general homeostatic mechanisms in the ageing brain.73 Other effects of 
vascular amyloid-β, including BBB disruption and active inflammation, could also 
contribute.38, 136 Moreover, even without vascular deposition, soluble amyloid-β can cause 
abnormal vascular reactivity,136 and induce the activation of inflammatory mediators 
including matrix metalloproteinase-9 and -2.38, 139, 140 
1.6 The expanding clinical spectrum of sporadic CAA 
There are at least four important clinical presentations associated with CAA: 
 Symptomatic intracerebral haemorrhage 
 Cognitive impairment and dementia 
 Rapidly progressive cognitive and neurological decline (inflammatory CAA) 
 Transient neurological symptoms 
1.6.1 Intracerebral haemorrhage 
1.6.1.1 The association between CAA and ICH 
CAA is most often recognized in life by symptomatic, spontaneous, lobar ICH in elderly 
patients. The majority of ICHs (>75%) in the elderly are classified as spontaneous 
(sometimes also termed primary or non-traumatic), resulting from rupture of small arteries 
affected by two main processes: hypertensive arteriopathy or CAA. Hypertensive 
arteriopathy - characterized by lipohyalinosis and fibrinoid necrosis of small lenticulostriate 
arterial perforators - is considered an important cause of spontaneous ICH in deep or 
infratentorial locations (basal ganglia, thalamus, and pons). By contrast, CAA-related ICHs 
preferentially affect cortical-subcortical (lobar) regions (especially the occipital and 
temporal lobes141), less commonly the cerebellum, and rarely deep or brainstem structures, 
reflecting the distribution of the underlying microangiopathy.37, 69, 109 The predilection for 
the occipital lobes is not well understood, but one hypothesis is that greater tortuosity of 
occipital small arteries impairs perivascular drainage.38 
Clinicopathological studies suggest that CAA-related ICH accounts for at least 5-20% 
of all spontaneous ICH,37, 56, 65, 72, 142, 143 and that the link is strongest for lobar ICH. 
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However, there are methodological challenges in attributing ICH to CAA: most 
pathological case-control studies did not systematically control for potential confounding 
risk factors for CAA, including cognitive impairment, ethnicity, or age. Furthermore, 
pathological studies showed differences in the prevalence of ICH only when comparing the 
presence of low grade CAA versus moderate-to-high grade CAA,62, 65, 72, 101, 144-147 suggesting 
that mild CAA may not confer such a high risk of ICH. Since many elderly individuals in 
population-based studies have subclinical CAA without haemorrhage, CAA (especially if 
mild) may not be a sufficient cause of lobar ICH alone, but may interact with other factors, 
for example hypertension, neurodegenerative pathology or the use of anticoagulant drugs.62, 
65, 72, 101, 144-147 
1.6.1.2 Clinical features of CAA-related ICH 
CAA-related ICHs have some distinct neuroimaging features, which are shown in Figure 
1.7.109, 148 However, the clinical presentation of CAA-related ICH is similar to other forms 
of lobar ICH (e.g. due to tumours or arterio-venous malformations) and varies according to 
ICH size and location. Patients usually present with an acute stroke syndrome with focal 
neurological deficits that may be associated with headache, nausea, vomiting, seizures 
and/or altered level of consciousness (especially large lobar bleeds).45 There may also be a 
history of apparently minor head trauma, which might predispose to ICH in individuals with 
CAA. The typical lobar location of haemorrhage more often leads to acute seizures than in 
deep ICH. A first-ever ICH due to CAA may be relatively mild clinically, but this is 
counterbalanced by the high risk of recurrent haemorrhages; indeed, subsequent ICH 
(which characteristically may cluster over a short period of time [days to weeks]) is often 
much more severe.149 In the longer term, survivors of lobar ICH are at higher risk of 
recurrence compared to deep ICH, with a rate of about 10% per year in elderly cohorts.37, 
149 Recurrent haemorrhages are typically lobar, often in the same lobe as the initial CAA-
related bleed.141 Multiple simultaneous lobar haemorrhages are characteristic of CAA-
related ICH. The recovery from lobar ICH is often poor: negative prognostic factors 
include older age84 and larger haematoma size;150 conversely, a small superficial ICH 
without intraventricular extension is associated with better outcome. 
1.6.1.3 Anticoagulant-related haemorrhage 
CAA may be an important risk factor or cause for ICH related to oral anticoagulation use. 
Over the last decade there has been a five-fold increase in the incidence of anticoagulant-
related ICH, which now accounts for about 15% of all ICH.151 This trend is probably due to 
increasing use of warfarin to prevent cardioembolic stroke in elderly patients with atrial 
fibrillation. Anticoagulant use per se should not cause ICH if cerebral vessels are intact, but 
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the presence of CAA, rendering vessels brittle and fragile, is a plausible aggravating factor 
for such haemorrhage; an otherwise innocuous minor and self-limiting vessel leak (e.g a 
cerebral microbleed [CMB], see below) could form a life-threatening haematoma if the 
leaking vessel is damaged by advanced CAA. Evidence supporting a link between CAA and 
anticoagulation-related ICH includes the following observations: first, most such ICH occur 
with international normalised ratios within the therapeutic range152 suggesting that an 
intrinsic disorder of cerebral small vessels could be important; and second, the APOE ε2 
allele is more common in warfarin-related ICH than in patients on warfarin without ICH, 
supporting a role for CAA.152 Although CAA may underlie a substantial proportion of 
anticoagulation-related haemorrhages, prospective studies with reliable diagnosis of CAA in 
life (e.g. by MRI evidence of lobar cerebral microbleeds or molecular imaging) in cohorts of 
patients treated with anticoagulants are urgently needed to answer this question (one large 
prospective MRI study is currently underway in the UK: www.ucl.ac.uk/cromis-2). 
CAA may also be a risk factor for ICH after thrombolysis: spontaneous CAA-related 
and thrombolysis-related haemorrhages share some features including a predilection of 
lobar brain regions, multiplicity of haemorrhages, age-dependency and an association with 
dementia and leukoaraiosis.153 In one small study, 2 of 5 cases of ICH after thrombolysis for 
acute myocardial infarction had severe CAA identified.154 
1.6.2 Cognitive impairment and dementia 
There is now increasing evidence that CAA is an important contributor to cognitive 
impairment,10, 106 although dissecting its independent cognitive impact is confounded by the 
presence of co-existing Alzheimer’s disease and other age-related pathologies (e.g. 
hypertensive arteriopathy). Nevertheless, in population-based clinical-pathological studies, 
the prevalence of CAA is consistently higher in demented compared to non-demented 
patients.58 In the population-based Medical Research Council Cognitive Function and Aging 
Study (MRC CFAS) CAA was significantly associated with dementia (OR 9.3, 95% CI 2.7–
41.0) even after controlling for age and dementia-related neuropathologies (e.g. neuritic and 
diffuse plaques).61 Similarly, the HAAS autopsy study revealed a significantly higher 
prevalence of severe CAA in demented versus non-demented patients (43% vs. 24%).62 
CAA may worsen the severity of cognitive dysfunction in Alzheimer’s disease: CAA 
together with Alzheimer’s disease pathology has been associated with significantly worse 
cognitive performance during life, compared to Alzheimer’s disease alone, even after 
controlling for age, neurofibrillary tangles and amyloid plaques number, infarctions and 
APOE genotype.62 There are few studies of the specific pattern of cognitive impairment 
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associated with CAA; a recent autopsy series found that moderate-to-severe CAA (present 
in 19% of the study population) was associated with lower performance in specific cognitive 
domains, notably perceptual speed and episodic memory, after accounting for Alzheimer’s 
disease pathology and other potential covariates.155 The pathophysiological mechanisms by 
which CAA could cause cognitive impairment have not been well established,10 but relevant 
lesions on brain imaging could include cerebral microbleeds,156 microinfarcts,73, 157 and white 
matter changes.158  
CAA is thus emerging as a potentially important link between neurodegenerative and 
cerebrovascular pathology.159 Vascular cognitive impairment and Alzheimer’s disease are 
now conceptualised as a continuum10, 160, 161 with complex interactions and shared risk 
factors.136, 159 CAA seems likely to exacerbate the deleterious effect of neurodegenerative 
pathology on the brain, lowering the threshold for overt dementia.10, 136 Unravelling the 
independent contribution of CAA to cognitive function is particularly important as it could 
lead to new therapeutic strategies. 
1.6.3 Rapidly progressive cognitive and neurological decline: 
CAA-related inflammation 
CAA is clearly a direct cause of cognitive impairment in the uncommon but clinically 
striking presentation of CAA-related inflammation (also termed cerebral amyloid angiitis, 
amyloid beta related angiitis and cerebral amyloid inflammatory vasculopathy).162 CAA-
related inflammation typically affects older adults, who present with acute to subacute 
cognitive decline, headache, behavioural change, seizures and focal neurological deficits.162 
Typical MRI findings include patchy or confluent, asymmetric T2-weighted or FLAIR white 
matter hyperintensities (with or without mass effect and leptomeningeal or parenchymal 
enhancement).162 T2*-weighted gradient recalled echo (T2*-GRE) or susceptibility weighted 
imaging (SWI) may reveal previous lobar haemorrhage and/or multiple cortical and 
subcortical microbleeds.162 The major differential diagnoses include infections (in particular 
progressive multifocal leucoencephalopathy), neuro-sarcoidosis, immune-related conditions 
(e.g. acute disseminated encephalomyelitis)163 and malignancies.162 Definite diagnosis 
requires brain and leptomeningeal biopsy showing perivascular inflammation with 
mononuclear or multinucleated giant cells associated with amyloid-β-laden vessels and/or 
frank vasculitis.162 Although the clinical course of CAA-related inflammation is varied, it is 
important to recognize because it may respond well to immunosuppressive treatment (e.g. 
high dose corticosteroids or cyclophosphamide).162, 164 This distinct syndrome has parallels 
with that observed in patients with Alzheimer’s disease who developed meningo-
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encephalitis after immunization against human Amyloid-β, where post mortem examination 
revealed inflammation and/or vasculitis associated with CAA.165, 166 
1.6.4 Transient focal neurological episodes  
After ICH, the next most commonly described clinical presentation of sporadic CAA is 
with transient neurologic episodes,167-169 sometimes termed “amyloid spells”. The most 
common type of attack involves recurrent, stereotyped episodes of “positive” spreading 
sensory symptoms (paraesthesias).167, 168 Although there are a number of small case reports 
and series,167, 168, 170, 171 no large systematic studies have investigated the prevalence or 
semiology of these phenomena. At least two other types of transient events have been 
described: partial motor seizure-like episodes (e.g. limb shaking); and visual disturbances 
(usually positive visual symptoms similar to migrainous auras). Spells are typically brief, 
almost always less than about 30 minutes, and usually less than a few minutes. The attacks 
seem likely to be related to haemorrhagic components of CAA: associated neuroimaging 
findings reported include cerebral microbleeds and convexity subarachnoid haemorrhage 
(cSAH) in the cortical region corresponding to the spell.167, 171 The diagnosis of these CAA-
related attacks is of clinical relevance, since they seem to precede serious symptomatic ICH 
in some patients; antiplatelet or anticoagulant use following such an attack misdiagnosed as 
a transient ischaemic attack (TIA) could therefore cause potentially avoidable intracranial 
bleeding. The underlying mechanisms of CAA transient spells remain unclear, but could 
include seizure-like activity (perhaps related to small areas of bleeding, e.g. microbleeding, 
cSAH or superficial siderosis); a direct effect of amyloid or bleeding on local cortical 
function; or spreading cortical depression.167 The responsiveness of these attacks to anti-
epileptic drugs as well as their spreading nature in many of the reported cases are in favor 
of a seizure-like mechanism for their pathophysiology. In a case series by Roth and co-
workers,168 four out of six patients with these transient attacks responded to 
anticonvulsants, while the other two patients showed improvement after the cessation of 
antiplatelet therapy. Typical TIA-like episodes have also been reported in CAA,169 but 
whether these are genuinely due to ischaemia and should be treated with antithrombotic 
agents requires further study. 
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Figure 1.7 The spectrum of imaging manifestations of sporadic cerebral amyloid angiopathy (CAA) . 
(A) An acute lobar haematoma on computer tomography (CT) scan. Some extension of the bleeding 
in the posterior horn of the left ventricle can be seen. (B) CT scan of a patient with a small posterior 
cortical haematoma. Acute cortical subarachnoid haemorrhage (cSAH) is evident in two adjacent 
sulci (arrowheads). (C) A T2-weighted MRI of a patient with probable CAA showing two lobar foci 
of recent/subacute intracerebral haemorrhage (ICH): in the medial aspect of the left occipital lobe, 
and in the right inferior frontal gyrus. There is also a large old lobar haemorrhage involving the right 
occipital lobe, some scattered cortical-subcortical cerebral microbleeds (CMBs) in posterior brain 
regions, as well as confluent white matter hyperintensities (leukoaraiosis: arrow). (D) SWI and T2*-
GRE (inset) done on the same day in a patient with a large lobar bleed. The detection of strictly 
lobar CMBs (better demonstrated on SWI) allowed the diagnosis of probable CAA. (E) cSAH (linear 
hypointensities in the subarachnoid space on T2*-GRE/SWI) and focal cortical siderosis 
(hyperintense on T2*-GRE/SWI). The inset in (E) demonstrates the co-existence of cSAH 
(arrowhead), focal cortical siderosis in an adjacent sulcus (arrow) and some CMBs (circles). Focal 
cortical siderosis represents the chronic lesion following an acute cSAH. (F) The use of SWI, in a 
patient presenting with progressive cognitive impairment let to the detection of multiple strictly 
lobar microbleeds, characteristic of CAA. Confluent white matter changes (arrow) are also visible. 
(G) Restricted diffusion (diffusion-weighted image on left, absolute diffusion-weighted imaging (DWI) 
on the right) consistent with a small acute ischaemic lesion in a patient with probable CAA.  
1.7 Neuroimaging (MRI) correlates of CAA 
The important MRI correlates of CAA (Figure 1.7) include:  
 Cerebral microbleeds 
 White matter hyperintensities (leukoaraiosis) 
 Convexity subarachnoid bleeding 
 Cortical superficial siderosis 
 Acute ischaemic lesions (cerebral microinfarcts) 
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1.7.1 Cerebral microbleeds 
The widespread use of T2*-weighted MRI sequences in the last decade or so has led to the 
increasing detection of cerebral microbleeds: small, well-demarcated, hypointense, rounded 
lesions, not detected on conventional MRI (Figure 1.7 D-f).35. Histopathological studies 
show that cerebral microbleeds correspond to focal accumulations of haemosiderin-laded 
macrophages (a blood-breakdown product) adjacent to abnormal small vessels affected by 
hypertensive angiopathy or CAA.172, 173 There is increasing evidence that hypertensive 
vasculopathy is associated with cerebral microbleeds in deep brain regions (basal ganglia, 
thalamus and brainstem), whereas CAA is characterised by cerebral microbleeds in a lobar 
distribution35, 173 with a predilection for the parietal lobes.141 The Rotterdam scan study174, 
175 showed a strong association between strictly lobar (but not deep) cerebral microbleeds 
and APOE ε4, consistent with the well-known relation of this allele with CAA.87 A recent 
imaging study in clinically probable CAA, using non-invasive amyloid imaging with Pittsburgh 
Compound B (PiB), found that cerebral microbleeds correspond to areas with a high 
concentration of amyloid.176 Further evidence derives from neuroimaging studies of 
cerebral microbleeds in patients presenting with symptomatic ICH: patients with deep ICH, 
predominantly caused by hypertensive arteriopathy, are more likely to have deep cerebral 
microbleeds; whereas those patients with multiple strictly lobar ICH, frequently caused by 
CAA (although the exact proportion of lobar ICH which are actually due to CAA in not 
known), are more likely to have multiple strictly lobar cerebral microbleeds.177-179 
Moreover, cerebral microbleeds correlate with the risk of lobar ICH recurrence180 
suggesting an important role in prognosis (as well as diagnosis) in CAA.27 
Recent population-based studies have revealed a high percentage of community-
dwelling elderly people with strictly lobar microbleeds, (particularly in the posterior brain 
regions) suggesting sub-clinical CAA.174, 175, 181, 182 This may have important implications: if 
strictly lobar cerebral microbleeds are validated as a diagnostic marker of CAA, such 
asymptomatic individuals could benefit from new therapeutic agents to reduce the 
progression of the disease. 
Neuroimaging studies have revealed lobar cerebral microbleeds in more than 20% of 
patients with Alzheimer’s disease,183 probably reflecting advanced CAA (in keeping with 
neuropathological findings). Patients with autosomal dominant forms of familial Alzheimer’s 
disease (who have a younger age at symptom onset), also seem to have a prevalence of 
lobar cerebral microbleeds similar to sporadic Alzheimer’s disease184 – a striking recent 
observation since these patients are much more likely to have ‘pure’ neurodegenerative 
Alzheimer’s disease without co-existing sporadic small vessel disease. It has been suggested 
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that the presence of multiple lobar cerebral microbleeds in patients with Alzheimer’s 
disease, may identify a specific subgroup of patients with a different clinical phenotype with 
therapeutic implications which need to be explored in future studies.183 
1.7.2 White matter hyperintensities 
White matter hyperintensities (also known as leukoaraiosis) is a radiological term which 
describes imaging changes (often confluent) in deep cerebral white matter. Leukoaraiosis 
appears as low attenuation on computer tomography (CT) scans or hyperintensity on T2-
weighted or FLAIR MRI, typically sparing subcortical U-fibres (Figure 1.7 C).5 Pathological 
substrates include demyelination, axon loss and mild gliosis. The pathogenesis of 
leukoaraiosis in CAA probably involves chronic hypoperfusion of the vulnerable peri-
ventricular white matter and disruption of the BBB due to amyloid in the overlying cortical 
small vessels.2, 24, 133 Another possible mechanism of leukoaraiosis in CAA is as a result of 
the accumulation of silent ischaemic lesions (microinfarcts).46, 73, 185 Indeed, leukoaraiosis is 
very common in CAA, preferentially involving posterior regions,186 although some studies 
suggest no major difference in the topography of leukoaraiosis in CAA compared to 
hypertensive arteriopathy.158, 186 A recent investigation suggested that subjects with CAA-
related lobar ICH have a higher prevalence of occipital dominant leukoaraiosis compared to 
normal elderly controls;187 this interesting finding requires further clinical attention and 
investigation. Leukoaraiosis may be an important contributor to overall disease burden, 
especially progressive cognitive impairment,188 given its tendency to accumulate over 
time.189 A recent study found that leukoaraiosis volume was greater in patients with CAA 
and hypertension than those without, suggesting that strict control of hypertension might 
reduce leukoaraiosis-related disability in CAA.188 
1.7.3 Acute convexity subarachnoid haemorrhage (cSAH) and 
cortical superficial siderosis 
Atraumatic convexity subarachnoid haemorrhage (cSAH) and cortical superficial siderosis 
are recently recognised imaging correlates of sporadic CAA190 which seem to be quite 
characteristic of the disorder (Figure 1.7 E). cSAH is localized bleeding, usually in up to 
several adjacent sulci, without other subarachnoid bleeding at the base of the brain in the 
pattern typically associated with saccular aneurysm rupture.191 Although rare in isolation, in 
CAA, cSAH often results from lobar ICH extending to the cortical surface.170, 190, 192 The 
largest cohort of patients with isolated cSAH published (n=29), found that CAA was a 
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frequent apparent cause in patients over 60 years old.191, 193 A recent retrospective analysis 
of consecutive patients admitted to a tertiary stroke unit with cSAH suggested that CAA 
could be a common cause in the elderly, with a characteristic clinical presentation of single 
or recurrent transient focal neurological attacks.171 Another recent study of a cohort of 
patients presenting with cSAH, reported similar findings.194 
Superficial siderosis describes haemosiderin deposition in the superficial layers of the 
cerebral cortex, and may follow repeated episodes of bleeding in the subarachnoid space.190 
On T2*-GRE MRI sequences superficial siderosis shows a characteristic “gyriform” pattern 
of hypointense signal (Figure 1.7 E).190 Linn et al. have recently detected superficial siderosis 
in 47.4% (n=38) of patients with a clinical diagnosis of CAA, compared to no controls 
(mean age, 54 years), suggesting that it might be helpful for the clinical diagnosis of CAA 
(see below).195 Compared to the well-known syndrome of central nervous system 
superficial siderosis, which typically affects the brainstem and posterior fossa (associated 
with cerebellar and brainstem signs), CAA-related siderosis has a predilection for the 
cerebral convexity196 and may be associated with transient neurological manifestations.168 
1.7.4 Small acute ischaemic lesions on diffusion-weighted 
imaging (DWI) 
Neuropathological evidence of asymptomatic ischaemic infarction (cerebral 
microinfarcts197) is an established finding in the brains of patients with advanced CAA.43, 101-
103 Recent studies using magnetic resonance DWI, -which is extremely sensitive to even 
small areas of acute ischaemia - have shed light on the dynamics of this phenomenon in vivo 
(Figure 1.7 G). A case report47 and a recent case-control study46 found a high prevalence of 
DWI-positive lesions, in patients with advanced CAA. These lesions were associated with 
CMB burden, suggesting shared pathophysiological pathways.198 Gregoire et al recently 
established that acute, subclinical ischaemic brain lesions are frequent after recent acute 
ICH, and are three times more common in CAA-related ICH than other spontaneous 
bleeds;73 the lesions were associated with the severity of leukoaraiosis and lobar cerebral 
microbleeds, suggesting that that they were due to a CAA-related occlusive arteriopathy.73 
However, a more recent larger study did not appear to show this higher prevalence of 
DWI lesions in CAA-related intracerebral haemorrhage, suggesting that both CAA and 
hypertensive arteriopathy trigger high rates of infarction.199 These data suggest a dynamic 
interplay between the haemorrhagic (“microbleeding”) and ischaemic (“microinfarction”) 
components in CAA and small vessel disease in general,198 though the therapeutic 
implications and prognostic significance of these findings require further study. The topic of 
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microinfarcts and DWI lesions in CAA as well as current uncertainties in the terminology 
and pathophysiology of these lesions, are further covered in Discussion (Chapter 11). 
1.8 Molecular imaging of vascular amyloid in vivo 
MRI indirectly detects the consequences of CAA (e.g. cerebral microbleeds, cSAH, and 
siderosis) rather than vascular amyloid itself. Consequently, a large proportion of “silent” 
CAA may be as yet undetectable. Positron emission tomography (PET) methods allow the 
in vivo imaging of amyloid in the brain, using several radioligands, of which the most widely 
studied is 11C Pittsburgh Compound B (PiB).200 Ly and colleagues demonstrated that CAA 
subjects had increased global PiB uptake relative to a healthy elderly control group, and 
found an occipital predominance of PiB retention in CAA compared with Alzheimer’s 
disease.50 PiB PET might therefore ultimately detect CAA in vivo, even before it causes 
symptomatic ICH or the known radiological sequelae including cerebral microbleeds.48, 49, 
176, 201 
1.9 Diagnostic approach to CAA: the critical role of 
neuroimaging 
A common clinical scenario where sporadic CAA should be suspected is in elderly patients 
presenting with lobar ICH. The most commonly used criteria for CAA diagnosis are the 
Boston criteria.202 In the absence of direct neuropathological examination, CAA is 
diagnosed based on characteristic neuroimaging findings.202 The diagnosis of probable CAA 
requires (Table 1.2): 
 Age >55 years 
 the detection of multiple haemorrhagic cerebral lesions  
 haemorrhages confined to cortical or cortical-subcortical (lobar) brain regions  
 exclusion of secondary causes of ICH, such as arteriovenous malformations, head 
trauma, brain tumour, vasculitis and excessive anticoagulation 
The specificity of the Boston criteria has been validated against the established gold 
standard of neuropathological diagnosis from autopsy, haematoma evacuation, or cortical 
biopsy.202 In this study, the criteria showed excellent specificity: all cases identified as 
“probable CAA” (n=13) had pathological evidence of severe CAA. However, the sensitivity 
of the probable category was 44%, so that it failed to identify over 50% of those with 
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severe CAA pathology.202 However, this study does not reflect current radiological practice 
since only 15 patients had T2*-GRE imaging. Recently, the application of the Boston criteria 
with a greater use of T2*-GRE MRI in Dutch-type hereditary CAA found a much improved 
sensitivity (especially when lobar cerebral microbleeds were included in the criteria).203 The 
rationale for the inclusion of lobar cerebral microbleeds in the criteria is that both lobar 
cerebral microbleeds and lobar ICH represent independent vascular rupture events which 
are considered to offer equal evidence for the presence of CAA.204 The recently 
introduced SWI, a three-dimensional T2*-GRE technique, enables visualization of cerebral 
microbleeds with much increased sensitivity, resulting in higher lesion counts (at least 67% 
more compared to conventional T2*-GRE) (Figure 1.7 D),205-207 but its effect on diagnostic 
accuracy for CAA requires further study. Superficial siderosis and cSAH, which have a high 
prevalence in CAA-related ICH but are rare in other forms of ICH, have been shown to 
enhance the sensitivity of the Boston Criteria without loss of specificity.195 
Table 1.2 Classic and modified Boston criteria for diagnosis of cerebral amyloid angiopathy (CAA). 
(*Modifications compared to the classic Boston criteria based on Linn et al.) 
1. Definite CAA 
Full post-mortem examination demonstrating: 
 Lobar, cortical, or cortical-subcortical haemorrhage 
 Severe CAA with vasculopathy 
 Absence of other diagnostic lesion 
 
2. Probable CAA with supporting pathology 
Clinical data and pathologic tissue (evacuated haematoma or cortical biopsy) 
demonstrating: 
 Lobar, cortical, or cortical-subcortical haemorrhage 
 Some degree of CAA in specimen 
 Absence of other diagnostic lesion 
 
3. Probable CAA 
Clinical data and MRI or CT demonstrating: 
 Multiple haemorrhages restricted to lobar, cortical, or cortical-subcortical regions 
(cerebellar haemorrhage allowed) 
*[OR single lobar, cortical, or cortical-subcortical haemorrhage and focalb or disseminatedc 
superficial siderosis] 
 Age≥55 years 
 Absence of other cause of haemorrhagea 
 
4. Possible CAA 
Clinical data and MRI or CT demonstrating: 
 Single lobar, cortical, or cortical-subcortical haemorrhage 
*[OR focalb or disseminatedc superficial siderosis] 
 Age ≥55 years 
 Absence of other cause of haemorrhage1 
Other causes of haemorrhage (differential diagnosis of lobar haemorrhages): 
Antecedent head trauma, haemorrhagic transformation of an ischaemic stroke, arteriovenous 
malformation, haemorrhagic tumour, warfarin therapy with international normalisation ratio > 3, 
vasculitis 
 
b Focal siderosis: siderosis restricted to 3 or fewer sulci 
c Disseminated siderosis: siderosis affecting at least 4 sulci 
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Although the value of T2*-weighted MRI and SWI to detect cerebral microbleeds, cSAH 
and siderosis has mainly been validated in cohorts of patients who presented with 
symptomatic ICH, such imaging may also have a role in the diagnosis of patients presenting 
without major haemorrhage, but with other syndromes raising suspicion of CAA; for 
example, elderly patients with progressive cognitive impairment.10, 171, 206, 208, 209 In addition, 
although at present T2* MRI or SWI sequences are not part of the routine investigation of 
TIA-like attacks, there might be useful in patients with CAA-related transient focal 
neurological episodes (“amyloid spells”) – rather atypical of TIAs.168, 171 However, current 
data are insufficient to make  evidence-based recommendations. 
Other biomarkers might also prove useful in the non-invasive diagnosis of CAA, in 
particular the assessment of amyloid-β concentrations in the cerebrospinal fluid (CSF). 
Decreased levels of CSF amyloid-β42 but not amyloid-β40 are found in Alzheimer’s 
disease,210 while it has been reported that both amyloid-β42 and amyloid-β40 concentrations 
are decreased in CAA, relative to control and Alzheimer’s disease patients.211 It has also 
been suggested that the combination of low amyloid-β42 with increased total tau levels in 
the CSF, can discriminate CAA patients from normal controls with high accuracy.211 
Another potentially promising marker of CAA might include retinal changes 
(microaneurysms and dot and blot haemorrhages212). A critical goal of all of these potential 
approaches is to reliably identify CAA at the early (asymptomatic) stages of the disease, to 
allow the best chance for disease modifying or preventive treatments to be effective. 
1.10 Management of CAA and its consequences 
1.10.1 Acute treatment 
No treatment is specific for symptomatic management of CAA or CAA-related ICH. As in 
all forms of spontaneous ICH, CAA-related haematomas enlarge in the first few hours after 
onset, providing a potential target for treatment. One of the most promising available 
treatments in acute ICH is intensive lowering blood pressure, which has been shown to 
reduce haematoma expansion in a randomized trial,213 presumably by reducing pressure 
into the ICH in the critical hyperacute phase. A further large study (INTERACT-2) showed 
that intensive blood pressure lowering in acute ICH patients did not result in a reduction in 
the rate of death or severe disability (a score of 3 to 6 on the modified Rankin scale). 
However, an ordinal analysis of modified Rankin scores indicated improved functional 
outcomes in the patient group with intensive lowering of blood pressure.214 The role of 
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neurosurgery in ICH is a topic of ongoing investigation. Although there have previously 
been concerns regarding surgery in CAA due the risk of bleeding from fragile amyloid-laden 
vessels, the available evidence does not suggest a particularly high operative risk.215-217 
Neurosurgery for haematoma evacuation appears relatively safe in at least some patients 
with CAA-related ICH, particularly in patients under 75-year old without intraventricular 
extension.217 This topic was recently explored in the STICH-2 trial (early surgery versus 
initial conservative treatment in patients with spontaneous supratentorial lobar 
intracerebral haematomas). STICH-2 confirmed that early surgery does not seem to 
increase the rate of death or disability at 6 months and might actually have a small but 
clinically relevant role in patients with spontaneous superficial ICH without intraventricular 
haemorrhage.218 Minimally invasive surgery plus recombinant tissue-type plasminogen 
activator (MISTIE trial) is also an area under investigation.219 Until further evidence for 
specific acute treatments is available, it is reasonable to follow the American Heart 
Association Stroke Council guidelines for acute management of ICH, without modification 
for individuals with suspected CAA.220 Active research into new approaches for acute ICH 
treatment is expected to benefit patients with CAA-related bleeds. Novel approaches 
including neuroprotective drugs221, 222 which target the multitude of processes that occur 
after ICH (e.g. cerebral edema, thrombin release, red blood cell lysis and haemoglobin-
induced neurotoxicity),223, 224 and iron-chelating agents (such as deferoxamine)225 are all 
being studied in early-phase trials.44, 220, 226 
1.10.2 Prevention of recurrent ICH 
1.10.2.1 Withholding anticoagulants and antiplatelets 
It is a paradox that many elderly patients at highest risk of occlusive vascular events are also 
at the highest risk of haemorrhage complications including ICH. Judging the balance of risk 
and benefit of antithrombotic treatment after ICH in those patients with an indication for 
vascular secondary prevention is thus a major clinical challenge. The available evidence on 
this topic is limited, consisting of generally small case-control and prospective observational 
studies. In a recent prospective cohort of patients with spontaneous lobar ICH, an 
association was found between aspirin use and ICH recurrence after adjusting for other 
potential ICH risk factors (HR 3.95, 95% CI 1.6–8.3, p <0.021).227 Re-bleeding risk was 
associated with the number of lobar cerebral microbleeds, and the presence of 
leukoaraiosis in posterior brain regions-possible markers of underlying CAA and its 
severity.227 Gregoire et al. in a small case-control study found that lobar cerebral 
microbleeds were associated with antiplatelet-related ICH, also supporting a link between 
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CAA and antiplatelet-related ICH.228 Another small case-control study of warfarin-related 
ICH and matched ICH-free warfarin users showed an association of warfarin with cerebral 
microbleeds, but with large confidence intervals around the odds ratios for the 
association.212 There are no randomized trial data, but a decision analysis suggested that in 
patients with CAA-related ICH, the use of anticoagulants to prevent future cardioembolic 
(atrial fibrillation-related) stroke would lead to an ICH rate that outweighs any benefit from 
the treatment.229 
For the moment, anticoagulation should usually be avoided in patients with a diagnosis 
of CAA and symptomatic lobar ICH, unless there is a very compelling need to treat that 
could outweigh the very high risk of recurrent ICH (e.g. life threatening pulmonary 
embolism or a mechanical heart valve). Although antiplatelet drugs probably also increase 
future ICH risk in CAA, it may be reasonable to consider them in selected patients with 
CAA for secondary prevention in whom the risk of intracerebral bleeding is judged to be 
low and the risk of occlusive vascular events high, based in their clinical and imaging 
characteristics. In primary prevention the risk/benefit ratio may favour withholding 
treatment in patients with multiple lobar cerebral microbleeds. Further randomized clinical 
trials are urgently needed to help clarify the optimum antithrombotic treatment in these 
different CAA patient groups. 
1.10.2.2 Blood pressure control 
A recent subgroup analysis of the PROGRESS trial reported that lowering blood pressure 
with the antihypertensive drug perindopril (with or without indapamide) reduced the risk 
of probable CAA-related ICH by 77% (95% CI, 19%–93%) over a follow-up period of 3.9 
years.76 Despite a small total number of CAA-related ICH events, this is the first trial to 
show that blood pressure-lowering treatment protects against CAA-related ICH, 
regardless of the presence of hypertension.76 Blood pressure lowering may also be 
associated with a more general benefit in cardiovascular risk and mortality in patients over 
the age of 80 years.230 Thus, most patients with CAA and a history of symptomatic ICH 
should be offered antihypertensive treatment, but further trials are clearly needed. 
1.10.2.3 Statins 
Recently, concerns have been raised over statins as a risk factor for ICH, in light of the 
results of the SPARCL trial of atorvastatin in patients with stroke, which showed a small 
increase in the incidence of ICH among patients receiving high doses of the drug;231 the 
hazard was higher for patients with baseline haemorrhagic compared to ischaemic stroke 
(HR 4.1 versus 1.6).232 A decision analysis showed that the risk of statin therapy likely 
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outweighs any potential benefit in patients with recent lobar ICH.233 Thus, although there 
are inadequate data and a hot debate for clear recommendations on statin use,220, 234, 235 
they should perhaps be avoided in the setting of a recent CAA-related ICH.236 For 
individuals with suspected CAA based on the presence of multiple lobar cerebral 
microbleeds (without any associated macro-bleeding) the risks and benefit of statin therapy 
are uncertain27 and randomised trials are needed. 
1.11 Conclusions 
During the last decade, there have been tremendous advancements in our understanding of 
CAA, relating to its pathophysiology, clinical spectrum, imaging manifestations and 
diagnosis.  
 Sporadic CAA is a common disease of the elderly and will become an increasingly 
important healthcare challenge as populations age further.  
 Sporadic CAA is an important contributor to cognitive decline and spontaneous or 
anticoagulant-related lobar ICH.152  
 Transient neurological spells in CAA may be misdiagnosed as TIAs, but seem to 
have characteristic clinical features; they need to be recognized since treating them 
with antithrombotic drugs may increase the risk of future ICH. 
 Recent advances in neuroimaging have provided a new imaging window into the 
dynamic haemorrhagic and ischaemic features of CAA.  
 Lobar cerebral microbleeds, cSAH and cortical superficial siderosis show promise 
to reliably diagnose CAA in life, though validation of these findings against their 
histopathological correlates requires further study.  
 Molecular imaging of amyloid-β may further improve our ability to detect this 
condition in vivo and define its true prevalence and burden.48-50, 176 
 The rapidly developing field of transgenic mouse modelling has provided significant 
insights into the pathophysiology of human CAA, including the key pathogenetic 
role of the perivascular drainage pathway and the differential effects of different 
APOE genotype.38  
Despite our improved understanding of CAA, there are still many questions to 
be answered in order to identify targets for therapeutic and preventive interventions. 
Exciting diagnostic and therapeutic developments are on the horizon for this fascinating 
small vessel disorder.  
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Aims and rationale of this PhD thesis 
The detection of CAA during life is becoming an increasingly important challenge, since 
approaches of prevention or treatment (disease-modification) are now emerging as realistic 
possibilities, including reducing amyloid-β production, clearing amyloid-β using immune-
based therapies or protecting small vessels from its toxic effects (covered in Chapter 11).1 
Determining the most promising treatments requires development of reliable biomarkers, 
the goal of my research. A biomarker is a measurable characteristic that reflects the 
presence or severity of a disease. Biomarkers may predict susceptibility to disease, improve 
understanding of mechanisms, improve the accuracy of diagnosis, or track progression, 
including treatment effects (when they are often termed “surrogate” markers); they may be 
based on clinical factors (e.g. clinical events), structural neuroimaging lesions, biological 
samples (blood, cerebrospinal fluid, genetic markers), or in the case of CAA, markers of 
vascular pathophysiology and direct amyloid-β radioligands. 
The main objective of this PhD thesis is to provide new insights into potential clinical 
and applied clinical neuroimaging biomarkers in patients with CAA. This is accomplished by 
a portfolio of research studies. 
Chapter 2 explores the clinical and radiological spectrum of transient focal 
neurological episodes as a potential clinical clue for CAA. This is a poorly characterised 
phenotype of CAA with important clinical relevance. 
Chapters 3 and 4 focus on cortical superficial siderosis as both a diagnostic and a 
prognostic marker of CAA respectively. Implications for mechanims are also explored. 
Chapters 5 to 7 are dedicated to MRI-visible perivascular spaces, a recently 
recognized (or rediscovered) potential neuroimaging marker of small vessel disease,30, 133 
which has often been ignored. Chapter 5 focuses on the imaging characteristics of 
perivascular spaces in relation to spontaneous ICH with the aim to determine the 
prevalence, distribution and severity of perivascular spaces in ICH, and investigate 
associations with other imaging markers of small vessel disease, and with ICH aetiology. In 
Chapter 6, results from an MRI-neuropathological study exploring MRI-visible perivascular 
spaces in the centrum semiovale (i.e. cerebral white matter) as a diagnostic marker of 
pathology-confirmed CAA are presented. Chapter 7 describes the relationship between 
centrum semiovale perivascular spaces and cerebrovascular amyloid-β burden in a PiB-PET-
MRI study across a range of CAA severity. 
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Chapter 8 discusses a novel association between white matter perivascular spaces 
and cortical superficial siderosis in CAA patients, and its potential pathophysiological 
importance. 
Chapter 9 explores potential pathological, neuroimaging and genetic differences in 
patients with pathology-proven CAA with and without intracerebral haemorrhage and 
presents evidence for different disease phenotypes. 
Chapter 10 is a systematic review and meta-analysis which assess the evidence 
whether the presence and burden of cerebral microbleeds on MRI scans is associated with 
an increased risk of recurrent spontaneous ICH, and if this risk is different according to 
MRI-defined microangiopathy subtype. 
This thesis concludes in Chapter 11 with a very brief review of the main findings, a 
discussion in the context of current knowledge and the description of further research 
plans in the field, including prospects for disease modifications in CAA. 
Although overlap has been minimized as far as possible, each chapter is designed to 
stand alone, so some repetition between chapters is inevitable and necessary. 
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Chapter 2 Clinical-radiological spectrum of 
transient focal neurological episodes in 
cerebral amyloid angiopathy: multicentre 
MRI cohort study and meta-analysis 
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ABSTRACT 
Objective: Transient focal neurological episodes (TFNE) are recognized in cerebral 
amyloid angiopathy (CAA) and may herald a high risk of intracerebral haemorrhage (ICH). 
We aimed to determine their prevalence, clinical-neuroimaging spectrum and association 
with future ICH risk. 
Methods: Multicentre retrospective cohort study of 172 CAA cases. Clinical, imaging and 
follow-up data were collected. We classified TFNE into: (1) predominantly positive 
symptoms (“aura-like” spreading paraesthesias/positive visual phenomena; or limb jerking); 
and (2) predominantly negative symptoms (“TIA-like” sudden-onset limb weakness, 
dysphasia, or visual loss). We pooled our results with all published cases identified in a 
systematic review. 
Results: In our multicentre cohort, 25 patients (14.5%; 95% CI: 9.6%-20.7%) had TFNE. 
Positive and negative symptoms were equally common (52% vs. 48% respectively). The 
commonest neuroimaging features were: leukoaraiosis (84%); lobar ICH (76%); multiple 
lobar cerebral microbleeds (58%); and superficial cortical siderosis/convexity subarachnoid 
haemorrhage (54%). CAA patients with TFNE had a significantly higher prevalence of 
superficial cortical siderosis compared to those without TFNE (50% vs. 19%; p=0.001.). 
Over a median period of 14 months, 50% of TFNE patients had a symptomatic lobar ICH. 
The meta-analysis showed a risk of symptomatic ICH of 25.3% (95% CI: 16.3%-38.0%) at 8 
weeks, related neither to clinical features, nor previous symptomatic ICH. 
Conclusions: TFNE are common in CAA, and include both positive and negative 
neurological symptoms. TFNE are associated with superficial cortical siderosis and predict a 
high early risk of symptomatic ICH (which may be amenable to prevention). Blood-sensitive 
MRI sequences are important in the investigation of such episodes. 
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2.1 Introduction 
Sporadic cerebral amyloid angiopathy (CAA) is a common age-related cerebral small vessel 
disease characterised by the progressive deposition of amyloid-β in the wall of cortical and 
leptomeningeal small arteries.28 CAA is a common cause of spontaneous lobar intracerebral 
haemorrhage (ICH) and cognitive impairment in the elderly.28 
Another characteristic clinical presentation associated with CAA is with transient 
focal neurologic episodes (TFNE), sometimes termed “amyloid spells”.167-169 Most published 
cases describe recurrent, stereotyped, spreading paraesthesias, usually lasting several 
minutes.167, 168 The recognition of these episodes is of clinical importance because: (a) they 
may have diagnostic value as the most common clinical presentation of CAA other than 
ICH; and (b) they may precede symptomatic ICH,237 a risk which could be reduced, for 
example by avoiding antithrombotic use following misdiagnosis of such an episode as a 
typical transient ischaemic attack (TIA). The available evidence on TFNE associated with 
CAA consists only of case reports and small case-series (<10 patients),167, 168, 170, 171, 194 
which may be subject to publication bias, limiting their generalizability. 
In the present study our aims were to determine the prevalence, clinical features, 
neuroimaging correlates and future ICH risk associated with CAA-related TFNE, using data 
from a multicentre CAA cohort. We hypothesised that TFNE are common in CAA and 
that they signify a high risk of future symptomatic ICH. We pooled our results with all 
previously published studies identified in a systematic review. 
2.2 Methods 
2.2.1 Participants 
We included patients diagnosed with CAA at four stroke centres in the United Kingdom 
and Belgium over defined time periods. The hospitals were: University College London 
Hospitals NHS Foundation Trust (London) (03/2003–09/2011), Addenbrooke’s Hospital 
(Cambridge) (07/2002–03/2010), Cliniques Universitaires Saint Luc (Brussels) (12/2003–
04/2010) and Université Catholique de Louvain (08/2005–03/2009). At all participating 
centres, MRI scanning is a routine investigation for all cases of suspected CAA, unless there 
are contra-indications. Our inclusion criteria were: (1) possible, probable or definite CAA, 
defined according to the Boston criteria;202 and (2) a clearly documented history of 
transient (≤24 hours), fully resolving, focal neurological episodes with no known alternative 
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explanation other than CAA (e.g. structural brain lesion, atrial fibrillation, extracranial or 
intracranial stenosis). We classified TFNE into two categories: (a) predominantly positive 
focal symptoms (“aura-like” spreading paraesthesias, positive visual phenomena or limb 
jerking); and (b) predominantly negative focal symptoms (“TIA-like” sudden-onset limb 
weakness, dysphasia, or visual loss). We excluded patients without an adequate medical 
history or imaging, those not meeting the criteria for CAA, and those with non-focal 
transient symptoms (e.g. generalized seizures, confusion, and disorientation). 
2.2.2 Data collection 
Cases were ascertained using multiple overlapping methods from prospective clinical 
databases and radiological reports; 172 patients with possible (n=54), probable (n=115), 
probable with supportive pathology (n=2) or definite (n=1) CAA were included. Two 
patients were excluded because of an alternative explanation of TFNE (one with significant 
carotid stenosis, one with sepsis), two because an adequate history was not available, and 
11 because episodes were not focal. 
Demographic and clinical information were collected using standardised data 
collection forms. Follow-up information on recurrent cerebrovascular events (including 
ICH) was obtained from prospective databases and medical records. 
2.2.3 Magnetic resonance imaging acquisition and analysis 
The MRI protocol was standardized in each hospital. Imaging was at 1.5T field strength for 
all patients and included T1-weighted, T2-weighted, fluid attenuated inversion recovery 
(FLAIR), and T2*-weighted gradient-recalled echo (T2*-GRE) sequences. For some patients 
susceptibility-weighted imaging (SWI) and diffusion-weighted imaging (DWI) were also 
available. All MRI scans were performed after the TFNE. MR images were reviewed blinded 
to clinical data. Haemorrhagic lesions, ischaemic lesions (chronic or acute) and white 
matter changes (leukoaraiosis) were recorded according to predefined standardized 
criteria. The presence and distribution of cerebral microbleeds (CMBs) were evaluated on 
T2*-GRE images using the Microbleed Anatomical Rating Scale.238 Prior symptomatic ICH 
was defined as a symptomatic stroke syndrome associated with imaging evidence of a 
corresponding ICH (>5 mm in diameter).198 Asymptomatic prior ICH (>5 mm in diameter) 
was also noted. Cortical subarachnoid haemorrhage (cSAH) was defined as linear 
hypointensity in the subarachnoid space affecting one or more cortical sulci of the cerebral 
convexities on T2*-GRE/SWI sequences with corresponding hyperintensity in the 
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subarachnoid space on T1-weighted and/or FLAIR images. Cortical superficial siderosis was 
defined as linear residues of blood products in the superficial layers of the cerebral cortex 
showing a characteristic “gyriform” pattern of low signal on T2*-GRE images without 
corresponding hyperintense signal on T1-weighted or FLAIR images. The distribution of 
superficial siderosis and cSAH was classified as either focal (restricted to ≤3 sulci) or 
disseminated (≥4 sulci).195 Leukoaraiosis was assessed with the four-step simplified Fazekas 
visual rating scale, from 0 to 3 (0=no lesions; 1=focal lesions; 2=early confluent; 
3=confluent).239 After MRI analysis, haemorrhagic lesions (ICH, microbleeds, cSAH and 
superficial cortical siderosis) or ischaemic lesions (chronic or acute) in the cerebral location 
corresponding to the clinical features of the TFNE were documented. For patients with a 
symptomatic ICH following their TFNE, we determined whether the location of the 
recurrent ICH corresponded to the likely anatomical origin of the preceding TFNE. 
2.2.4 Systematic review: Search strategy, selection criteria 
and data extraction 
We undertook a systematic review of all published cases of sporadic CAA with clearly 
documented TFNE and no known alternative explanation other than CAA. Articles 
published in full in any language were identified through a search of PubMed and Embase 
(January 1970 - October 2011) (Appendix A, Table 1). Reference lists from all included 
articles were also searched for relevant publications. We extracted and used individual 
patient data from each study where available (including follow-up data on ICH). 
2.2.5 Statistical analysis 
Survival analysis was used to examine the time to symptomatic ICH from the start of TFNE 
using Kaplan-Meier analysis. Cox proportional hazard analyses and log rank tests were used 
to compare the time to symptomatic ICH according to whether patients had experienced 
predominantly positive or negative symptoms. The proportional hazards assumption was 
tested, to ensure that there was no evidence of non-proportionality (P>0.2). Multivariable 
Cox proportional hazards analyses were performed after adjusting for gender and age. 
Other statistical tests were been used as indicated: continuous variables were compared 
using Student’s t-test (normally distributed) or Mann-Whitney U test (non-normally 
distributed) and categorical variables using Chi-squared tests or Fisher’s exact test. 
All statistical tests were two-sided. Analyses were performed using Stata 11.2 
(StataCorp LP, Texas). 
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We prepared this report according to STROBE guidelines for observational 
studies.240 
2.3 Results 
2.3.1 Multicentre cohort study 
In our multicentre cohort study we identified 172 patients with CAA; of these, 25 (definite 
CAA=1; probable CAA with supporting pathology=2; probable CAA=18; possible CAA=4) 
(14.5%; 95% CI: 9.6% to 20.7%) had a history of TFNE meeting the study inclusion criteria 
(Table 2.1). 
Thirteen patients (52%) had predominantly positive (“aura-like”) symptoms; 12 (48%) 
had predominantly negative (“TIA-like”) symptoms. The most common positive symptom 
was transient paraesthesias (with or without numbness), in eight patients (32%); a gradual 
spread to continuous body parts was described in five of these. The sensory symptoms 
affected the mouth or hand in all cases, and both regions in four cases. Four patients (16%) 
had limb-jerking episodes and four (16%) patients had episodes of visual disturbances 
involving monocular blurred vision, flickering or flashing lights, transient “zigzags” 
(teichopsia), or visual loss. Four (16%) patients had focal weakness and seven (28%) had 
dysphasia. Most participants (17/25; 68%) had multiple (≥2) stereotyped episodes. The 
episodes typically lasted less than 10 minutes and in 70% of the patients less than 30 
minutes. In seven patients (28%), antiplatelets or anticoagulants were started following 
TFNE. 
All except one patient (with pathologically proven CAA) had a brain MRI undertaken 
after the TFNE; the median time from the episodes to MRI was 7 days (interquartile range: 
6.5-30 days). Nineteen patients (76%) had evidence of lobar ICH: 9 patients (36%) had 
evidence of acute lobar ICH while 10 patients (40%) had evidence of chronic lobar ICH. 
Only one patient had a previous cortical infarct. Multiple strictly lobar CMBs were present 
in 14 patients (58%), cortical superficial siderosis or cSAH in 14 cases (58%). DWI was 
available in 17 patients (71%) and susceptibility-weighted imaging (SWI) in ten patients 
(42%). Among patients with DWI, seven (41%) were scanned within 2 weeks of the start of 
TFNE; acute ischaemia was noted in only one of these patients. 
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Table 2.1 Demographic, clinical and MRI characteristics of multicentre cohort. 
Characteristics 
Values 
(n=25) 
Clinical demographics  
Age, mean (95% CI:), years 69.7 (66.9 to 72.5) 
Sex, male (%) 14 (56) 
Hypertension (%) 13 (52) 
Smoking history (%) 3 (13) 
On antithrombotics at onset of TFNE(%) 8 (32) 
Previous symptomatic ICH (%) 8 (32) 
Clinical features of TFNE  
Predominantly positive symptoms (%) 13 (52) 
Predominantly negative symptoms (“TIA-like”) (%) 17 (68) 
Associated headache (%) 3 (12) 
Patients with >1 type of attack (%) 4 (16) 
Patients with multiple (≥2) episodes (%) 17 (68) 
Episodes’ duration  
<6 minutes (%) 11 (44) 
6-19 minutes (%) 5 (20) 
>20 minutes (%) 9 (36) 
MRI findings (n=24)  
Median time (days) from episodes to MRI 
(interquartile range) 
7 (6.5-30) 
Superficial cortical siderosis (%) 12 (50) 
    Focal (≤3 sulci) (%) 4 (17) 
    Disseminated (≥4 sulci) (%) 8 (33) 
cSAH (%) 4 (17) 
cSAH or superficial cortical siderosis (%) 14 (58) 
Acute ischaemic lesions 1 
Evidence of lobar ICH (%) 19 (76) 
    Acute lobar ICH evidence (%) 9 (36) 
    Chronic lobar ICH evidence (%) 10 (40) 
Multiple lobar cerebral microbleeds (≥2) (%) 14 (58) 
Leukoaraiosis: Fazekas category (%)                         0 
                                                                             1 
                                                                             2 
                                                                             3 
4 (16) 
9 (36) 
8 (32) 
4 (16) 
Antiplatelets/anticoagulants given after TFNE (%) 7 (28) 
   Aspirin 6 (24) 
    Aspirin + Clopidogrel 1 (4) 
Follow-up information (n=24)  
Median follow-up duration (interquartile range) 14 months (4-35 months) 
Occurrence of symptomatic ICH (%) 12 (50) 
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Figure 2.1 (A) Patient 7 had 
recurrent brief episodes of smoothly 
migrating tingling, starting in the 
fingers of the left hand: T2*-GRE MRI 
shows extensive superficial cortical 
siderosis in the right hemisphere and 
lobar cerebral microbleeds (CMBs). 
(B) Patient 2 had recurrent episodes 
of tingling in the right thumb, index 
and middle finger: T2*-GRE shows 
cortical superficial siderosis (arrows) 
and lobar CMBs (arrowheads). (C-D) 
Patient 12 had episodes of visual 
disturbances in the right hemifield: 
T2*-GRE shows superficial cortical 
siderosis in the parietal and occipital 
lobes. 
 
Figure 2.2 Patient 20 experienced 
two episodes of dysphasia and 
lightheadedness. (A) Diffusion-
weighted imaging one week after the 
first episode shows two small 
ischaemic lesions in the left parietal 
lobe and a lesion in the right 
cerebellar hemisphere (inset). (B) 
Susceptibility-weighted imaging 
indicates cortical superficial siderosis 
in the sulci very close the ischaemic 
lesions. (C) Cortical superficial 
siderosis extends to many sulci, 
especially in the left hemisphere 
(dotted arrows), associated with lobar 
microbleeds (arrowheads) [not visible 
on T2-weighted MRI (D)]. 
 
In 23 patients (92%; patients 1-4, 6-16 and 18-25) the clinical features of the TFNE 
could be anatomically correlated with haemorrhagic cortical or cortico-subcortical 
radiological lesions (Figure 2.1and Figure 2.2). Inter-ictal electroencephalography (EEG) was 
obtained in 5 patients (Patients 1, 8, 13, 17 and 25) and did not show any epileptiform 
features. 
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Pathological samples were available in three of the 25 patients (Patient 5, 17 and 18); 
haematoxylin and eosin staining and immunohistochemical detection of amyloid-β revealed 
moderate to severe CAA, without vasculitis. In patient 5, who presented with multiple, 
recurrent episodes of sudden numbness of the right hand, a biopsy of the left temporal lobe 
revealed multiple cortical micro-infarcts, Alzheimer-type pathology and severe CAA 
(without vasculitis). 
Follow-up data was available in all except one patient with TFNE over a median 
duration of 14 months (interquartile range 4 to 35 months), during which 12 of 24 patients 
(50%) had a symptomatic spontaneous lobar ICH; three had multiple consecutive ICHs. 
Only one patient had an acute ischaemic stroke. For seven patients with ICH occurring 
after TFNE (58%) the subsequent ICH was in a cortical area corresponding to the likely 
origin of their TFNE (based on the clinical presentation). Kaplan–Meier ICH analysis 
indicated that within two months of the TFNE 37.5% (95% CI: 21.6% to 59.7%) of the 
patients experienced a symptomatic ICH (Figure 2.3). Patients with a subsequent ICH did 
not differ from those without future ICH, either in clinical and imaging characteristics nor in 
antiplatelet or anticoagulant use (data not shown). 
Patients with and without TFNE were not significantly different in age, prevalence of 
vascular risk factors, antithrombotic use or previous history of symptomatic lobar ICH 
(Table 2.2). Among neuroimaging characteristics, the prevalence of superficial cortical 
siderosis was significantly higher in patients with TFNE compared to those without (50% vs. 
19%; p= 0.001). Disseminated cortical superficial siderosis (≥4 sulci) was more than twice 
as common in CAA patients with TFNE compared to those without (33% vs.14%; p=0.005). 
There were no significant differences in other neuroimaging findings (acute ischaemic 
lesions, leukoaraiosis, cSAH, presence of multiple lobar CMBs, presence of ICH, or CMB 
count) between patients with and without TFNE. 
2.3.2 Systematic review and meta-analysis 
We included 21 studies in the systematic review containing data on 68 patients with CAA-
related TFNE (Appendix A, Figure 1). Previously published studies had a significantly higher 
proportion of “aura-like” positive spreading sensory disturbances compared to our 
multicentre cohort (82% vs. 36%; p<0.0001) (Figure 2.4). Fifteen studies (six case series and 
nine case reports; n=43) had adequate follow-up data. This population was similar in age, 
gender and proportion of cases with a history of prior symptomatic ICH to our multicentre 
cohort.  
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Figure 2.3 Kaplan-Meier analyses for event-free rates of symptomatic intracerebral haemorrhage 
after transient focal neurological episodes (TFNE) in our multicentre cohort (n=24; A), all published 
studies (n=43, B), and combined (n=67; C). 
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Table 2.2 Characteristics of patients with cerebral amyloid angiopathy (CAA) and transient focal 
neurological episodes (TFNE) vs. CAA patients without TFNE. 
Characteristics 
CAA patients 
with TFNE 
(n=25) 
CAA patients 
without TFNE 
(n=147) 
P-value 
Age, mean (95% CI:), years 
69.7 
(66.9-72.5) 
73.1 
(71.4-74.9) 
0.08 
Sex, male (%) 14 (56) 73 (50) 0.558 
Hypertension (%) 13 (52) 92 (67) 0.145 
On antithrombotics (%) 8 (32) 41 (30) 0.801 
Previous symptomatic ICH (%) 8 (32) 54 (39) 0.532 
Superficial cortical siderosis (%) 12 (50) 24 (19) 0.001 
    Focal (≤3 sulci) (%) 4 (17) 10 (8) 0.187 
    Disseminated (≥4 sulci) (%) 8 (33) 14 (11) 0.005 
cSAH (%) 4 (17) 8 (7) 0.106 
cSAH or superficial cortical siderosis (%) 14 (58) 30 (25) 0.001 
Acute ischaemic lesions (%) 1 (6) 12 (11) 0.512 
Chronic lobar ICH evidence (%) 10 (40) 72 (53) 0.248 
Acute lobar ICH evidence (%) 9 (36) 65 (48) 0.250 
Multiple lobar CMBs (≥2) (%) 14 (58) 71 (56) 0.975 
Number of CMBs, median  
(IQR range) 
3 (0-16) 2.5 (0-8) 0.552 
Leukoaraiosis: Fazekas category (%)  
                                                      0 
                                                      1 
                                                      2 
                                                      3 
 
4 (16) 
9 (36) 
8 (32) 
4 (16) 
 
25 (19) 
43 (32) 
43 (32) 
22 (17) 
0.981 
A meta-analysis combining these 15 studies with our cohort showed a future risk of 
symptomatic ICH of 27.6% (95% CI: 18.3% to 40.2%) at two months (Figure 2.3). Patients 
with negative symptoms had a similar risk of future ICH to patients with positive symptoms 
(hazard ratio: 0.91; 95% CI: 0.40-2.08; p=0.83). There was a borderline significant lower risk 
of future ICH among patients with prior symptomatic ICH compared to those without 
(hazard ratio: 0.47; 95% CI: 0.22-1.01). 
2.4 Discussion 
In our multicentre cohort study we found TFNE in 14% of patients with CAA. Our study 
confirms previous reports that CAA-related TFNE are mostly recurrent, stereotyped and 
brief (usually >30 minutes).167, 168 However, unlike published studies, in which “aura-like” 
sensory episodes seem to be most frequent, in our cohort, negative symptoms were just as 
common. This difference might reflect previous publication bias in favour of CAA cases 
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with spreading sensory phenomena not typical of TIAs. All episodes of aura-like sensory 
symptoms in our cohort (n=8) involved the face or hand; three involved the corner of the 
mouth and the hand consistent with a cortical cheiro-oral syndrome. In two of these, 
cortical siderosis/cSAH were present over the frontal or parietal lobes, whilst the third 
case had multiple lobar CMBs. Although the numbers of cases was small, the cheiro-oral 
syndrome may be rather characteristic of CAA-related TFNE. 
The clinical features of the episodes indicate a cortical rather than a subcortical 
origin; moreover, they were often correlated anatomically with haemorrhagic MRI lesions, 
including CMBs, superficial cortical siderosis and lobar ICH. Thus, TFNE are probably 
related to the haemorrhagic rather than the ischaemic components of CAA: possible 
mechanisms include focal seizure-like activity or migraine aura-like cortical spreading 
depression, as suggested by previously published small case series.167, 168, 241 Twenty three 
patients in our cohort had haemorrhagic imaging findings in a neuroanatomical location 
corresponding to their TFNE symptoms; eight had superficial cortical siderosis, reflecting 
previous episodes of acute bleeding in the subarachnoid space of adjacent cortical sulci. 
Three other recent case series have also emphasized the possible role of non-traumatic 
cSAH in CAA-related TFNE.171, 191, 194 Our finding that superficial cortical siderosis was 
significantly more common in CAA patients with TFNE than those without (p=0.001) 
provides strong evidence that this pattern of bleeding is likely to be an important cause of 
TFNE. 
 
Figure 2.4 The prevalence of different types of transient focal neurological symptoms in published 
cases (n=54) and in our multicentre cohort of CAA patients. Percentages were compared using 
Pearson Chi-squared tests. (Percentages do not add up to 100 as some patients experienced multiple 
episode types). 
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Nevertheless, a role for ischaemic lesions in CAA-related TFNE cannot be ruled out 
by our study: small (apparently asymptomatic) ischaemic lesions have been detected in vivo 
in clinically probable CAA,73 and “microinfarcts” are a frequent neuropathological finding in 
the brains of patients with CAA.28 Since not all cases in our study had DWI soon after the 
onset of TFNE, we may have underestimated the contribution from small acute ischaemic 
lesions. 
We report a strikingly high early risk of symptomatic lobar ICH (37.5% at two 
months) following CAA-related TFNE, which we confirmed in a meta-analysis of our data 
with all published studies. We found only a borderline difference in the risk of ICH among 
patients with previous symptomatic ICH compared to those without, suggesting that TFNE, 
rather than simply the presence of CAA with previous symptomatic ICH (with a known 
recurrent ICH risk of up to about 10% per year28, 37), are an independent  marker of high 
early future ICH risk. TFNE in CAA may thus be a clinical marker for cerebral areas of 
focally-active and severe CAA pathology, with more vascular leakage leading to an 
increased risk of future ICH. This is supported by our finding of a significantly higher 
prevalence of superficial cortical siderosis in CAA patients with TFNE, since superficial 
siderosis is hypothesized to result from recurrent bleeding into the subarachnoid space, 
leading to subpial accumulation of blood-breakdown products. However, the role of 
superficial siderosis as a prognostic imaging marker of increased ICH risk in CAA requires 
further study. 
Although in 58% of patients with ICH following TFNE the new haematoma was 
located in a cortical area corresponding to the likely origin of their TFNE (based on the 
clinical presentation), further work is also needed to establish whether this apparent 
clustering of ICH in brain regions implicated by TFNE symptoms is greater than predicted 
by chance. 
Our study has several potential limitations. We may have underestimated the true 
prevalence of CAA-related TFNE because of the retrospective study design; further large 
prospective studies with systematic enquiry about previous TFNE are needed. Some of our 
CAA cohort may have been misdiagnosed due to the imperfect specificity of the Boston 
criteria (particularly the “possible CAA” category).202 MRI was performed at different times 
from TFNE onset; this, combined with the lack of availability of acute DWI sequences in all 
cases may have influenced the detection of haemorrhagic over ischaemic lesions. We also 
acknowledge the potential for referral, selection and publication bias in the cases identified 
in the systematic review. Our multicentre cohort results might not be generalizable to all 
CAA patients, but only to those presenting to vascular neurology services in whom other 
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possible causes of transient focal neurological symptoms have been excluded. Although this 
study includes the largest number of CAA-related TFNE cases to date, we did not have 
sufficient statistical power to definitively determine potential predictors for ICH. 
We have shown that TFNE are common in CAA and signify a very high early future 
risk of ICH. Hence, their diagnosis has important clinical implications. Our findings clearly 
suggest a key role for T2*-GRE MRI (or other blood-sensitive sequences) in the 
investigation of patients with unexplained TFNE-especially in individuals without known risk 
factors for TIA. The very high early risk of lobar ICH following TFNE in CAA may be an 
opportunity to commence preventive strategies: we suggest clinicians should discontinue 
and avoid giving antiplatelets or anticoagulants in cases of TFNE with imaging evidence of 
CAA, even if the episodes seem clinically likely to be ischaemic. Since TFNE were observed 
in patients without a previous history of symptomatic ICH, they may also prove to be a 
useful diagnostic marker of CAA, potentially allowing diagnosis earlier in its disease 
course.28 
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ABSTRACT 
Objective: We investigated the prevalence and clinical-radiological associations of cortical 
superficial siderosis (cSS) in patients with probable cerebral amyloid angiopathy (CAA) 
compared to those with intracerebral haemorrhage (ICH) not attributed to CAA. 
Methods: Retrospective multicentre cohort study of 120 patients with probable CAA and 
two comparison groups: 67 patients with either single lobar ICH or mixed (deep and lobar) 
haemorrhages; and 22 patients with strictly deep haemorrhages. We rated cSS, ICH, white 
matter changes (WMC) and cerebral microbleeds (CMBs). 
Results: cSS was detected in 48/120 (40%; 95%CI: 31.2%-49.3%) patients with probable 
CAA, 10/67 (14.9%; 95%CI: 7.4-25.7%) with single lobar ICH or mixed haemorrhages, and 
1/22 (4.6%; 95%CI: 0.1%-22.8%) patients with strictly deep haemorrhages (p<0.001 for 
trend). Disseminated cSS was present in 29/120 (24%: 95%CI: 16.8-32.8%) probable CAA 
patients, but none of the other ICH patients (p<0.001). In probable CAA, age (OR: 1.09; 
95%CI: 1.03-1.15; p=0.002), chronic lobar ICH (OR: 3.94, 95%CI: 1.54-10.08; p=0.004) and 
transient focal neurological episodes (OR: 11.08; 95%CI: 3.49-35.19; p<0.001) were 
independently associated with cSS. However, cSS occurred in 17 of 48 probable CAA 
patients (35.4%, 95%CI: 22.2-50.5%) without chronic ICH. 
Conclusions: cSS (particularly if disseminated) is a common and characteristic feature of 
CAA. Chronic lobar ICH is an independent risk factor for cSS, but the causal direction and 
mechanism of association is uncertain. Haemorrhage into the subarachnoid space, 
independent of previous (chronic) lobar ICH, must also contribute to cSS in CAA. 
Transient focal neurological episodes are the strongest clinical marker of cSS. 
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3.1 Introduction 
Sporadic cerebral amyloid angiopathy (CAA) is a common age-related small vessel disease 
due to progressive deposition of amyloid–β in the walls of small arteries, arterioles and 
capillaries in the cerebral cortex and overlying leptomeninges.28 CAA is most often 
recognised in life by symptomatic, lobar intracerebral haemorrhage (ICH) in elderly 
patients.28, 37, 242 CAA is also associated with characteristic magnetic resonance imaging 
(MRI) findings including lobar cerebral microbleeds (CMBs) and white matter 
hyperintensities (leukoaraiosis).28, 35 
Recent studies have identified cortical superficial siderosis (cSS) as another 
manifestation of CAA.171, 191, 194, 195 In CAA, cSS has a characteristic predilection for the 
cerebral convexities, reflecting linear blood residues in the superficial layers of the cerebral 
cortex or in the subarachnoid space.190, 195, 243 cSS may have clinical relevance as an 
important cause of transient focal neurological episodes (sometimes called “amyloid 
spells”),244, 245 and potential “warning sign” for future symptomatic ICH.246 
Although cSS is a promising diagnostic neuroimaging marker of CAA,8 the strength of 
the association and underlying mechanisms have not been systematically studied. In the 
present study we therefore sought to determine the prevalence and extent of cSS in a 
European multicentre cohort of patients with clinical-radiological probable CAA, and 
investigate its associations with other imaging findings including CMBs, white matter 
changes and ICH. We hypothesized that cSS: (1) is common in subjects with probable CAA, 
and more prevalent compared to comparison subjects with other spontaneous ICH not 
attributed to probable CAA; and (2) is associated with other hemorrhagic manifestations of 
CAA (lobar ICH and lobar CMBs). 
3.2 Methods 
3.2.1 Study population 
We included consecutive patients diagnosed with probable CAA (according to the original 
Boston criteria202 – i.e. not including cSS as a criterion, see below) at four stroke centres 
over defined time periods (Appendix B Figure 1). At participating centres, MRI scanning is a 
routine investigation for cases of suspected CAA, unless there are contra-indications. 
Essential inclusion criteria for the main CAA case group were: (1) probable or 
pathologically verified CAA, defined according to the Boston criteria202 – including lobar 
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CMBs, but not cSS; and (2) available MRI sequences of adequate quality including T2*-
weighted gradient-recalled echo (T2*-GRE) and FLAIR MRI sequences. Cases defined as 
possible CAA according to the Boston criteria202 (i.e. single lobar ICH without lobar 
microbleeds), were included in one of the comparison groups (see next paragraph). 
As comparison groups we included patients with other symptomatic, spontaneous ICH 
not fulfilling the Boston criteria for probable CAA, seen in the four stroke centres over the 
same time period, with available MRI scans of adequate quality including T2*-GRE and 
FLAIR sequences. Cases were systematically and consecutively ascertained using multiple 
overlapping methods from prospective clinical and radiological databases. The two non-
CAA comparison groups were as follows: (a) single lobar ICH (without any CMBs) and 
mixed (deep and lobar) haemorrhages (including any combination of ICH or CMBs) which 
we subsequently refer to as “single lobar ICH and mixed haemorrhages”; and (b) strictly 
deep haemorrhages (including ICH and CMBs in the basal ganglia and brainstem). 
In total, 149 subjects were excluded from our study because MRI scans were 
unavailable (Appendix B Figure 1); those excluded were not significantly different from 
those included in gender, age or measures of stroke severity (all p values>0.10). 
3.2.2 Standard Protocol Approvals, Registrations, and Patient 
Consents 
The study received ethical approval by the National Hospital for Neurology and 
Neurosurgery and Institute of Neurology Joint Research Ethics Committee, the 
Commission d’Ethique Biomedicale Hospitalo Facultaire of the Faculte de Medicine 
(Universite Catholique de Louvain), and the Comite d’ethique medicale of the CHU Mont 
Godinne UCL. 
3.2.3 Data collection 
Demographic and clinical information was obtained from prospective databases and by 
medical records review using standardised data collection forms. Hypertension was defined 
as a history of hypertension, taking antihypertensive treatment or documented elevated 
blood pressure (systolic >150 or diastolic >95mmHg) before admission, diabetes as ongoing 
use of a hypoglycaemic agent and smoking as history of tobacco use before admission. In 
patients with probable CAA, a clearly documented history of transient (≤24 hours), fully 
resolving, focal neurological episodes with no known alternative explanation other than 
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CAA (e.g. structural brain lesion, atrial fibrillation, extracranial or intracranial stenosis) was 
ascertained by review of medical records. 
3.2.4 Magnetic resonance imaging acquisition and analysis 
The MRI protocol was similar in each hospital. Imaging was at 1.5T field strength for all 
patients and included T1-weighted, T2-weighted, fluid attenuated inversion recovery 
(FLAIR), T2*-GRE (slice thickness 5 mm, repetition time 500–1,000 ms, echo time 
40/26/15/50-70 ms) and diffusion-weighted imaging (DWI) sequences. Images were 
reviewed blinded to clinical data. Hemorrhagic lesions,35, 195, 198, 238 ischaemic lesions 
(chronic or acute)73 and white matter hyperintensities (leukoaraiosis)239 were recorded 
according to predefined standardized criteria. CMBs were evaluated on T2*-GRE images.35, 
238 Prior symptomatic ICH was defined as a symptomatic stroke syndrome associated with 
imaging evidence of a corresponding “macro” ICH (>5 mm in diameter on T2*-GRE).198 
Asymptomatic prior ICH (>5 mm in diameter on T2*-GRE MRI) was also noted: chronic 
ICH was defined on neuroimaging as ICH with no acute bleeding identified on either CT or 
MRI scans. Acute convexity subarachnoid haemorrhage (cSAH) was defined as linear 
hypointensity in the subarachnoid space affecting one or more cortical sulci of the cerebral 
convexities on T2*-GRE sequences with corresponding hyperintensity in the subarachnoid 
space on T1-weighted or FLAIR images. cSS was defined as linear residues of chronic blood 
products in the superficial layers of the cerebral cortex showing a characteristic “gyriform” 
pattern of low signal on T2*-GRE images, without corresponding hyperintense signal on T1-
weighted or FLAIR images. We did not include cSS if it was contiguous with any ICH. The 
distribution of cSS and acute cSAH was classified as focal (restricted to ≤3 sulci) or 
disseminated (≥4 sulci).195 We also noted whether cSS was contralateral or ipsilateral to 
any chronic ICH. Using a sample of MRI scans from probable CAA patients (n=48) and 
control non-CAA cases (n=27), the inter-rater agreement for the presence or absent of 
cSS was 93.3% (Cohen’s kappa=0.85) and for cSS categories was 95.1% (weighted Cohen’s 
kappa=0.86). White matter hyperintensities (leukoaraiosis) were assessed with the four-
step simplified Fazekas rating scale, from 0 to 3 (0=no lesions; 1=focal lesions; 2=early 
confluent; 3=confluent).239 
3.2.5 Statistical analysis 
We compared demographic, clinical and imaging characteristics of probable CAA patients 
with versus without cSS. Both binary and ordinal logistic regression analysis was used to 
identify predictors of cSS (cSS presence and cSS extent respectively). Multivariable analysis 
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was adjusted for age, lobar CMBs (used as a categorical variable: 0, 1, 2-4, and >4 CMBs), 
presence of chronic lobar ICH and history of transient focal neurological episodes, based 
on the results of univariable analysis, plus other biologically plausible confounders. As a 
sensitivity analysis we repeated these analyses with the addition of hypertension in our 
multivariable regression models. Because the results of binary and ordinal logistic 
regression analysis were consistent, we present only the results of binary logistic regression 
analysis. A P-value ≤0.05 was considered to be statistically significant. Data was missing in 
less than 5% of participants; these cases were excluded from univariable and multivariable 
analyses that included a missing variable of interest. For the main multivariable model 
presented, there were no missing data. All statistical analyses were carried out using 
STATA (Version 11.2, StataCorp.). 
3.3 Results 
The final cohort consisted of 209 patients: 120 patients with probable CAA (9 with 
supportive pathology) based on the Boston criteria and 89 patients with other ICH not 
fulfilling the Boston criteria for probable CAA, forming two comparison groups: 67 patients 
with a single lobar ICH or mixed (lobar and deep) haemorrhages; and 22 patients with 
strictly deep haemorrhages (Table 3.1). 
Table 3.1 Characteristics of patients with probable cerebral amyloid angiopathy (CAA) and our 
comparison patients groups with spontaneous symptomatic ICH not fulfilling the Boston criteria for 
probable CAA: “single lobar ICH and mixed haemorrhages” and “strictly deep haemorrhages”. 
Characteristics 
Probable CAA 
(n=120) 
Comparison groups not fulfilling criteria 
for probable CAA 
Single lobar 
ICH/mixed deep 
and lobar 
haemorrhages 
(n=67) 
Strictly deep 
haemorrhages 
(n=22) 
Age, mean (95% CI:), years 71.8 (70-73.5) 72.6 (61.3-75.3) 61.2 (58.5-71.8) 
Sex, male (%) 67 (55.8) 35 (52.3) 15 (68.2) 
Hypertension (%) 72 (64.3) 48 (71.6) 21 (99.5) 
On antithrombotics (%) 25 (22.1) 24 (35.8) 7 (31.8) 
Any symptomatic ICH (%) 104 (86.7)* 67 (100) 22 (100) 
cSS (%) 48 (40) 10 (14.9) 1 (4.6) 
   Focal, ≤3 sulci (%) 19 (15.8) 10 (14.9) 1 (4.6) 
   Disseminated, ≥4 sulci (%) 29 (24.2) 0 (0) 0 (0) 
Acute cSAH (%) 15 (12.5) 3 (4) 0 (0) 
* One hundred-four of the probable CAA patients were admitted for spontaneous lobar ICH, 8 with transient focal 
neurological episodes, 2 due to cognitive decline, 2 with acute convexity subarachnoid haemorrhage and 2 because of an 
ischaemic stroke. 
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cSS was detected in 48 out of 120 (40%; 95%CI: 31.2%-49.3%) patients with probable 
CAA, compared to 10/67 (14.9%; 95%CI: 7.4-25.7%) of the patients with a single lobar ICH 
or mixed (lobar and deep) haemorrhages, and only 1/22 (4.6%) patients with strictly deep 
haemorrhages (p<0.001 for trend) (Table 3.1). Within the single lobar ICH or mixed 
haemorrhage group, cSS was found in 2/33 (6.1%) of patients with single lobar ICH and no 
CMBs, 2/11 (18%) of patients with lobar ICH and deep or mixed CMBs, and 3/17 (18%) of 
patients with deep ICH and lobar or mixed CMBs (see Appendix B Table 1 for the 
frequency of cSS in detailed patient subgroups). Disseminated cSS was observed in 29/120 
of probable CAA patients (24.2%; 95% CI 16.8-32.8) but in none of the other 89 patients 
not fulfilling the original Boston criteria for probable CAA (p<0.001). In patients with single 
lobar ICH or mixed haemorrhages, cSS (10/67) was always focal; of these 10 patients with 
cSS, 7 (70%) had lobar CMBs (Appendix B Table 2). 
Table 3.2 Characteristics and comparison of CAA patients with and without superficial cortical 
siderosis. P-values refer to differences between CAA patients with vs. without cortical superficial 
siderosis (cSS), using chi-square tests and the Fisher’s exact test for categorical variables, and two-
sample t-tests or Mann-Whitney U-tests depending on the distribution of continuous variables. 
Characteristics 
All probable 
CAA (n=120) 
cSS (+) 
(n=48) 
cSS (-) 
(n=72) 
p-value 
Age, mean (95% CI:), years 71.8 (70-73.5) 74.8 (72.3-77.3) 69.7 (67.4-72.1) 0.005 
Sex, male (%) 67 (55.8) 25 (52.1) 42 (58.3) 0.499 
Hypertension (%)* 72 (64.3) 20 (46.5) 52 (75.4) 0.002 
On antithrombotics (%)* 25 (22.1) 9 (20.9) 16 (22.9) 0.811 
History of prior ICH (%)* 46 (40.7) 18 (41.9) 28 (40) 0.845 
History of TFNE (%) 26 (21.7) 19 (39.6) 7 (9.7) <0.001 
Chronic lobar ICH (%) 61 (51.3) 31 (64.6) 30 (42.3.) 0.017 
Acute lobar ICH (%) 57 (48.3) 26 (54.2) 31 (44.3) 0.291 
Acute ischaemic lesions (%) 20 (18.7) 10 (23.3) 10 (15.6) 0.321 
Number of CMBs, median  
(IQR range) 
4 (2-13.5) 4.5 (1-10.5) 4 (2-15.5) 0.147 
Lobar CMBs     
0 (%) 13 (10.8) 9 (18.8) 4 (5.6)  
1 (%) 16 (13.3) 7 (14.6) 9 (12.5)  
2-4 (%) 34 (28.3) 8 (16.7) 26 (36.1)  
≥5 (%) 57 (47.5) 24 (50) 33 (45.8)  
Acute cSAH (%) 15 (12.5) 9 (18.8) 6 (8.3) 0.091 
Moderate-severe leukoaraiosis (%) 63 (53.4) 22 (46.8) 41 (57.6) 0.244 
† p-value for trend; *There were 10 patients with missing data for one or more of these variables: Hypertension 
(n=9), On antithrombotics (n=8), History of prior symptomatic ICH (n=7). 
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Thirty-one of the 48 probable CAA patients with cSS had chronic lobar ICH; the cSS 
was contralateral to the ICH or bilateral in 24 of these patients (87.4%) and restricted to 
the hemisphere ipsilateral to chronic lobar ICH in only 7 patients (22.6%) (i.e. in most 
cases, cSS was present distant from any chronic lobar ICH). In 17 of the 48 probable CAA 
patients with cSS (35%) there was no evidence of chronic lobar ICH. Representative 
examples of cSS are shown in Figure 3.1. 
Within the probable CAA group, patients with cSS were older and less often 
hypertensive compared to patients without cSS (Table 3.2). Patients with cSS more often 
had a history of transient focal neurological episodes and chronic lobar ICH on MRI than 
patients without cSS. However, we found no association between the presence of cSS and 
acute lobar ICH, lobar CMBs or white matter hyperintensity severity. 
 
Figure 3.1 T2*-GRE and 
FLAIR MRI of two patients 
with probable cerebral 
amyloid angiopathy and a 
patient with mixed deep and 
lobar haemorrhages. (A) A 
patient with probable CAA 
and an acute right frontal 
intracerebral haemorrhage 
(ICH) and multifocal cortical 
superficial siderosis (cSS) in 
the left hemisphere. Multiple 
lobar cerebral microbleeds 
(CMBs) are also present, 
sometimes close to cSS. (B) 
A patient with probable 
CAA with focal, bilateral cSS 
and lobar CMBs, in whom no 
ICHs were present. (C) A 
patient with a mixed pattern 
of bleeds (ICH and CMBs) 
not fulfilling the Boston 
criteria for CAA: note the 
focal cSS in left occipital lobe 
and the lobar CMBs in close 
vicinity to cSS. 
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Table 3.3 Multivariate regression analysis showing the factors associated with cortical superficial 
siderosis in patients with probable cerebral amyloid angiopathy. The model remains consistent when 
history of hypertension and acute cSAH (%) are included. 
 OR (95%CI) P-Value 
Age (years) 1.09 (1.03-1.15) 0.002 
Lobar CMBs 
(for each category increase) 
0.77 (0.50-1.21) 0.260 
Chronic lobar ICH 3.94 (1.54-10.08) 0.004 
History of transient focal 
neurological episodes 
11.08 (3.49-35.19) <0.001 
In univariable logistic regression analysis, factors associated with cSS were age, 
history of transient focal neurological episodes and chronic lobar ICH (Appendix B Table 
3). Hypertension showed a negative association with cSS. In multivariable logistic regression 
analysis, age, presence of chronic lobar ICH and history of transient focal neurological 
episodes (were independently associated with cSS, after adjusting for lobar CMBs (Table 
3.3). These results remained consistent after additional adjustment for hypertension and 
acute cSAH (data not shown). The results of cSS predictors in ordinal logistic regression 
(i.e. predictors of cSS extent: no cSS vs. focal vs. disseminated) were consistent and of 
similar effect size. 
3.4 Discussion 
To our knowledge, this multicentre retrospective study is the first systematic survey of the 
prevalence and clinical-radiological associations of cSS in patients with probable sporadic 
CAA (diagnosed by the original Boston criteria) compared to those with ICH not fulfilling 
these criteria. A previous study investigated the presence of cSS in patients diagnosed with 
CAA on histopathology:195 cSS was detected in 60.5% of patients with histopathologically-
proven CAA (n=38; mean age 70 years), compared with none of the controls with 
histopathologically proven non-CAA ICH (n=22; mean age 54 years).195 The authors 
suggested that cSS might be helpful for the clinical diagnosis of CAA.195 cSS has also been 
found in patients with hereditary cerebral haemorrhage with amyloidosis–Dutch type, a 
distinct genetic type of CAA, and always in the direct vicinity of a lobar ICH or a CMB.203 
Our findings strengthen the hypothesis that cSS (especially if disseminated) is a 
characteristic neuroimaging marker for CAA. We noted cSS in 40% of probable CAA 
patients, disseminated cSS only in patients with probable CAA, and found that cSS is much 
rarer (prevalence less than 5%) in patients with a “strictly deep” pattern of ICH than in 
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probable CAA. We also detected cSS in 15% of patients with a single lobar ICH or mixed 
(lobar and deep) haemorrhages; however, in most of these mixed patients, lobar CMBs 
were also present, suggesting that they might in fact harbour some degree of CAA 
pathology. 
Among patients with a single lobar ICH and no CMBs (i.e. “possible CAA” according 
to the original Boston criteria202) the prevalence of cSS was also very low (6%). In a 
validation of these criteria, 16 of 26 patients (62%) classified as possible CAA had 
pathologically-confirmed CAA,202 but only 11 of the pathologically diagnosed patients had 
T2*-GRE imaging, limiting the generalizability of the findings to current cohorts (including 
our study), in which such imaging is now routine. In another validation study of the Boston 
criteria, using T2*-weighted gradient echo MRI in a hereditary Dutch-type CAA population, 
all patients with lobar ICH also had CMBs.203 Our data suggest that further pathological 
correlation is required to determine the prevalence of pathologically-confirmed CAA in 
patients with a single lobar ICH (and no CMBs or cSS) on appropriate blood-sensitive MRI 
sequences. Further studies with histopathological confirmation or in vivo amyloid imaging176 
will also help to determine whether cSS is a useful diagnostic feature of CAA in patients 
with mixed patterns of haemorrhage.  
In the healthy population-based Rotterdam Scan Study cSS was found in 0.7% (7/1062) 
of elderly individuals (mean age 69.6 years), all of whom had lobar CMBs (6 had strictly 
lobar CMBs, 5 of whom had multiple CMBs), in close vicinity to the cSS.243 In agreement 
with our findings, the mean age of persons with cSS was higher than those without cSS 
(mean age 79.9 vs. 69.6 years; p<0.001), and also compared to persons who had CMBs but 
no cSS (mean age 71.8 years).243 Since the severity of CAA is age-related,28, 37 these finding, 
together with our data showing an association of cSS with chronic ICH, suggest that cSS 
might be a marker of more advanced CAA, but this also requires pathological confirmation, 
with standardized grading of CAA severity. 
Experimental studies confirm that repeated bleeding into the subarachnoid space leads 
to subpial haemosiderin deposition.247 There are thus at least two possible 
pathophysiological mechanisms which could lead to cSS deposition in CAA: (a) repeated 
episodes of haemorrhage from brittle superficial cortical or leptomeningeal CAA-affected 
vessels into the subarachnoid space (independent of lobar ICH); and (b) leakage from a 
previous lobar ICH (or superficial lobar CMBs) into the subarachnoid space. Our 
observation of cSS in 17 patients without chronic lobar ICH, and even in those with chronic 
lobar ICH mostly distant from the ICH (in nearly 90% of cases in the contralateral 
hemisphere or bilaterally), favours a contribution from direct haemorrhage into the 
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subarachnoid space, independent of lobar ICH. This implies that cSS may arise 
independently of known characteristic imaging features of CAA (lobar ICH and CMBs), 
supporting its role as an independent diagnostic marker; further studies are needed to 
confirm the value of cSS in improving the sensitivity of in vivo CAA diagnosis.  
Perhaps surprisingly, we did not find any association between lobar CMBs and cSS, 
which may reflect selection bias towards generally advanced disease with high lobar CMBs 
prevalence in our cohort. Nevertheless in some cases cSS was observed close to one or 
more lobar CMBs (see example in Figure 2), suggesting that leakage from very superficial 
CMBs may also be a mechanism of cSS. 
Another interpretation of the association between cSS and lobar ICH is that cSS 
precedes lobar ICH. Although our cross-sectional data cannot confirm this hypothesis, some 
recent data support this explanation. A retrospective study of 51 patients with cSS and due 
to possible or probable CAA found that after a median 35.3 months follow-up, 47.1% of the 
patients had new radiological ICH or cSAH, often at the site of pre-existing siderosis,246 
providing preliminary evidence that cSS heralds a high risk of future ICH. A small 
neuropathological series of six autopsy cases of subcortical haematoma caused by CAA 
showed that at least in some cases the primary haemorrhage appeared to originate from 
the subarachnoid space.248 Further prospective studies are urgently required to determine 
the risk of future intracranial bleeding associated with cSS in CAA. 
Our study confirms a strong independent association of cSS with transient focal 
neurological episodes (sometimes called “amyloid spells”249), which are increasingly 
recognized in CAA and can resemble transient ischaemic attacks, migraine auras or focal 
seizures.167, 244, 249 Such attacks could plausibly be caused by disruption of cortical function 
due to cSS, for example by superficial cortical haemosiderin deposition inducing focal 
seizures or cortical spreading depression.244, 249-251 CAA-related transient focal neurological 
episodes are associated with a high early risk of symptomatic lobar ICH (24.5% [95% CI: 
15.8%–36.9%] at 8 weeks);244 cSS may be one mechanism underpinning this increased 
clinical risk, reflecting focally active CAA near the cortical surface.252 
Our study has several strengths including the systematic evaluation of MRI scans by 
trained raters using validated scales for a range of imaging markers of small vessel disease. A 
limitation is the lack of pathological confirmation of the CAA pathology. In view of the 
imperfect specificity of the Boston criteria, especially for the “possible CAA” category,202 
we focussed on patients fulfilling the criteria for probable CAA, for which the specificity is 
between 82-100%.202, 203 Limitations of our study include the retrospective design, the 
variation in inception point of the disease at inclusion, and the potential of bias in our 
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sample as MRIs were done as part of routine clinical care, tending to exclude more severe 
cases of CAA and ICH. 
Our study indicates that cSS (particularly if disseminated) is a characteristic 
neuroimaging feature of CAA. Chronic lobar ICH is an independent risk factor for cSS, but 
the causal direction and mechanism of the association is uncertain: although leakage from 
previous lobar ICH into the subarachnoid space may lead to cSS, it is also possible that cSS 
heralds an increased risk of future lobar ICH. Further prospective studies are needed to 
clarify how cSS relates to future ICH risk, which may have important clinical relevance, for 
example regarding antithrombotic treatment. Our results also show that haemorrhage into 
the subarachnoid space, independent of lobar ICH, must also contribute to cSS in CAA, 
suggesting that cSS should be considered an additional neuroimaging marker of CAA-
related haemorrhage. 
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Chapter 4 Cortical superficial siderosis and 
intracerebral haemorrhage risk in patients 
with sporadic cerebral amyloid angiopathy: 
multicentre MRI cohort study 
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ABSTRACT 
Objective: To investigate whether cortical superficial siderosis (cSS) on MRI, especially if 
disseminated (involving more than 3 sulci), increases the risk of future symptomatic lobar 
intracerebral haemorrhage (ICH) in cerebral amyloid angiopathy (CAA). 
Methods: European multicentre cohort study of 118 CAA patients (104 with baseline 
symptomatic lobar ICH) diagnosed according to the Boston criteria. We obtained baseline 
clinical, MRI and follow-up data on symptomatic lobar ICH. Using Kaplan-Meier and Cox 
regression analyses, we investigated cSS and ICH risk, adjusting for known confounders. 
Results: During a median follow-up time of 24 months (interquartile range 9–44 months), 
23/118 (19.5%, 95%CI: 12.8-27.8) patients experienced symptomatic lobar ICH. Any cSS, 
and disseminated cSS were predictors of time until first or recurrent ICH (log-rank test: 
p=0.0045 and p=0.0009 respectively). ICH risk was 25% (95%CI: 7.6-28.3%) for patients 
without siderosis; 28.9% (95%CI: 7.7-76.7%) for patients with focal siderosis; and 74% 
(95%CI: 44.1-95.7) for patients with disseminated cSS (log-rank test: p=0.0031). In Cox 
regression models, any cSS and disseminated cSS were both independently associated with 
increased lobar ICH risk, after adjusting for ≥2 microbleeds and age (HR: 2.53; 95%CI: 1.05-
6.15; p=0.040 and HR: 3.16; 95%CI: 1.35-7.43; p=0.008, respectively). These results 
remained consistent in sensitivity analyses including only patients with symptomatic lobar 
ICH at baseline. 
Conclusions: Our findings indicate that cSS, particularly if disseminated, is associated with 
an increased risk of symptomatic lobar ICH in CAA. cSS may help stratify future bleeding 
risk in CAA, with implications for prognosis and treatment. 
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4.1 Introduction 
Sporadic cerebral amyloid angiopathy (CAA) is a highly prevalent age-related small vessel 
disease61 caused by amyloid–β deposition in cortical and leptomeningeal vessel walls.28 CAA 
is a major cause of lobar intracerebral haemorrhage (ICH), particularly in elderly patients.28, 
33, 37, 242 Spontaneous ICH is one of the most catastrophic forms of stroke, with a high risk 
of recurrence;220, 253, 254 CAA-related lobar ICH may carry a greater risk than deep ICH 
presumed due to hypertensive arteriopathy,254, 255 but this is currently difficult to predict. 
Predisposing factors for lobar ICH and lobar ICH recurrence in CAA include: APOE 
ε4 and ε2 alleles;87 hemorrhagic neuroimaging markers of CAA such as lobar cerebral 
microbleeds (CMBs);180 and anticoagulant or antiplatelet use.227 Little is known about 
cortical superficial siderosis (cSS), a recently identified neuroimaging marker of CAA,195 and 
the risk of subsequent ICH. cSS reflects linear blood residues in the superficial (subpial) 
layers of the cerebral cortex.190 One likely mechanism leading to cSS is repeated episodes 
of haemorrhage into the subarachnoid space from brittle superficial cortical or 
leptomeningeal CAA-laden vessels, potentially heralding a high risk of future lobar ICH. A 
recent study showed that nearly 50% of CAA patients with cSS experienced intracranial 
haemorrhage over a period of 35 months,246 but this study did not include patients without 
cSS as a control group. 
We tested the hypothesis that in CAA patients, cSS, especially involving multiple sulci 
(reflecting more widespread or active disease), is associated with an increased risk of future 
symptomatic lobar ICH, in a European multicentre cohort study. 
4.2 Patients and Methods 
4.2.1 Study population and baseline data collection 
We included consecutive patients diagnosed with CAA (according to the original Boston 
criteria,202 – not including cSS as a criterion) at four stroke centres over defined time 
periods. The centres were: University College London Hospitals NHS Foundation Trust 
(London) (03/2003–09/2011), Addenbrooke’s Hospital (Cambridge) (07/2002–03/2010), 
Cliniques Universitaires Saint Luc (Brussels) (12/2003–04/2010) and CHU Mont-Godinne 
UCL (08/2005–03/2009). At participating centres, MRI scanning is a routine investigation for 
cases of suspected CAA, unless there are contra-indications. Our inclusion criteria were: 
(1) patients fulfilling the original Boston criteria for CAA;202 (2) available MRI sequences 
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including T2*-weighted gradient-recalled echo (T2*-GRE) and fluid attenuated inversion 
recovery (FLAIR) MRI; and (3) available follow-up information on symptomatic ICH, 
confirmed by neuroimaging. We included all patients with CAA, including survivors of 
spontaneous lobar ICH and those who, during investigation for other symptoms, were 
found to have strictly lobar CMBs (or asymptomatic lobar ICH). We excluded CAA 
patients without adequate MR imaging (n=26), or reliable follow-up data (n=37). Excluded 
subjects (n=63) did not differ significantly from those included in any baseline characteristics 
(all p>0.05). 
Clinical data at the time of presentation (age, gender, vascular risk factors including 
hypertension, use of antithrombotics and previous symptomatic ICH) were obtained from 
prospective databases and by medical records review using standardised data collection 
forms. A clearly documented prior history of transient (≤24 hours), focal neurological 
episodes with no known alternative explanation other than CAA (e.g. structural brain 
lesion, atrial fibrillation, extracranial or intracranial stenosis) was ascertained by review of 
medical records. 
4.2.2 Standard Protocol Approvals, Registrations, and Patient 
Consents 
The study received ethical approval by the National Hospital for Neurology and 
Neurosurgery and Institute of Neurology Joint Research Ethics Committee, the 
Commission d’Ethique Biomedicale Hospitalo Facultaire of the Faculte de Medicine 
(Universite Catholique de Louvain), and the Comite d’ethique medicale of the CHU Mont 
Godinne UCL. 
4.2.3 Magnetic resonance imaging acquisition and analysis 
The MRI protocol was similar in each hospital. Imaging was at 1.5T field strength for 
all patients and included T1-weighted, T2-weighted, FLAIR and axial T2*-GRE (slice 
thickness 5 mm, repetition time 500–1,000 ms, echo time 15-70ms). Images were reviewed 
by a trained clinical research fellow blinded to clinical and follow-up data. The presence and 
distribution of CMBs were evaluated on T2*-GRE images using the Microbleed Anatomical 
Rating Scale.238 Asymptomatic or symptomatic prior ICH (>5 mm in diameter on T2*-GRE 
MRI) was also noted.198 cSS was defined as linear residues of chronic blood products in the 
superficial layers of the cerebral cortex showing a characteristic “gyriform” pattern of low 
signal on T2*-GRE images, without corresponding hyperintense signal on T1-weighted or 
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FLAIR images (i.e. without acute subarachnoid haemorrhage). We did not include cSS 
contiguous with any ICH. The distribution of cSS was classified as focal (restricted to ≤3 
sulci) or disseminated (>3 sulci).195 White matter changes were evaluated using the four-
step simplified Fazekas rating scale (0-3: 0=no lesions; 1=focal lesions; 2=early confluent; 
3=confluent).239 
4.2.4 Follow-up 
Follow-up data were obtained from a systematic review of multiple overlapping sources 
including prospective databases, medical records review (including discharge summaries, 
follow-up outpatient and general practitioner letters) and radiological databases, using 
standardized data collection forms. We collected information on clinically symptomatic 
ICH, defined as a symptomatic stroke syndrome associated with neuroimaging evidence of 
a corresponding ICH (>5 mm in diameter),198 and death of any cause. Outcome events 
were assessed using all clinical, radiological, and pathological information available, blinded 
to the presence of cSS at baseline MRI. We determined whether the location of 
symptomatic ICH at follow-up corresponded to the anatomical distribution of cSS on 
baseline MRI. 
4.2.5 Statistical analysis 
We compared clinical and imaging characteristics of CAA patients with symptomatic lobar 
ICH during follow-up to patients without ICH, using chi-square tests and the Fisher’s exact 
test for categorical variables, and two-sample t-tests or Mann-Whitney U-tests depending 
on the distribution of continuous variables. The reliability of rating for presence and 
category rating of cSS was assessed in a sample of MRI scans from probable CAA patients 
(n=48) by calculating Cohen’s kappa and weighted kappa statistic respectively.  We also 
compared basic clinical and imaging characteristics of patients with vs. without cSS. We 
determined the presence of cSS and disseminated cSS as univariate predictors of ICH risk 
using Kaplan-Meier plots with significance testing by the log-rank test. Survival time was 
calculated from date of baseline MRI scan until the date of symptomatic lobar ICH at 
follow-up or the last known date without the outcome event of interest. For individuals 
experiencing multiple lobar ICHs during follow-up, data were censored at time of first ICH. 
Data were also censored at the time of death from causes other than documented 
symptomatic ICH. Cox regression analysis was performed to calculate univariate hazard 
ratio (HR) as a measure of the effect size. 
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We estimated that our study would have a power of 88% to detect a difference in 
ICH risk between CAA patients with and without cSS, assuming 50% and 20% rates of ICH 
over four years respectively180, 227, 246 (two-tailed test and with alpha values of 0.05). 
According to the ‘rule of 10’ for developing proportional hazards models, we require 
approximately 10 outcome events for each potential covariate in multivariable analyses.256, 
257 Therefore, we investigated the effect the following prespecified potential predictors 
using Cox proportional-hazards model: presence of cSS or disseminated cSS, the presence 
of multiple CMBs (≥2), prespecified on the basis of the hypothesised effect on ICH risk 
from previous published series in CAA,180, 227 and age, being an important potential 
confounder. As sensitivity analyses, we repeated all statistical tests in CAA patients with 
symptomatic lobar ICH at baseline, and those who had their MRI within six months of the 
index ICH. We also undertook exploratory multivariable models incorporating previous 
ICH as another potential confounding factor. The proportional hazard assumption was 
tested using graphical checks and Schoenfeld residuals-based tests. 
A P-value≤0.05 was considered to be statistically significant. All analyses were 
performed using STATA (Version 11.2). The manuscript has been prepared with reference 
to the STROBE guidelines.258 
4.3 Results 
The final cohort consisted of 118 patients fulfilling the Boston diagnostic criteria202 for 
CAA: 8 with pathologically-proven CAA, 86 with probable CAA and 24 with possible CAA. 
Of these, 104 (88%) patients presented with symptomatic lobar ICH at baseline, 8 with 
transient focal neurological episodes, 3 with cognitive decline, 1 with acute convexity 
subarachnoid haemorrhage and 2 with ischaemic stroke. The inter-rater agreement for the 
presence or absent of cSS was 89.6% (Cohen’s kappa=0.79) and for cSS categories was 
89.6% (weighted Cohen’s kappa=0.75). Forty-one patients (43.8%, 95% CI: 26.2%-44.6%) 
had cSS at baseline. The presence of cSS was strongly associated with a prior history of 
transient focal neurological episodes (48.8% vs. 8.8%; p<0.001 respectively) and the 
presence of ≥5 CMBs (48.8% vs. 27.3%; p=0.019 respectively) (Appendix C Table 1). CAA 
patients with cSS were slightly older compared to patients without siderosis (mean age; 
95%CI: 73.2; 70.4-76 vs. 70.3; 68.2-72.5 respectively, p=0.111). 
During a median follow-up time of 24 months (interquartile range 9–44 months), 23 
of 118 patients (19.5%, 95%CI: 12.8-27.8) experienced a symptomatic lobar ICH; four of 
these 23 patients experienced multiple (>1) sequential symptomatic lobar ICH during 
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follow-up. The characteristics of our cohort according to subsequent lobar ICH are shown 
in Table 4.1. Fourteen of 23 patients (61%) with lobar ICH during follow-up had cSS on 
baseline MRI: three had focal cSS and eleven had disseminated cSS (Table 4.1). For seven of 
these fourteen patients, the subsequent ICH was anatomically correlated with the area of 
cSS (Figure 4.1). Two of the four patients with multiple symptomatic lobar ICH at follow-up 
had disseminated cSS. One patient (without cSS at baseline) experienced a symptomatic 
deep (thalamic) ICH. 
In the group of CAA patients without symptomatic lobar ICH at baseline (n=14; one 
patient with pathologically-proven CAA, 12 patients with probable CAA, and one with 
possible CAA), seven had cSS, which was disseminated in five cases. During a median 
follow-up time of 15.1 months (interquartile range 7.8–39.8), three of these patients 
experienced a symptomatic lobar ICH, all of whom had disseminated cSS at baseline scans. 
Table 4.1 Characteristics and comparison of CAA patients according to symptomatic lobar 
intracerebral haemorrhage at follow-up. The p-values refer to differences between patients with vs. 
without symptomatic lobar intracerebral haemorrhage at follow-up. The median time between all 
baseline symptomatic ICH and first MRI was 17 days (IQR: 3-75.5 days). 
Characteristics 
No ICH at 
follow-up (n=95) 
ICH at follow-up 
(n=23) 
p-value 
Age, mean (95% CI), years 70.4 (68.5-72.3) 75.2 (71.5-78.9) 0.026 
Median follow-up time (months) 
(IQR range) 
24.6 (9-51.3) 21.3 (6-38.5) 0.429 
Sex, male (%) 51 (53.7) 10 (43.5) 0.379 
Hypertension (%) 53 (63.5) 12 (52.2) 0.322 
On antithrombotics at baseline (%) 36 (25.3) 6 (26.1) 0.936 
Presented with symptomatic ICH 
at baseline (%) 
84 (88.4) 20 (87) 1.000 
Previous symptomatic ICH (%) 
(other than index event) 
23 (24.1) 7 (30.4) 0.538 
History of TFNE (%) 17 (17.9) 9 (39.1) 0.027 
Superficial cortical siderosis (%) 27 (28.4) 14 (60.9) 0.003 
   Focal, ≤3 sulci (%) 11 (11.6) 3 (13) 1.000 
   Disseminated, >3 sulci (%) 16 (16.8) 11 (47.8) 0.002 
Presence of CMBs (%) 62 (65.3) 18 (78.3) 0.231 
Number of CMBs, median  
(IQR range) 
2 (0-8) 3 (1-15) 0.412 
≥2 CMBs (%) 54 (56.8) 15 (65.2) 0.465 
≥5 CMBs (%) 32 (33.7) 9 (39.1) 0.623 
Moderate-to-severe white matter 
changes (Fazekas score 2 or 3) (%) 
41 (44.1) 11 (47.8) 0.747 
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Figure 4.1 Subsequent intracerebral haemorrhage (ICH) at the site of pre-existing siderosis in two 
patients with cSS. 85-year-old female patient; time interval between baseline imaging (A) and incident 
ICH (B): 19 months. 80-year-old male patient, time interval between baseline imaging (C) and 
incident ICH (D): 35 months. A, C Baseline magnetic resonance imaging, T2*-weighted images; B, D 
Follow-up unenhanced computed tomography scans. 
In Kaplan-Meier analysis the presence of cSS and disseminated cSS at baseline scans 
were predictors of time until ICH (p=0.0045 and p=0.0009 respectively, by the log-rank 
test) (Figure 4.2). The risk of symptomatic lobar ICH at 4 years of follow-up was 25% 
(95%CI: 7.6-28.3%) for patients without cSS at baseline, 28.9% (95%CI: 7.7-76.7%) for those 
with focal cSS, and 74% (95%CI: 44.1-95.7) for patients with disseminated cSS (p=0.0031 by 
the long-rank test for each category increase). 
In univariate analysis, any cSS presence was a predictor of symptomatic lobar ICH 
(HR: 3.18; 95%CI: 1.37-7.39; p=0.007), with an increased risk associated with disseminated 
cSS (HR: 4.07 compared to no siderosis; 95%CI: 1.66-9.96; p=0.002). Focal cSS was 
associated with a non-significant increased hazard of subsequent ICH (HR: 1.91 compared 
to no siderosis; 95%CI: 0.51-7.19; p=0.340). For each increase in category of cSS (i.e. from 
no siderosis, to focal, and to disseminated siderosis) the associated HR was 2.06 (95%CI: 
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1.31-3.24; p=0.002). A history of previous symptomatic haemorrhage (before the index 
symptomatic ICH) (HR: 1.87; p=0.177), presence of CMBs (HR: 2.17; p=0.125), presence of 
≥2 or ≥5 CMBs (HR: 1.55; p=0.318 and HR: 1.33; p=0.507 respectively) were not 
associated with future symptomatic lobar ICH in univariate analysis. Only age was 
associated with an increased hazard of subsequent ICH (HR: 1.07; p=0.006). 
 
Figure 4.2 Kaplan-Meier estimates of progression to symptomatic lobar intracerebral haemorrhage 
(ICH) in the presence of: (A) cortical superficial siderosis (cSS); (B) focal cSS; and (C) disseminated 
(>3 sulci) cortical superficial siderosis in all patients with cerebral amyloid angiopathy (CAA). Testing 
of significance is by the log-rank test. 
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Table 4.2 Prespecified multivariate analyses of predictors of symptomatic lobar intracerebral 
haemorrhage during follow-up in patients with cerebral amyloid angiopathy. The models remain 
consistent if number of cerebral microbleeds (CMBs), presence of CMBs or ≥5 CMBs are included. 
Model 1: HR (95%CI) p-value 
Presence of cortical superficial siderosis 2.53 (1.05-6.15) 0.040 
Presence of ≥2 CMBs 1.10 (0.45-2.71) 0.836 
Age (for each year increase) 1.06 (1.01-1.11) 0.028 
Model 2: HR (95%CI) p-value 
Disseminated cortical superficial siderosis 3.16 (1.35-7.43) 0.008 
Presence of ≥2 CMBs 1.07 (0.44-2.63) 0.876 
Age (for each year increase) 1.07 (1.01-1.13) 0.017 
Prespecified multivariable Cox regression models demonstrated that cSS and 
disseminated cSS were independently associated with increased risk of symptomatic lobar 
ICH at follow-up, after adjusting for the presence of ≥2 CMBs and age (Table 4.2). These 
effect sizes remained consistent in similar multivariable models controlling for CMBs 
number, CMBs presence and ≥5 CMBs. Our main results were also consistent in sensitivity 
analyses including cSS, CMBs, previous history of symptomatic ICH and age in multivariable 
models (Appendix C Table 2). 
All the results of Kaplan-Meier and prespecified Cox regression analyses remained 
consistent in sensitivity analyses which included only CAA patients with symptomatic lobar 
ICH at baseline (Appendix C Figure 1) and patients who had their MRI within six months of 
the index ICH (data not shown). 
4.4 Discussion 
In this multicentre retrospective cohort study we found that cSS on T2*-GRE MRI 
(reflecting hemosiderin deposition in the subpial superficial cortical layers) significantly 
increases the risk of future symptomatic lobar ICH in patients with CAA.202 The risk rate 
for ICH was greatest for patients with disseminated cSS, involving multiple sulci on baseline 
scans. These results remained consistent after adjusting for age, the presence of multiple 
(≥2) lobar CMBs (a haemorrhagic marker of CAA previously shown to influence the risk of 
ICH)227, and previous symptomatic ICH prior to the index inclusion event. In a subanalysis 
 87 
of those patients who presented with symptomatic ICH at baseline, cSS remained a 
predictor of ICH risk, consistent with the main analysis. 
cSS is emerging as a common and characteristic feature of CAA.28, 243 One study 
reported cSS in 60.5% (n=38; mean age 70±6.4 years) of patients with histopathologically 
proven CAA, compared with no control subjects with histopathologically proven non-CAA 
ICH (n=22; mean age 54±18 years).195 Another recent study found cSS in 40% of patients 
with a clinic-radiological diagnosis of probable CAA-related ICH but only 5% of patients 
with purely deep ICH, presumed due to hypertensive arteriopathy.259 Increasing data 
support the hypothesis that cSS might precede lobar ICH in patients with CAA.191, 237, 260 In 
a recent retrospective study, 51 patients with cSS and no apparent cause other than CAA 
were identified through a single centre systematic database search and followed-up for a 
median of 35.3 months.246 Over this period 24 patients (47.1%) experienced any new 
“intracranial haemorrhage” (ICH or acute convexity subarachnoid haemorrhage): 18 
patients (35.3%) had an ICH, of which 13 were at the site of pre-existing siderosis.246 This 
study was limited by the incomplete ascertainment of outcome intracranial bleeding events 
(without details of how many were symptomatic), and the lack of a comparison group 
without cSS at baseline. 
Our larger study confirms that cSS is a risk factor for future symptomatic ICH in 
CAA, independent of multiple lobar CMBs. It is hypothesized that repeated episodes of 
haemorrhage from brittle superficial cortical or leptomeningeal CAA-affected vessels into 
the subarachnoid space leads to subpial haemosiderin deposition and cSS on MRI.247 The 
finding of cSS without previous ICH, and its tendency to occur distantly from previous ICH, 
favour this “primary” mechanism,195, 246 rather than leakage of blood into the subarachnoid 
space secondary to previous lobar “macro” ICH.259 Consequently, cSS may be a marker of 
increased cortical and leptomeningeal small vessel fragility, high CAA disease activity, and 
vulnerability to subarachnoid bleeding, which in some  circumstances may extend and 
develop into a lobar ICH.248 Indeed, a neuropathological series of six autopsy cases of 
subcortical haematoma caused by CAA, showed that multiple leptomeningeal arteries can 
rupture into the subarachnoid space and the brain parenchyma.248 This hypothesis is 
supported by the observation that symptomatic ICH has been noted at (or close to) the 
site of previous siderosis,246 though we found that ICH only occurred at the site of cSS in 
50% of cases. We found the highest ICH risk in patients with disseminated cSS, which may 
indicate widespread and numerous leptomeningeal vessels damaged by advanced CAA, 
providing multiple potential initiation sites for future ICH, increasing the probability of this 
outcome.248 Further serial MRI studies will help to unravel the sequence of events and 
mechanisms linking CAA, cSS and lobar ICH, including asymptomatic bleeding.252 
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Assessment of the associations between ApoE genotype (which was not available in our 
cohort) and the extent or severity of CAA-related pathology in leptomeningeal vessels may 
also be of interest. 
Although our results suggest an increased risk of subsequent ICH in CAA patients 
with cSS on MRI, antithrombotic drug use probably also plays a role in this risk by impairing 
haemostatic mechanisms.28, 227, 255 In our retrospective cohort, it was not possible to 
systematically collect data on the use of antithrombotic drugs. However, routine clinical 
practice in all four centres in our study was to avoid of all antiplatelet agents (including 
aspirin) and anticoagulants in patients with suspected CAA, unless there was a very strong 
indication, so is unlikely to have contributed significantly to the outcome events in our 
study. 
Our findings might have important implications for patients presenting with transient 
focal neurological episodes (sometimes called “amyloid spells”249) resembling transient 
ischaemic attacks, migraine auras or focal seizures,167, 244, 249 which are increasingly 
recognized in CAA. It was recently reported that such attacks are often related to cSS and 
herald a high early risk of symptomatic lobar ICH (24.5% [95%CI: 15.8%–36.9%] at 8 
weeks).244 Thus, these types of attacks (which are often recurrent and stereotyped) should 
alert the clinician to the possibility of cSS; giving antithrombotic drugs to these patients due 
to misdiagnosis as TIA, could significantly increase the risk of serious future ICH.252 
Moreover, our current data suggest that disseminated siderosis may be a particular risk 
factor for future ICH in this situation. 
Perhaps surprisingly, we did not find a significant association between multiple lobar 
CMBs and future ICH risk,180, 227 which may reflect selection bias towards generally 
advanced disease with high prevalence of multiple lobar CMBs in our cohort. Although our 
study had adequate power to detect an increase in the risk of ICH in the presence of cSS, 
our sample size was not large enough to investigate additional potential baseline predictors 
of ICH (e.g. index ICH volume, ApoE genotype) or to investigate ICH risk in the subset of 
patients without lobar ICH at baseline. Other potential limitations include the retrospective 
design, and the potential of bias in our sample since the requirement for MRI may exclude 
more severe cases of ICH. Furthermore, a proportion of otherwise eligible patients did not 
have reliable follow-up data. Finally, we did not have pathological confirmation of CAA 
pathology; and acknowledge that the Boston criteria have imperfect specificity, especially 
for the “possible CAA” category.202, 203 
Our findings nevertheless suggest that cSS is a useful independent prognostic marker 
of intracerebral bleeding risk in CAA. Larger cohorts are needed to confirm our results and 
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explore the potential implications for CAA treatment (e.g. avoiding antithrombotic agents 
in patients with disseminated cSS). cSS could also have implications for future disease-
modifying treatments in CAA which may cause amyloid–β shifts between brain parenchyma 
and blood vessels (e.g. immunotherapy); CMBs have been considered a possible caution for 
such treatments,261 but the role of cSS in this setting remains to be determined. 
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Chapter 5 MRI-visible perivascular spaces 
as a marker of underlying arteriopathy in 
intracerebral haemorrhage: Multicentre 
MRI cohort study 
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ABSTRACT 
Objective: Small vessel disease (mainly hypertensive arteriopathy and cerebral amyloid 
angiopathy [CAA]) is an important cause of spontaneous intracerebral haemorrhage (ICH), 
a devastating and still poorly-understood stroke type. Enlarged perivascular spaces (PVS) 
are a promising neuroimaging marker of small vessel disease. Based on the underlying 
arteriopathy distributions, we hypothesised that severe centrum semiovale PVS are more 
common in lobar ICH attributed to CAA than other ICH. We evaluated PVS prevalence, 
severity and distribution, and their clinical-radiological associations. 
Methods: Retrospective multicentre cohort study of 121 ICH patients. Clinical 
information was obtained using standardised forms. Basal ganglia and centrum semiovale 
PVS on T2-weighted MRI [graded 0-4 (>40 PVS)], white matter changes, cerebral 
microbleeds (CMBs) and lacunes were rated using validated scales. 
Results: Patients with probable or possible CAA (n=76) had a higher prevalence of severe 
(>40) centrum semiovale PVS compared to other ICH patients (35.5% vs. 17.8%; p=0.041). 
In logistic regression age (OR: 1.43; 95%CI: 1.01-2.02; p=0.045), deep CMBs (OR: 3.27, 
95%CI: 1.27-8.45; p=0.014) and mean white matter changes score (OR: 1.29; 95%CI: 1.17-
1.43; p<0.0001) were independently associated with increased basal ganglia PVS severity; 
only age was associated with increased centrum semiovale PVS severity (OR: 1.50; 95%CI: 
1.08-2.10; p=0.017). 
Conclusions: PVS are common in ICH. Different mechanisms may account for PVS 
according to their anatomical distribution. Severe centrum semiovale PVS may be 
secondary to, and indicative of, CAA with value as a new neuroimaging marker. By 
contrast, basal ganglia PVS severity is associated with markers of hypertensive arteriopathy. 
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5.1 Introduction 
Spontaneous (non-traumatic) intracerebral haemorrhage (ICH) is usually defined as ICH 
not due to any structural, vascular or other primary cause (e.g. tumour, arteriovenous 
malformation, aneurysm, cavernoma) and therefore attributed to intrinsic disease of the 
cerebral small vessels. Spontaneous ICH accounts for more than 75% of ICH in adults, 
leading to high rates of death and disability.45 It results from the rupture of small arteries 
damaged by two main age-related cerebral small vessel diseases: hypertensive arteriopathy 
(including arteriolosclerosis) and cerebral amyloid angiopathy (CAA). Hypertensive 
arteriopathy typically affects the small perforating end-arteries of the deep grey nuclei and 
deep white matter and is an important cause of ICH in deep structures. CAA is 
characterised by the progressive deposition of amyloid-β in the walls of small vessels in the 
cerebral cortex, overlying leptomeninges and grey–white matter junction and is a major 
cause of lobar ICH in the elderly.28 There is an urgent need to better understand the 
pathophysiology of cerebral small vessel disease and spontaneous ICH, to enhance 
diagnosis, prevention and treatment. 
Perivascular spaces (also known as Virchow-Robin spaces) are interstitial fluid-filled 262 
cavities surrounding the small penetrating vessels which function as the brain drainage 
system,263 and have been recognized pathologically for many years. Enlarged perivascular 
spaces (PVS) can also be seen on MRI, and have attracted attention as a potential 
neuroimaging marker of small vessel disease.30, 133 Although PVS are common finding in the 
elderly,264, 265 and show consistent associations with other markers of small vessel damage 
[6], they have received relatively little attention to date–usually being considered 
unimportant or even normal. PVS are visible on T2-weighted cerebral MRI as 
characteristically small, high-signal areas in the basal ganglia  and centrum semiovale.30 
ICH is perhaps the most devastating clinical consequence of small vessel disease, yet 
PVS have not been systematically studied in this population. There is an urgent need to 
develop more sensitive diagnostic markers of the arteriopathies underlying ICH, particularly 
CAA.28 In the present study our aims were to determine the prevalence, distribution and 
severity of PVS in ICH, and investigate their associations with other imaging markers of 
small vessel disease, and with presumed ICH aetiology. We hypothesized that, in patients 
with ICH: (1) PVS are common; (2) PVS severity is associated with other small vessel 
disease MRI markers including white matter changes, lacunes and cerebral microbleeds 
(CMBs); and (3) patients with strictly lobar ICH attributed to CAA have a higher 
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prevalence of severe PVS in the centrum semiovale compared to other ICH, due to the 
expected distributions of the underlying arteriopathies. 
5.2 Patients and Methods 
5.2.1 Study participants and data collection 
We performed a retrospective analysis of patients with spontaneous ICH (defined as ICH 
without evidence for an underlying cause, except for small vessel disease) referred to four 
specialist stroke centres over defined time periods in the United Kingdom and Belgium. 
The hospitals were: University College London Hospitals NHS Foundation Trust (09/2004-
06/2011), Cliniques Universitaires Saint Luc (Brussels) (12/2004–04/2008), CHU Mont-
Godinne UCL (Belgium) (08/2005–06/2008) and Addenbrooke’s Hospital (Cambridge) 
(07/2002–12/2009). At all participating centres, MRI scanning is a routine investigation for 
ICH, unless there are contra-indications. Cases were systematically ascertained using 
multiple overlapping methods from prospective clinical databases and radiological reports. 
A total of 377 patients with ICH were screened, of whom 129 were excluded because of 
diagnosis of non-spontaneous ICH (e.g. secondary to aneurysms, tumours, cavernomas 
etc.), and 127 because MRI with the necessary sequences of adequate quality was not 
available for analysis. 
We categorised cases of spontaneous ICH as either strictly lobar, consistent with a 
diagnosis of CAA (clinically possible or probable CAA according to the Boston criteria202) 
or "other ICH" (i.e. deep ICH and mixed deep and lobar ICH). Demographic and clinical 
information (e.g. age at time of MRI, gender, vascular risk factors, use of antithrombotics 
etc.) was obtained from prospective databases and by medical records review using 
standardised data collection forms. Hypertension was defined as a history of hypertension, 
taking antihypertensive treatment or documented elevated blood pressure (systolic >150 
or diastolic >95mmHg) prior to ICH, diabetes as ongoing use of a hypoglycaemic agent and 
smoking as history of tobacco use before admission. 
The study received ethical approval by the National Hospital for Neurology and 
Neurosurgery and Institute of Neurology Joint Research Ethics Committee, the 
Commission d’Ethique Biomedicale Hospitalo Facultaire of the Faculte de Medicine 
(Universite Catholique de Louvain), and the Comite d’ethique medicale of the Cliniques 
Universitaires UCL de Mont Godinne. 
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Figure 5.1 Axial T2-weighted MRI. (A, B) Dot-like hyperintensities characteristic of enlarged 
perivascular spaces (PVS) in the basal ganglia in a patient with spontaneous deep intracerebral 
haemorrhage (ICH). (C, D) Linear hyperintensities typical of PVS in the centrum semiovale in a 
patient with CAA-related lobar ICH. Note that deep brain regions (e.g. basal ganglia) are not 
affected by PVS (D). (For within group comparisons of the proportion of patients with centrum 
semiovale PVS vs. basal ganglia EPVS for lobar ICH and other ICH see Appendix D). 
5.2.2 Magnetic resonance imaging acquisition and analysis 
The MRI stroke protocol was similar in each hospital. Imaging was at 1.5T field strength and 
included axial T1-weighted, T2-weighted, coronal fluid-attenuated inversion recovery 
(FLAIR), axial diffusion-weighed imaging (DWI) and T2*-weighted gradient-recalled echo 
(T2*-GRE) sequences (Appendix D Table 1). 
MR images were reviewed on medical imaging workstations, blinded to clinical details. 
The presence, number and distribution (lobar-including cerebellum, as suggested in the 
Boston criteria202 and deep-including brainstem) of ICHs were recorded. The presence, 
number and distribution of CMBs were evaluated on T2*-GRE images using the Microbleed 
Anatomical Rating Scale.238 White matter hyperintensities were rated on a four-point scale 
(0-3)266 on coronal FLAIR, T1-weighted and T2-weighted MR images. 
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PVS were rated on axial T2-weighted MR images by a trained observer, using a 
validated visual rating scale.30, 267 PVS were defined as small, sharply delineated structures of 
CSF intensity (or close to CSF intensity), measuring <3mm following the course of 
perforating or medullary vessels (Figure 5.1). Lacunes were distinguished form PVS by their 
larger size (>3mm), spheroid shape and surrounding hyperintensity on FLAIR. PVS were 
rated in basal ganglia and centrum semiovale regions. For both of these anatomical areas, 
the PVS rating categories applied were: 0=no PVS, 1=<10 PVS, 2=11-20 PVS, 3=21-40 PVS 
and 4=>40 PVS. The numbers refer to PVS on one side of the brain: after reviewing all 
relevant slices for the anatomical area being assessed, the slice and side with the highest 
number of PVS was recorded.30, 267 In patients with other ICH, basal ganglia PVS were 
evaluated contralateral of the lesion if deep ICH was present. The assessment of PVS may 
have been influenced by the presence of confluent white matter changes; in such cases, as 
per guidance provided for the rating scale we used,30 estimation was made of the closest 
PVS rating category, using the appearance of non-involved white matter, and cortical gray 
matter. Similarly, in cases of large lobar ICH, centrum semiovale PVS were assessed 
contralateral to the index ICH lesion; an estimation of the closest centrum semiovale PVS 
rating category ipsilateral to the lesion was made, and the highest number of PVS was 
recorded. Intra-rater reliability testing (n=30 scans) showed an excellent intra-rater 
Cohen’s kappa value of 0.91 for basal ganglia PVS and 0.82 for centrum semiovale PVS. 
5.2.3 Statistical analysis 
We compared clinical and imaging characteristics of patients with strictly lobar ICH 
(attributed to CAA according to the Boston criteria) to those with other ICH, using chi-
square tests and the Fisher’s exact test for categorical variables, and two-sample t-tests or 
Mann-Whitney U-tests depending on the distribution of continuous variables. To test our 
hypothesis, we sought to compare the prevalence of severe centrum semiovale and basal 
ganglia PVS (>40 PVS) in the two ICH groups. However, since only one patient had severe 
basal ganglia PVS, in a post-hoc analysis we compared frequent-to-severe basal ganglia PVS 
(>20) in the two ICH groups. Both crude and age-adjusted severe PVS centrum semiovale 
prevalence rates are reported. For the logistic regression analysis, severity of PVS was 
trichotomized due to the small number of patients with no PVS or >40 PVS [1 (mild; 1 to 
10), 2 (moderate; 11-20) and 3 (severe; over 21)]. Ordinal logistic regression analysis was 
used to identify predictors of increasing PVS severity in the two anatomical areas (centrum 
semiovale and basal ganglia) and for total brain PVS. Multivariable analysis was adjusted for 
age, lobar microbleeds, deep microbleeds, white matter changes score and lacunes, based 
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on the results of univariable analysis, plus other biologically plausible confounders, especially 
neuroimaging markers of small vessel disease. As a sensitivity analysis we repeated these 
analyses with the addition of other variables in our model (including sex, hypertension, 
CAA-group etc.). Using a likelihood ratio test, the assumption of proportional odds for the 
ordinal logistic regression models was met. A p-value ≤0.05 was considered to be 
statistically significant. All statistical analyses were carried out using STATA data analysis 
and statistical software (Version 11.2, StataCorp.). 
5.3 Results 
Patients with spontaneous ICH excluded from the study were not significantly different 
from those included in measures of ICH severity including: median (IQR range) ICH volume 
(10.5 cm3; 2.93–18.81 cm3 versus 12.84 cm3; 4.05–25.31 cm3; p=0.288), median (IQR range) 
Glasgow Coma Score on admission (14; 11–15 versus 15; 14–15; p=0.087) in patients 
excluded versus patients included respectively. Patients excluded had a higher prevalence of 
deep ICH (50.5% versus 27.4%, p=0.005). The final cohort consisted of 121 patients with 
ICH [mean age 69.4 (95%CI: 67.2–69.6); 69 (57%) male]; 76 (63%) had strictly lobar ICH, 
fulfilling the Boston criteria for probable (n=53) or possible (n=23). The clinical and 
radiological characteristics of the ICH cohort overall and according to ICH location are 
reported in Table 5.1. The median time from ICH to MRI was 10 days (interquartile range: 
3-61 days). 
5.3.1 Prevalence and distribution of PVS in ICH 
Almost all patients had some degree of PVS (Table 5.1); the mean total score was 4.38 
(95%CI: 4.18-4.58). 
Patients with strictly lobar ICH had a significantly higher prevalence of severe PVS (>40 
PVS) in the centrum semiovale compared to other ICH patients (35.5% vs. 17.8%, 
respectively; p=0.041) (Figure 5.2). The age-adjusted prevalences of severe PVS in the 
centrum semiovale are 29.3% (95% CI: 23.1% to 35.5%) in the strictly lobar ICH group vs. 
13.5% (95% CI: 9.3% to 17.8%) in the “other ICH” group (p<0.05). 
It was not possible to test for differences between the strictly lobar and other ICH 
groups in the prevalence of severe basal ganglia PVS since only one patient had severe basal 
ganglia PVS. However, in a post-hoc analysis the proportion of patients with frequent-to-
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severe basal ganglia PVS (>20) was higher in those with other ICH than in strictly lobar ICH 
(20% vs. 4%, p=0.009). 
There was no relationship between basal ganglia and centrum semiovale PVS severity 
(compared using chi square test across categories; Appendix D Table 2). 
Table 5.1 Patient characteristics. P-values refer to differences between strictly lobar (clinically 
probable or possible CAA) and other ICH. 
n (%) Overall 
(N=121) 
Strictly lobar 
ICH 
(N=76) 
Other ICH 
(N=45) 
P-value 
Age, mean (95%CI), years 69.4 (67.2-69.6) 71.1 (68.4-73.8) 66.6 (62.8-72.4) 0.05 
Sex, male 69 (57) 41 (54) 28 (62.2) 0.449 
History of hypertension 86 (72.9) 49 (67.1) 37 (82.2) 0.090 
Smoking history 39 (33.3) 22 (30.1) 17 (38.6) 0.419 
Diabetes 20 (17.1) 11 (15.1) 9 (20.5) 0.459 
On statins 26 (22) 15 (20.6) 11 (25) 0.648 
On antithrombotics 38 (32.8) 27 (37) 11 (25.6) 0.226 
First-ever ICH 68 (63) 40 (62.5) 28 (63.6) 1.000 
Lacunar infarct 25 (49) 11 (37.9) 14 (63.6) 0.093 
Multiple ICHs 47 (39.8) 34 (46.6) 13 (28.9) 0.081 
Microbleeds presence 79 (67.5) 45 (62.5) 34 (75.6) 0.160 
Lobar microbleeds 77 (64.7) 45 (62.5) 30 (68.2) 0.556 
Deep microbleeds 28 (23.1) 0 28 (63.6) <0.0001 
Mean total white matter changes score 
(95%CI) 
8.58 (7.59-9.57) 8.21 (6.95-9.46) 
9.18 (7.53-
10.83) 
0.346 
Mean total PVS score (95%CI) 4.38 (4.18-4.58) 4.29 (4.04-4.54) 4.53 (4.17-4.9) 0.255 
Mean basal ganglia PVS score (95%CI) 1.50 (1.37-1.63) 1.32 (1.18-1.45) 1.8 (1.56-2.05) 0.0003 
Mean centrum semiovale PVS score 
(95%CI) 
2.85 (2.72-3.05) 2.97 (2.76-3.19) 2.73 (2.47-2.99) 0.1590 
PVS centrum semiovale     
Mild: 1-10 7 (5.8) 4 (5.3) 3 (6.7) 
0.338† 
Moderate: 11-20 36 (29.8) 21 (27.6) 15 (33.3) 
Frequent: 21-40 43 (35.5) 24 (31.6) 18 (40) 
Severe: >40 35 (28.9) 27 (35.5)* 8 (17.8)* 
PVS basal ganglia     
No EPVS 2 (1.7) 2 (2.6) 0 (0) 
0.005† 
Mild: 1-10 70 (57.9) 51 (67.1) 19 (42.2) 
Moderate: 11-20 37 (30.6) 20 (26.3) 17 (37.8) 
Frequent: 21-40 11 (9.1) 3 (4) 8 (17.8) 
Severe: >40 1 (0.8) 0 (0) 1 (2.2) 
†p-value for trend across groups  
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Figure 5.2 Age-adjusted 
prevalence of severe centrum 
semiovale PVS (>40 EPVS) in 
patients with strictly lobar 
intracerebral haemorrhage ICH, 
attributed to cerebral amyloid 
angiopathy (CAA), compared to 
other ICH. Age was used as a 
continuous variable. 
 
 
 
 
Table 5.2 Univariable (unadjusted) ordinal logistic regression analysis showing predictors of 
increased basal ganglia and centrum semiovale PVS severity in the whole cohort. 
(Yes vs. No) 
Basal ganglia PVS Centrum semiovale PVS 
OR (95%CI) P-Value OR (95%CI) P-Value 
Age (per 10 years older) 1.41 (1.02-1.95) 0.036 1.36 (0.98-1.87) 0.065 
Sex, male 0.53 (0.26-1.10) 0.088 0.56 (0.27-1.18) 0.128 
History of hypertension  1.05 (0.57-2.33) 0.469 0.68 (0.28-1.63) 0.381 
Smoking history 2.89 (1.35-6.18) 0.006 1.20 (0.53-2.71) 0.666 
Diabetes 1.26 (050-3.16) 0.622 1.11 (0.39-3.13) 0.851 
On statins 0.71 (0.29-1.72) 0.441 0.74 (0.31-1.81) 0.514 
On antithrombotics 0.62 (0.28-1.38) 0.240 0.70 (0.31-1.57) 0.387 
First ever ICH 0.64 (0.30-1.37) 0.248 1.07 (0.47-2.46) 0.866 
Other ICH (non-CAA aetiology) 3.58 (1.70-7.54) 0.001 0.74 (0.35-1.57) 0.431 
Lacunar infarct 2.75 (0.93-8.14) 0.068 2.84 (0.87-9.29) 0.083 
Multiple ICHs 0.71 (0.34-1.47) 0.350 0.87 (0.41-1.86) 0.724 
Microbleeds presence 2.29 (1.01-5.21) 0.048 1.62 (0.73-3.56) 0.233 
Strictly lobar microbleeds 0.99 (0.48-2.04) 0.985 1.59 (0.73-3.47) 0.246 
Lobar microbleeds 1.81 (0.82-3.99) 0.140 1.89 (0.87-4.13) 0.109 
Deep microbleeds 2.25 (1.01-4.98) 0.046 0.97 (0.41-2.26) 0.937 
Mean total WMH score (for 
each unit increase) 
1.23 (1.13-1.33) <0.0001 1.01 (0.94-1.08) 0.772 
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Table 5.3 Multivariable (adjusted) ordinal logistic regression analysis showing predictors of 
increased basal ganglia and centrum semiovale EPVS severity in the whole cohort. 
 
Basal ganglia PVS Centrum semiovale PVS 
OR (95%CI) P-Value OR (95%CI) P-Value 
Age  (per 10 years older) 1.43 (1.01-2.02) 0.045 1.50 (1.08-2.10) 0.017 
Lobar microbleeds 0.43 (0.16-1.20) 0.107 1.92 (0.74-4.96) 0.180 
Deep microbleeds 3.27 (1.27-8.45) 0.014 0.91 (0.35-2.38) 0.850 
Mean total WMH score 
(for each unit increase) 
1.29 (1.17-1.43) <0.0001 0.99 (0.91-1.08) 0.856 
Lacunar infarct 1.00 (1.00-1.01) 0.362 1.00 (0.99-1.00) 0.918 
 
5.3.2 Predictors of increased PVS severity in logistic 
regression 
In univariable ordinal logistic regression analysis, significant predictors of increasing PVS 
severity in the basal ganglia were age, smoking history, the presence of CMBs, presence of 
deep CMBs, presence of lacunes, mean white matter changes score and other ICH (non-
CAA aetiology) (Table 5.2). In multivariable logistic regression analysis (Table 5.3) age (OR: 
1.43, per 10 years increase; 95%CI: 1.01-2.02; p=0.045), presence of deep CMBs (OR: 3.27, 
95%CI: 1.27-8.45; p=0.014) and mean white matter changes score (OR: 1.29, per unit 
increase; 95%CI: 1.17-1.43; p<0.0001) were independent predictors of increased basal 
ganglia PVS severity, after adjusting for the presence of lobar CMBs and lacunes. 
No clinical or radiological variables were found to be significantly associated with 
increasing PVS severity in the centrum semiovale, at the 5% level, in univariable analysis; age 
was marginally significant. In multivariable analysis, age was the only significant independent 
predictor of increasing PVS severity in the centrum semiovale: for every 10 years increase 
in age the odds of having an increase in centrum semiovale PVS was 1.50 (95%CI: 1.08-2.10; 
p=0.017). 
5.4 Discussion 
In this multicentre retrospective study we found that the distribution of severe PVS differed 
according to the location of ICH: severe centrum semiovale PVS were twice as common in 
patients with strictly lobar (i.e. probable or possible CAA) than in those with other ICH. By 
contrast, the ICH patients not fulfilling these criteria for CAA more often had frequent-to-
severe basal ganglia PVS compared to strictly lobar ICH patients. In the whole cohort, we 
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found that age, white matter changes and deep CMBs were independently associated with 
basal ganglia PVS severity, but only age was independently associated with increased 
centrum semiovale PVS severity. Our study thus provides new evidence that the 
distribution of severe PVS reflects the underlying arteriopathy type in spontaneous ICH. 
We found PVS in almost every participant in our study, and moderate to severe 
centrum semiovale and basal ganglia PVS in more than 90% and 40% of them respectively. 
To our knowledge, no previous imaging study has investigated the prevalence and 
distribution of PVS in spontaneous ICH. A recent prospective study which evaluated PVS in 
patients with acute lacunar stroke (n=129), cortical stroke (n=124) and age-matched non-
stroke controls (n=97), found that PVS were more prevalent in small vessel (lacunar) 
ischaemic stroke than large vessel stroke.30 In this study, Doubal and colleagues30 used the 
same PVS rating scale, applied to T2-weighted images, as in our study, thus allowing 
comparisons to be made. The mean total PVS score in our ICH cohort (4.38, 95% CI: 4.18-
4.58) is close to that of patients with lacunar stroke (3.81, SD: 1.76) but higher than non-
stroke controls (1.02, SD: 0.89).30 However, the absence of a non-ICH control group in our 
study makes it difficult to directly compare PVS counts with other patient groups. 
Although PVS have not been studied in ICH cohorts, previous pathological and 
neuroimaging studies in other patient populations have shown a significant association 
between hypertension, white matter changes, and PVS.24, 268 The associations we found 
between the severity of basal ganglia and total PVS with the severity of white matter 
changes further add to evidence that PVS are an imaging manifestation of cerebral small 
vessel disease rather than an incidental finding. The association of PVS with white matter 
changes seems consistent across different populations including vascular dementia,269 
Alzheimer’s disease and mild cognitive impairment. A large population-based study also 
reported an association between the degree of PVS and the volume of white matter 
changes, as well as with the prevalence of lacunes.270 
We also found that PVS associations vary according to their distribution, suggesting 
different pathophysiological mechanisms relevant to the underlying arteriopathy in ICH. 
Basal ganglia PVS were independently associated with age, white matter changes burden and 
deep CMBs, suggesting hypertensive arteriopathy as a possible underlying mechanism. It is 
likely that at least some white matter changes share a common pathophysiological 
mechanism with PVS, perhaps related to blood-brain barrier disruption, a potentially key 
pathogenic process in cerebral small vessel disease.133 Indeed, it has been suggested that 
white matter changes tend to form around PVS133 and that PVS may be an early imaging 
marker of small vessel disease and blood-brain barrier alteration. By contrast, in the 
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present study, PVS in the centrum semiovale were only associated with age, and not with 
other imaging or clinical factors. In the study by Doubal et al30 in patients with minor 
ischaemic stroke, total PVS were also associated with white matter changes after adjusting 
for age, the presence of stroke and vascular risk factors (p<0.001); centrum semiovale PVS 
were not associated with any explanatory variables, in keeping with our findings.30 It is thus 
possible that a distinct pathophysiological process other than hypertensive arteriopathy 
contributes to the development of centrum semiovale PVS: CAA is a likely candidate, a 
hypothesis consistent with evidence that advancing age is the strongest clinical risk factor 
for sporadic CAA.28 Although we did not find a significant association between PVS severity 
in the centrum semiovale and the presence of lobar microbleeds (a putative neuroimaging 
marker of CAA) at the 5% level, the odds ratio suggests a possible effect (OR: 1.92; 95%CI: 
0.74-4.96; Table 3), our ability to detect any association may be limited by our sample size 
and the high prevalence of hypertension, which can also contribute to lobar CMBs. In 
addition, the absence of association between basal ganglia and centrum semiovale PVS 
severity further supports the notion that PVS in these two anatomical compartments are 
related to different pathophysiological processes. 
Severe PVS in our ICH cohort showed a different anatomical pattern depending on the 
location and the presumed small vessel arteriopathy underlying ICH. In patients with strictly 
lobar, presumed CAA-related ICH the centrum semiovale was more often affected by 
severe PVS compared to other ICH patients. A predilection of severe PVS for the centrum 
semiovale most parallels the topography of CAA pathology, since amyloid-β is deposited 
primarily in cortical and leptomeningeal small vessels, largely sparing small vessels in the 
basal ganglia.28 Moreover, several lines of evidence suggest that perivascular spaces have a 
key role in the pathophysiology of CAA.28 It is hypothesized that an important mechanism 
underlying vascular amyloid-β deposition is impaired clearance of amyloid-β along 
perivascular drainage pathways.28 As amyloid-β is deposited in the walls of small arteries it 
could block perivascular drainage, leading to dilation of perivascular spaces downstream in 
the underlying deep white matter, even in regions not directly affected by CAA pathology. 
This regional preference for severe PVS further supports our hypothesis that severe 
centrum semiovale PVS are at least partly related to CAA, whereas basal ganglia PVS are 
most likely related to hypertensive arteriopathy affecting deep perforators. Severe centrum 
semiovale PVS may therefore be a potential useful new neuroimaging marker of CAA, in an 
appropriate clinical context. The diagnosis of CAA currently depends on the radiological 
demonstration of multiple strictly lobar haemorrhages; existing criteria have high specificity 
but limited sensitivity.202, 203 Whether severe PVS presence and topography might usefully 
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improve the sensitivity for current diagnostic criteria for CAA202 requires further study 
with pathological verification of CAA. 
Our multicentre study has several strengths including the systematic evaluation of MRI 
scans by trained raters using validated scales for a range of imaging markers of small vessel 
disease, and the use of a validated PVS rating scale.30 A potential limitation is the lack of 
pathological confirmation of the CAA pathology as a cause of ICH, in view of the imperfect 
sensitivity and specificity of the Boston criteria (particularly their overall sensitivity and the 
specificity of the “possible CAA” category).202 We may thus have misclassified some 
patients as CAA-related ICH when their ICH was related to hypertensive arteriopathy. It is 
also likely that some of the patients with “other ICH” (e.g. spontaneous deep ICH), many 
of whom had lobar CMBs, not classified as CAA-related might in fact have some degree of 
CAA pathology as well as hypertensive arteriopathy. However, any misclassification of 
patients would tend to bias toward a null result (no between-group differences in PVS 
severity or distribution), suggesting that PVS may in fact be a more powerful marker for 
CAA than we have been able to demonstrate here. It was not possible to blind the PVS 
rater to ICH location, potentially introducing a bias towards the study hypothesis. We also 
acknowledge the potential of bias in our sample as MRIs were done as part of routine 
clinical care and many patients were excluded from this analysis because of inadequate MRI 
data. Finally, due to the retrospective and cross-sectional nature of our study we were not 
able to determine the prognostic significance of PVS in this cohort. 
In summary, we found that PVS are present in almost all patients with spontaneous 
ICH, but with evidence for different underlying mechanisms according to their distribution. 
Basal ganglia PVS severity is associated with markers of hypertensive arteriopathy including 
white matter changes and deep CMBs, whilst centrum semiovale PVS are associated with 
age and are more often severe in patients with strictly lobar ICH attributed to CAA. A 
predilection of severe PVS for the centrum semiovale rather than the basal ganglia may 
therefore be secondary to, and indicative of, CAA. Further studies with pathological 
verification are needed to determine the relevance of PVS for improving the sensitivity of 
CAA diagnostic criteria. Longitudinal studies are required to explore whether PVS are an 
early feature of the small vessel disease underlying ICH, their change over time, and 
prognostic implications for clinical outcome.267, 271 
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Chapter 6 MRI-visible perivascular spaces 
as a neuroimaging marker of cerebral 
amyloid angiopathy: MRI-histopathological 
study 
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ABSTRACT 
Objective: We investigated whether severe MRI-visible Perivascular Spaces (PVS) in the 
cerebral hemisphere white matter (centrum semiovale) are more common in patients with 
pathology-proven CAA vs. those with pathology-proven non-CAA related intracerebral 
haemorrhage (ICH). 
Methods: Using a validated 4-point scale on axial T2-weighted MRI, we compared PVS in 
patients with pathology-proven CAA to those with spontaneous ICH but no 
histopathological evidence of CAA. In a preliminary analysis restricted to patients with T2*-
weighted gradient-recalled echo MRI, we also investigated whether including severe 
centrum semiovale PVS increases the sensitivity of existing diagnostic criteria for probable 
CAA. 
Results: Fourteen CAA patients and 10 non-CAA related ICH patients were included. 
Eight of the CAA patients were admitted for symptomatic spontaneous lobar ICH, one 
because of ischaemic stroke, one with transient focal neurological episodes, and four due to 
cognitive decline. Severe (>20) centrum semiovale PVS were more frequent in patients with 
CAA compared to controls (12/14 [85.7%; 95%CI: 57.2-98.2%] vs. 0/10 [one-sided 95%CI: 
0-30.8%], p<0.0005); this was robust to adjustment for age. The original Boston criteria for 
probable CAA showed a sensitivity of 76.9% (95% CI: 46.2-95%), which increased to 92.3% 
(95% CI: 64-99.8%), without loss of specificity, after including severe centrum semiovale 
PVS. 
Conclusions: Severe centrum semiovale PVS on MRI may be a promising new 
neuroimaging marker for the in vivo diagnosis of CAA. However, our findings are 
preliminary and require confirmation and external validation in larger cohorts of pathology-
proven CAA. 
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6.1 Introduction 
Sporadic cerebral amyloid angiopathy (CAA),2 caused by progressive vascular amyloid-β 
deposition in small cortical and leptomeningeal vessels, is a major and increasingly frequent 
cause of lobar intracerebral haemorrhage (ICH) and cognitive impairment in older 
patients.28, 37, 242 CAA is associated with neuroimaging markers including lobar ICH and 
strictly lobar cerebral microbleeds, which allow its clinical-radiological diagnosis using the 
Boston criteria.28, 202, 203 However, these criteria have limited sensitivity in some studies; 
new non-invasive diagnostic markers of CAA are therefore needed, particularly to identify 
early disease.28, 242 
Recently, perivascular spaces (PVS) have emerged as a potential MRI marker of the 
presence and severity of cerebral small vessel disease.30, 31, 272-275 Perivascular spaces are 
interstitial fluid-filled cavities surrounding small penetrating vessels, which function to allow 
interstitial fluid and solute efflux from the brain.129, 263, 276 CAA almost invariably 
accompanies Alzheimer’s disease (AD), and in this setting vascular amyloid-β is associated 
with enlargement of perivascular spaces.38, 128, 132, 277 However, whether PVS are associated 
with sporadic CAA is not known. We hypothesized that progressive amyloid-β deposition 
in CAA impairs interstitial fluid drainage, causing MRI-visible severe PVS in the cerebral 
hemisphere white matter (centrum semiovale). To test this hypothesis, we compared the 
prevalence of severe centrum semiovale PVS in patients with pathology-proven sporadic 
CAA compared to patients with pathology-proven non-CAA related spontaneous ICH. In a 
preliminary analysis, we also investigated whether including severe centrum semiovale PVS 
increases the sensitivity of existing diagnostic criteria for CAA.202 
6.2 Methods 
6.2.1 Study participants and data collection 
We included all eligible patients from four stroke centres identified retrospectively by a 
systematic keyword search of pathology reports (Appendix E Figure 1). Cases were defined 
as subjects with both pathology-proven CAA (from routinely collected brain biopsy, biopsy 
at haematoma evacuation or autopsy) and adequate T2-weighted MRI sequences. Controls 
were defined as subjects with spontaneous symptomatic ICH, no pathological evidence of 
CAA, and adequate T2-weighted MRI. 
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6.2.2 Standard Protocol Approvals, Registrations, and Patient 
Consents 
The study was approved by the National Hospital for Neurology and Neurosurgery and 
Institute of Neurology Joint Research Ethics Committee and the Commission d’Ethique 
Biomedicale Hospitalo Facultaire of the Faculte de Medicine (Universite Catholique de 
Louvain). 
6.2.3 Pathological analysis 
Brain biopsies or haematoma evacuation samples were fixed in 10% formalin, embedded in 
paraffin and processed for paraffin sectioning. Routine haematoxylin-eosin staining was 
performed for morphological assessment and the presence or absence of vascular amyloid-
β deposition was confirmed by immunohistochemical detection. Samples not containing any 
assessable vessels were excluded from analysis. We assessed CAA presence and severity in 
all available vessels (in all cases from solid tissue fragments except in 1 case from isolated 
vessels); we also determined, wherever possible, whether vessels were leptomeningeal or 
parenchymal. CAA severity was graded using the modified Vonsattel grading system;67, 72 all 
included CAA cases had a severity of at least grade 2 (i.e. replacement of the whole vessel 
wall by amyloid-β) in line with previous recommendations.67 Non-CAA was defined as 
absence of vascular amyloid-β deposition. 
6.2.4 Magnetic resonance imaging data and analysis 
Mandatory imaging included axial T2-weighted sequences in all patients (slice thickness: 
5mm, field strength: 1.5T) and, whenever available, T2*-weighted gradient-recalled echo 
(T2*-GRE) sequences. MR images were reviewed blinded to clinical details, 
histopathological diagnosis and microbleeds status. PVS were defined and rated on T2-
weighted MR images, according to STandards for ReportIng Vascular changes on 
nEuroimaging (STRIVE),31 by a trained observer using a validated 4-point visual rating scale 
(0=no PVS, 1=<10 PVS, 2=11-20 PVS, 3=21-40 PVS and 4=>40 PVS) in the basal ganglia and 
centrum semiovale (cerebral hemisphere white matter).30, 267 Intra-rater reliability testing of 
the PVS scale using an independent dataset of ICH scans (n=30) showed an intra-rater 
Cohen’s kappa of 0.91 for basal ganglia PVS and 0.82 for centrum semiovale PVS. 
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6.2.5 Statistics 
We compared clinical characteristics between the patients with vs. without CAA on 
neuropathology, using the Fisher’s exact test for categorical variables, and Mann-Whitney 
U-test for age (not normally distributed continuous variable). We pre-specified a definition 
of severe centrum semiovale PVS as >20 (Grade 3). Although arbitrary, this definition is in 
line with the most severe category of white matter PVS used in a previous study (and found 
to relate to vascular risk factors),270 and provided two numerically-balanced categories 
consistent with our aim of increasing the sensitivity of CAA diagnosis. We compared both 
the crude and age-standardized prevalence of severe PVS between groups using Fisher’s 
exact test. We calculated the sensitivity and specificity after the addition of severe centrum 
semiovale PVS to the original Boston diagnostic criteria for CAA (including strictly lobar 
cerebral microbleeds)202 in line with Standards for Reporting of Diagnostic Accuracy 
(STARD) guidelines.278 The histopathological information was not taken into account for 
the classification. The analysis for clinically probable CAA was restricted to patients with 
T2*-GRE MRI sequences available. Significance level was set at 0.05 for all analyses. 
Statistical analyses were carried out using STATA (Version 11.2, StataCorp.). 
6.3 Results 
Fourteen CAA patients and 10 non-CAA ICH patients were included (Table 6.1) out of 56 
screened; 30 patients were excluded because of no MRI available, 1 non-CAA patient 
because of no evidence of ICH on MRI, and another non-CAA patient in whom the tissue 
sample contained no assessable vessels. Eight of the CAA patients were admitted with 
symptomatic spontaneous lobar ICH, one with ischaemic stroke, one with transient focal 
neurological episodes, and four with cognitive decline (one of these also had radiological 
evidence of a previous ICH). All non-CAA patients were admitted with symptomatic 
spontaneous ICH. Twenty-three of the 24 available pathological samples contained at least 
2 assessable parenchymal or leptomeningeal vessels. There were 23 solid tissue samples 
including vessels, and one sample including only isolated vessels. All 14 CAA cases 
contained >10 assessable vessels; 12 cases with both cortical and leptomeningeal, and 2 
with only leptomeningeal vessels. Of the 10 non-CAA cases, 4 contained >10 assessable 
vessels, while the other 6 cases contained a median number of 2 assessable vessels 
(Interquartile Range: 2-3); 1 case contained both cortical and leptomeningeal, 5 only 
cortical, and 3 only leptomeningeal vessels; in the case containing only isolated vessels, their  
 108 
Table 6.1 Patient and imaging characteristics. 
n (%) 
CAA† 
(N=14) 
Non-CAA ICH† 
(N=10) 
p-value 
Age, median (IQR), years 66.9 (65.3-71.4) 56.9 (48.8-66.5) 0.035* 
Sex, female 11 (78.6%) 5 (50%) 0.204 
History of hypertension 4 (28.6%) 3 (30%) 1.000 
Presence of radiological ICH 9 (64.3%) 10 (100%) 0.053 
Lobar ICH on MRI (symptomatic or 
asymptomatic) 
9 (64.3%) 8 (80%) 0.653 
Deep ICH on MRI 0 (0%) 2 (20%) 0.163 
Cerebral microbleeds  
(T2* GRE MRI was available in 13 CAA and 8 non-CAA patients) 
  
Cerebral microbleeds presence 11/13 (84.6%) 5/8 (62.5%) 0.325 
Lobar (cortical-subcortical) CMBs 11/13 (84.6%) 1/8 (12.5%) 0.002* 
Deep CMBs 1/13 (7.7%) 2/8 (25%) 0.531 
Cerebellar CMBs 0/13 (0%) 1/8 (12.5%) 0.381 
PVS centrum semiovale    
Severe PVS (>20) 12(85.7%) 0 (0%) <0.0005* 
No PVS 0 (0%) 1 (10%) 0.417 
1-10 PVS 0 (0%) 4 (40%) 0.020* 
11-20 PVS 2 (14.3%) 5 (50%) 0.085 
21-40 PVS 6 (42.9%) 0 (0%) 0.024* 
>40 PVS 6(42.9%) 0 (0%) 0.024* 
PVS basal ganglia    
1-10 PVS 13 (92.9%) 9 (90%) 1.000 
11-20 PVS 1 (7.1%) 1 (10%) 1.000 
21-40 PVS 0 0 - 
>40 PVS 0 0 - 
†CAA cases: 8 haematoma evacuations, 5 brain biopsies and 1 autopsy; non-CAA ICH: 10 
haematoma evacuations; CAA severity grading: Vonsattel Grade 2 (n=6), Grade 3 (n=6) and Grade 4 
(n=2).67 
origin could not be determined. The amount of available pathological tissue was generally 
greater in the CAA cases than the non-CAA cases. 
Severe (>20) centrum semiovale PVS were detected in 85.7% (95%CI: 57.2-98.2%) of 
patients with histopathologically-confirmed CAA, but in none (one-sided 95%CI: 0-30.8%) 
of the controls with histopathologically confirmed non-CAA ICH (p<0.0005) (Figure 6.1). 
The age-standardised prevalences of severe centrum semiovale PVS were 85.7% (95%CI: 
65.7%-100%) in the CAA group versus 0% in the non-CAA ICH group. The prevalence of 
the most severe category of centrum semiovale PVS (>40) was also higher in CAA than 
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non-CAA ICH (Table 6.1). Within the CAA group, 7/8 (87.5%; 95%CI: 47.4%-99.7%) 
patients who presented with symptomatic lobar ICH had severe centrum semiovale PVS 
(p<0.0005 compared with the non-CAA ICH group). There was no difference in the 
prevalence of any basal ganglia PVS category between the CAA and non-CAA ICH group. 
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Figure 6.1 MRI-visible white matter perivascular spaces in CAA and non-CAA ICH. Perivascular 
spaces (PVS) are defined as small, sharply delineated structures of (or close to) cerebrospinal fluid 
intensity, measuring <3mm following the course of perforating or medullary vessels, in basal ganglia 
and centrum semiovale. In (A) and (B) the left panels show dot-like hyperintensities (florid PVS) on 
representative axial T2-weighted MRI at 1.5 Tesla in the centrum semiovale, in patients with 
histopathologically confirmed cerebral amyloid angiopathy (CAA); the right panels show the 
corresponding pathology (immunostaining for Aβ) with dense amyloid deposition spanning the 
entire vessel wall of a cortical (A, right panel) and a leptomeningeal arteriole (B, right panel). (C) and 
(D) show axial T2-weighted MRI from two of the non-CAA cases, showing a paucity of centrum 
semiovale PVS. 
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Table 6.2 Diagnosis of cerebral angiopathy (CAA) using the original Boston criteria (including 
strictly lobar microbleeds) with and without the inclusion of severe centrum semiovale PVS (>20 
PVS). Only cases with T2*-GRE were included in this analysis (n=21). Inclusion of severe centrum 
semiovale PVS resulted in the diagnostic upgrading of three patients: two from possible to probable 
CAA and one from non-CAA to possible CAA. 
Clinical Diagnosis 
Original Boston criteria 
With inclusion of severe 
centrum semiovale PVS 
n 
Pathologic diagnosis 
n 
Pathologic diagnosis 
CAA (+) CAA (-) CAA (+) CAA (-) 
Probable CAA 11 10 1 13 12 1 
Non-probable CAA 10 3 7 8 1 7 
   -Possible CAA 4 2 2 3 1 2 
   -Non CAA 6 1 5 5 0 5 
Total 21 13 8 21 13 8 
T2*-GRE MRI was available in 13 CAA and 8 non-CAA ICH patients. Adding severe 
centrum semiovale PVS (>20 PVS) to the original Boston criteria for CAA resulted in the 
diagnostic upgrading of three patients (Table 6.2). The original Boston criteria showed a 
sensitivity of 92.3% (95% CI: 64-99.8%) for possible or probable CAA diagnosis, while 
inclusion of severe centrum semiovale PVS increased their sensitivity to 100% (95% CI: 
75.3-100%), without loss of specificity (62.5%; 95% CI: 24.5-91.5%). For probable CAA the 
original Boston criteria had a sensitivity of 76.9% (95% CI: 46.2-95%); inclusion of severe 
centrum semiovale PVS increased this to 92.3% (95% CI: 64-99.8%). The specificity for 
probable CAA was 87.5% (95% CI 47.3–99.7%) for both criteria. 
6.4 Discussion 
We have shown that severe PVS in the centrum semiovale white matter are more common 
in subjects with pathology-proven sporadic CAA than control non-CAA subjects. These 
findings suggest that severe centrum semiovale PVS, in this patient population, may be a 
promising new neuroimaging marker to improve the sensitivity of in vivo diagnosis of CAA. 
However, the sensitivity and specificity of severe centrum semiovale PVS require external 
validation, ideally in a larger independent cohort. 
Perivascular spaces are a key route for the drainage of interstitial fluid and solutes 
(including soluble amyloid-β) from the brain. Progressive amyloid-β deposition in small 
cortical and leptomeningeal arteries in CAA could gradually impair perivascular drainage, 
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causing retrograde dilation of perivascular spaces in the underlying white matter of the 
centrum semiovale, either by blocking bulk flow, or by diminishing the pulsatility of small 
vessels (required for efficient interstitial fluid drainage) due to smooth muscle cell loss.263, 
279 Impaired perivascular drainage could then further exacerbate vascular and perivascular 
amyloid-β deposition creating a “feed-forward loop”.274, 276 Consistent with this hypothesis, 
a post-mortem study of AD found that amyloid-β blocks perivascular drainage pathways in 
CAA associated with AD, and the degree of enlargement of white matter perivascular 
spaces correlates with CAA severity.132 Moreover, a recent MRI study in ICH patients 
reported that very severe centrum semiovale PVS were associated with CAA defined 
according to clinical-radiological criteria.272 However, more studies are needed to 
definitively determine the pathological basis of MRI-visible PVS. 
We found no increased prevalence of basal ganglia PVS in CAA, consistent with deep 
perforating arteries being largely spared by amyloid-β deposition.37 Previous studies report 
that neuroimaging markers of hypertensive arteriopathy (lacunes, deep cerebral 
microbleeds and white matter changes) are more strongly linked to basal ganglia than 
centrum semiovale PVS, also suggesting that the distribution of PVS may reflect the 
underlying arteriopathy.30, 272, 274, 275 Since lobar ICHs are more likely to be surgically 
evacuated, our sample of non-CAA ICH is biased towards lobar ICH, which may contribute 
to the lack of severe basal ganglia PVS in the non-CAA group. However, non-CAA ICH 
cases more often had milder (1-10) centrum semiovale PVS compared to CAA cases. 
Limitations of our study include the small cohort and selection bias due to the 
requirement for T2-weighted MRI. Because we included routinely collected haematoma 
evacuation samples, which may be suboptimal in comparison to post-mortem examinations, 
it was not possible to definitively assess in all patients whether vessels were parenchymal or 
leptomeningeal. Due to limited tissue sampling it is possible that some non-CAA ICH 
patients might have had undetected CAA. Moreover, the amount of available tissue (and 
number of assessable cortical and leptomeningeal vessels) was generally higher in the CAA 
group, which could have led to a higher chance of sampling error in the non-CAA group. 
However, misclassification and small sample size would tend to bias toward a null result. 
Although CAA patients were older than non-CAA patients, the difference in severe 
centrum semiovale PVS was robust to adjustment for age; furthermore, the CAA group had 
a higher prevalence of PVS only in the centrum semiovale, while confounding by age would 
be expected to increase PVS severity in both the centrum semiovale and basal ganglia.270, 272, 
274 Finally, although the PVS raters were blinded to clinical and histopathological information 
as well as microbleeds status, it was impossible to blind them to ICH presence. 
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Our findings are preliminary and hypothesis-generating, requiring external validation 
in larger independent cohorts with pathological verification of CAA. Nevertheless, if 
confirmed, PVS in the centrum semiovale may help improve the sensitivity of MRI for in vivo 
diagnosis of sporadic CAA in an appropriate clinical context. Further studies are also 
needed to determine whether centrum semiovale PVS precede other imaging features of 
CAA280, which might help identify CAA earlier in its natural history.  
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Chapter 7 MRI-visible white matter 
perivascular spaces: a marker of 
cerebrovascular amyloid burden? 
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ABSTRACT 
Objective: To investigate the relationship between MRI-visible centrum semiovale 
perivascular spaces (CSO-PVS), a biomarker of impaired interstitial fluid drainage, and PET-
based amyloid-β burden across a wide range of cerebrovascular amyloid deposition, we 
analyzed a sample merging healthy subjects of variable age, a fraction of whom is expected 
to harbor significant cerebrovascular amyloid, and patients diagnosed with probable 
cerebral amyloid angiopathy (CAA). 
Methods: Thirty-one non-demented subjects (11 patients with probable CAA, 10 age-
matched healthy subjects >60yrs, and 10 healthy subjects <60yrs), had brain MRI and PiB-
PET. CSO-PVS was evaluated on axial T2-weighted sequences using a validated 4-point 
scale and further classified as high (score>3) or low (score≤3) degree for pre-specified 
analyses. Linear regression was used to assess the association between whole cortex PiB 
and CSO-PVS. 
Results: In multivariable linear regression adjusting for age, white matter changes and 
microbleeds count, whole cortex PiB binding was associated with CSO-PVS degree both as 
continuous variable (coefficient: 0.11; CI: 0.01-0.22, P=0.040) and as dichotomous variable 
(coefficient: 0.27; 95% CI: 0.11-0.44, p=0.002). In addition, the median PiB retention was 
higher in high compared to low CSO-PVS degree (median1.42; IQR: 1.37-1.50 vs. 1.14; IQR: 
1.12-1.23, p=0.0007), an association also present within the healthy subjects group 
separately (p=0.023). All results remained consistent in sensitivity analyses excluding 
healthy subjects <60 years. 
Conclusion: These results suggest a strong association between PiB uptake and CSO-PVS, 
which has important pathophysiological implications for both cerebrovascular amyloid 
deposition and CSO-PVS, but also highlights the possible utility of the latter as a surrogate 
for cerebrovascular amyloid burden. 
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7.1 Introduction 
Perivascular (or Virchow-Robin) spaces are interstitial fluid-filled cavities surrounding small 
penetrating vessels,281 which function to allow interstitial fluid and solute efflux from the 
brain.129, 263, 276 Accumulating evidence suggests that MRI-visible perivascular spaces in the 
centrum semiovale (CSO-PVS) and basal ganglia (BG-PVS) are potential neuroimaging 
markers of cerebral small vessel disease.30, 31, 272-275 PVS are also very common in healthy 
elderly subjects,264, 270 in whom CSO-PVS are a risk factor for dementia.271 CSO-PVS on 
MRI are also attracting increasing attention as a promising indicator of cerebrovascular 
amyloid deposition, a common age-related neuropathological process characterised by 
progressive amyloid-β accumulation within the walls of leptomeningeal and cortical small 
arteries, arterioles and occasionally capillaries.28, 37  
Recent studies emphasize not only that cerebrovascular amyloid deposition is widely 
prevalent in the aged population, affecting up to 30-40% of healthy elderly,58, 174 but also 
that it has become a major cause of spontaneous lobar intracerebral haemorrhage (ICH)28, 
37, can also cause or contribute significantly to cognitive impairment,58, 155 and is almost 
invariably present in Alzheimer’s disease.65 CSO-PVS is important to consider in this 
context as it might reflect impaired interstitial fluid drainage from the white matter to the 
cortical surface and in turn contribute to cerebrovascular amyloid deposition.276 Indeed, 
emerging evidence suggests that cerebrovascular amyloid deposition is a “protein 
elimination failure angiopathy”:282 as perivascular drainage pathways fail with age (or are 
overloaded by reduced capacity of other elimination mechanisms), amyloid-β is increasingly 
trapped in the perivascular compartment and deposited in the walls of small arteries.276 
However, the precise relationship and mechanisms between MRI-visible CSO-PVS and 
cerebrovascular amyloid deposition has not been explored in vivo. 
11C-Pittsburgh compound B (PiB) has been developed as a positron emission 
tomography (PET) radioligand for imaging both parenchymal and vascular fibrillar amyloid-β 
deposits, and has revolutionized research into potential pathomechanisms of 
cerebrovascular amyloid deposition and Alzheimer’s disease.48-50, 283-285 If MRI-visible CSO-
PVS and perivascular amyloid-β deposition are indeed linked, one would expect cortical PiB 
retention to be associated with the overall CSO-PVS burden. If confirmed, this would in 
turn further strengthen the potential of CSO-PVS as a surrogate for vascular amyloid 
burden. To investigate this relationship across as wide a range of cerebrovascular amyloid 
burden and CSO-PVS as possible, we analysed in an MRI-PET pilot study a well-sized sample 
purposely merging patients diagnosed with probable cerebral amyloid angiopathy (CAA) 
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and healthy subjects across the adult age span, a fraction of whom is expected based on 
established neuropathological knowledge58 to harbour some degree of both 
cerebrovascular amyloid and CSO-PVS.264, 270 
7.2 Subjects and Methods 
7.2.1 Study subjects 
Non-demented lobar ICH patients fulfilling the original Boston criteria for probable CAA195 
were recruited through the Addenbrooke’s Hospital Stroke Unit or ICH clinic. 
Consecutive eligible patients were approached to take part in the study. Admission records 
and clinic files were screened for discharged potentially eligible patients who were then 
contacted. All included CAA patients lived independently and their Mini-mental State 
Examination (MMSE) was >23 in all. Age at PiB PET, gender and presence of vascular risk 
factors were ascertained by medical records review and by patient and caregiver interview. 
Medication-free healthy subjects with no memory or cognitive complaints and normal 
MMSE results (≥29) were also enrolled through advertisements posted at the University of 
Third Age and hospital inboard. The absence of memory or cognitive complaint was 
specifically verified, and to avoid any recruitment bias the participants were informed that 
they would not be given any results from their scans (MR or PET) unless an unexpected 
lesion was found. The healthy sample comprised both a group of healthy elderly individuals 
≥60 years age-matched to the CAA group and a group of healthy adults <60 years of age.  
All subjects underwent a brain 11C-PiB PET scan and structural MRI on the same day. 
7.2.2 PET 
The methodology used for 11C-PiB production and PET scanning in our centre has 
previously been described.286 Briefly, PET scanning was performed on a GE Advance PET 
scanner. Following a 68Ge/68Ga transmission scan (15 minutes) for attenuation correction, 
~550 MBq of 11C-PiB was injected as a bolus through an antecubital vein, and the 90 min 
dynamic 11C-PIB-PET scan was reconstructed using the PROMIS 3D filtered backprojection 
algorithm.287 
The PET data analysis was completely automated and carried out by a physicist blinded 
to the results of the MRI (YTH). To facilitate segmentation, spatial normalization and 
delineation of anatomical regions of interest (ROIs), participants also underwent a 
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structural T1-weighted MRI scan on a 3T Siemens Tim-Trio (Siemens Medical Solutions, 
Erlangen, Germany), using a 3-dimensional MPRAGE scan (magnetization-prepared rapid 
gradient-echo sequence; repetition time/echo time/inversion time=2300 milliseconds/2.98 
milliseconds/900 milliseconds; flip angle, 9°; 1 average; 176 slices; 256256 matrix size; 
111 mm voxel size). To allow the use of standard space ROIs, the MRI, and thence the 
co-registered PET images, was spatially normalised to the MNI/ICBM152 T1-weighted 
template using the symmetric image normalisation method (SyN).288 
As previously described,289 ROIs were defined on these spatially normalized images as 
the intersection between ≥65% thresholded grey matter segments and Automated 
Anatomic Labeling (AAL) ROIs. ROIs overlapping with areas affected by the ICH were 
excluded a priori. In order to mitigate the partial volume effects of cortical atrophy, the CSF 
probability map for each subject, smoothed to match the PET spatial resolution, was used 
to correct each voxel time-activity curve (TAC) for CSF fraction (fCSF) through division by 
(1-fCSF).290, 291 For each ROI, distribution volume ratio (DVR) was estimated from the mean 
CSF-corrected TAC using the reference tissue Logan graphical method fitted over the 35-
90min post-injection interval, with the cerebellum as the reference tissue.292 Whole cortex 
DVR was obtained through volume-weighted averaging of the cortical ROI DVR values 
across both hemispheres. 
7.2.3 MRI data and analysis 
On the same day as the PiB-PET study, each subject underwent detailed structural MRI at 
3T (slice thickness: 4mm, slice gap: 5mm), which included T2-weighted, T1-weighted MP-
RAGE, FLAIR and T2*-GRE, using standard sequences. MR images were reviewed blinded 
to clinical and PET data. PVS were defined and rated on axial T2-weighted MR images, 
according to STandards for ReportIng Vascular changes on nEuroimaging (STRIVE),31 by a 
trained observer using a validated 4-point visual rating scale (0=no PVS, 1=<10 PVS, 2=11-
20 PVS, 3=21-40 PVS and 4=>40 PVS) in the basal ganglia (BG) and CSO.30, 272, 293 The 
numbers refer to PVS on one side of the brain: after reviewing all relevant slices for the 
anatomical area being assessed, the slice and side with the highest number of PVS was 
recorded. In cases of large lobar ICH, centrum semiovale PVS were assessed contralateral 
to the index ICH lesion; an estimation of the closest category ipsilateral to the lesion was 
made, and the highest severity was recorded. Intra-rater reliability testing of the PVS scale 
using an independent dataset of ICH scans (n=30) showed an intra-rater Cohen’s kappa of 
0.91 for BG-PVS and 0.82 for CSO-PVS. White matter hyperintensities of presumed 
vascular origin were assessed using the age-related white matter changes (ARWMC) 
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scale.294 CMBs were evaluated on T2*-GRE (echo time=20 ms) images according to the 
Microbleeds Anatomic Rating Scale (MARS) and published guidelines.35, 238 
7.2.4 Standard Protocol Approvals, Registrations, and Patient 
Consents 
The study received ethical approval by the Cambridgeshire Regional Ethics Committee and 
all participants provided signed informed consent. 
7.2.5 Statistical analysis 
We compared basic demographic, clinical and imaging characteristics of CAA patients 
versus healthy subjects and age-matched elderly healthy subjects using appropriate 
univariable tests: chi-square test or Fisher’s exact test for categorical variables, and Mann-
Whitney U test for continuous variables. The relationship between whole cortex DVR and 
CSO-PVS degree, both included as continuous variables, was explored across the whole 
sample using Kendall's non-parametric correlation analysis. Linear regression analyses were 
then used to quantify the relationship between PiB DVR and CSO-PVS grade after 
adjustment for other biologically plausible covariates found to be related to both PiB 
retention and PVS in previous studies, including age, white matter hyperintensities total 
score and lobar CMBs count.284, 295 We repeated the regression analysis using the CSO-PVS 
degree dichotomised into high (score >3) or low (score ≤3) (i.e. >40 CSO-PVS vs. ≤40 
CSO-PVS respectively). This definition was pre-specified and is in line with the most severe 
category of CSO-PVS which might be more characteristic and sensitive for CAA.270 This 
cut-off separated our data into two balanced groups. As a sensitivity analysis, we repeated 
the above linear regression models excluding healthy subjects <60 years (i.e. using only 
probable CAA patients and age-matched healthy elderly cases). 
We also compared PiB retention (i.e. whole cortex DVR) between subjects with high 
vs. low CSO-PVS degree within the whole study population, and then separately within the 
CAA patients and the healthy group. 
All tests of significance were 2-tailed, with values below the 10% level considered 
indicative of a trend. Statistical analyses were carried out using STATA (Version 12.1, 
StataCorp.). 
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7.3 Results 
Eleven eligible CAA patients and 20 healthy subjects (ten elderly individuals ≥60 years and 
ten adults <60 years) were recruited and selected for the study (Table 7.1). One young 
healthy subject was excluded from the analysis post-hoc because of lack of adequate MRI 
sequences. All CAA patients presented with symptomatic lobar ICH (four patients had two 
symptomatic ICHs and one had three). 11C-PiB-PET was performed within 3 years of first 
symptomatic lobar ICH. Two CAA patients had evidence of new asymptomatic lobar ICH 
on follow-up MRI. 
PiB retention was higher in CAA patients compared to the whole healthy group 
(p=0.0082; Table 7.1), but similar between CAA patients and age-matched healthy subjects 
(p=0.53). High (>40) CSO-PVS degree was more common in CAA patients compared with 
the healthy group (p=0.003) and the age-matched elderly healthy subgroup (63.6% vs. 20%; 
p=0.08). 
 
Table 7.1 Basic demographic and imaging characteristics of the study population. The p-values refer 
to the comparison between probable cerebral amyloid angiopathy cases (CAA) and age-matched 
elderly healthy subjects 
Characteristics 
Healthy 
subjects 
(n=20) 
Probable 
CAA patients 
(n=11) 
Age-matched 
elderly 
healthy 
subjects 
(n=10) 
P-value 
Age, median (IQR), years 59.5 (34.5-63.5) 71 (63-77) 63.5 (61-68) 0.06 
Sex, male (%) 5 (50) 9 (81.8) 5 (50) 0.18 
MMSE, median (IQR) 30 (29-30) 26 (25-28) 30 (29-30) 0.003 
Hypertension, n (%)* 0 6 (54.6) 0 0.012 
Lobar CMB presence, n (%) 1 (5)* 11 (100) 1 (10)* <0.0001 
Lobar CMBs count, median (IQR) 0 4 (2-50) 0 0.0002 
Total WMH score, median (IQR) 2.5 (0-4) 11 (9-14) 4 (4-6) 0.0002 
High degree CSO-PVS, n (%) 2 (10) 7 (63.6) 2 (20) 0.08 
Whole cortex DVR, median (IQR) 1.14 (1.11-1.21) 1.37 (1.23-1.43) 1.21 (1.13-1.65) 0.53 
* A healthy elderly subject had 3 lobar CMBs. 
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Figure 1 is the scatter plot of the relationship between whole-cortex PiB DVR and 
CSO-PVS degree across the whole cohort, showing a clear, nearly linear increase in PiB 
DVR as CSO-PVS increases, which was significant using non-parametric Kendall's 
correlation (tau-b = +0.552; p=0.0001). There was a trend for a correlation when only 
probable CAA patients and age-matched healthy elderly were included in the analysis 
(Kendall's tau-b=0.3289; p=0.068). In linear regression, PiB binding was positively associated 
with CSO-PVS degree both in the whole cohort and in sensitivity analyses, even after 
adjusting for age, CMBs and total white matter hyperintensities score (Table 7.2 and Table 
7.3). There was a mean 0.11 (0.01-0.22) higher PiB retention for each increase in CSO-PVS 
degree (p=0.04) and 0.27 (95% CI: 0.11 to 0.44) higher PiB retention for CSO-PVS degree 
>40 versus ≤40 (p=0.002). This relationship was still significant in just the healthy group 
alone, and remained so when excluding the subject with CMBs. 
 
Figure 7.1 Scatterplot of whole cortex PiB retention (i.e. DVR) and centrum semiovale perivascular 
spaces (CSO-PVS) severity categories in cerebral amyloid angiopathy (CAA) healthy subjects. There 
was a positive correlation between PiB retention and increasing CSO-PVS categories across the 
whole group (Kendall's tau-b=0.552; p=0.0001). 
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Table 7.2 Univariable and multivariable linear regression analysis of the association between whole 
cortex PiB retention (DVR) and CSO-PVS grade (as continuous variable) in the whole study 
population and in sensitivity analyses including only probable CAA patients and the age-matched 
healthy elderly (≥60 years) subgroup. 
CMBs: cerebral microbleeds; CSO-PVS: centrum semiovale perivascular spaces; WMH: White 
matter hyperintensities 
 
Table 7.3 Univariable and multivariable linear regression analysis of the association between whole 
cortex PiB retention (DVR) and high CSO-PVS degree (>40) in the whole study population and in 
sensitivity analyses including only probable CAA patients and the age-matched healthy elderly (≥60 
years) subgroup. 
 
  
Whole cohort 
PiB retention 
Coefficient (95% CI) p-value 
CSO-PVS, unadjusted 0.12 (0.06-0.18) <0.0001 
CSO-PVS, adjusted for age, CMBs and WMH 0.11 (0.01-0.22) 0.040 
Probable CAA + age-matched healthy elderly 
CSO-PVS, unadjusted 0.11 (-0.01-0.22) 0.071 
CSO-PVS, adjusted for CMBs and WMH 0.13 (-0.01-0.26) 0.059 
Whole cohort 
PiB retention 
Coefficient (95% CI) p-value 
CSO-PVS, unadjusted 0.28 (0.14-0.42) <0.0001 
CSO-PVS, adjusted for age, CMBs and WMH 0.27 (0.11-0.44) 0.002 
Probable CAA + age-matched healthy elderly 
CSO-PVS, unadjusted 0.21 (0.04-0.39) 0.021 
CSO-PVS, adjusted for CMBs and WMH 0.29 (0.08-0.49) 0.009 
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Across the whole cohort, whole cortex DVR was higher in subjects with a high 
CSO-PVS degree compared to low CSO-PVS degree (median1.42; IQR: 1.37-1.50 vs. 1.14; 
1.12-1.23, respectively; p=0.0007). This was also true within the healthy group (1.82; 1.80-
1.84 vs. 1.13; 1.11-1.18, respectively; p=0.023) as well as the healthy elderly (≥60 years) 
subgroup (1.82; 1.80-1.84 vs. 1.17; 1.12-1.36, respectively; p=0.037). The same trend was 
observed in the CAA group. There was no significant association between BG-PVS and PiB 
retention (data not shown). 
7.4 Discussion 
The present study is the first to address the relationship between cerebrovascular amyloid 
burden and CSO-PVS. Our data suggest a strong association between whole cortex 
amyloid burden and MRI-visible CSO-PVS in a combined cohort of patients diagnosed with 
probable CAA-related ICH and healthy elderly subjects without any memory or cognitive 
complaint, expected to represent a continuum of the degree of neuropathological vascular 
amyloid deposition.58, 174 Furthermore, this association remained strongly significant after 
adjusting for potential covariates that may affect the severity of CSO-PVS and PiB binding, 
including age, WMH and CMB count. Importantly, the link between PiB binding and CSO-
PVS was also present within the healthy elderly group alone, and showed similar trends in 
the CAA group. Finally, this association was not present with BG-PVS, i.e., it was specific 
for CSO-PVS, as it. 
The design of the present study including in the same analysis both probable CAA-
related lobar ICH patients and healthy controls was based on the strong neuropathological 
and in vivo MR evidence detailed in the Introduction that both cerebrovascular amyloid and 
CSO-PVS are present in the healthy elderly and form a continuum with symptomatic CAA. 
This also underlies the rationale for not excluding from this analysis the healthy subject 
who had 3 lobar CMBs and might therefore have incipient CAA. In order to test our 
hypothesis that CSO-PVS and cerebrovascular amyloid deposition are linked, we used PiB 
PET. Several lines of evidence have established that PiB PET detects not only parenchymal 
but also vascular amyloid-β deposits. Thus, radiologic-pathologic correlation studies 
showed that PiB binds to vascular amyloid.201, 296 Moreover, increased PiB retention is 
spatially related to lobar CMBs in CAA176 and may predict sites of future haemorrhage.285 
Significant amyloid burden on PET imaging is found in 20-40% healthy elderly individuals 
after age 60, despite normal cognition.297, 298 Given the high prevalence of both Alzheimer’s 
disease pathology and incipient CAA, increased PiB burden in healthy aged people is 
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thought to reflect not only very early Alzheimer’s disease-related parenchymal 
accumulation of amyloid-β but also underlying asymptomatic cerebrovascular amyloid.58, 174 
Accordingly, in a recent study in asymptomatic older adults, PiB uptake was strongly 
associated with lobar CMBs, a putative marker of CAA, independent from APOE ε4 status, 
vascular risk factors, and antiplatelet therapy.295 All these factors may explain why in the 
present sample there was no significant difference in whole cortex PiB retention or regional 
ratios between CAA patients and healthy subjects (see Baron et al289 for further details and 
a discussion on this). The rationale of the present study, namely a continuum in 
cerebrovascular amyloid across healthy participants and probable CAA patients, was 
strongly supported by the significant relationship between CSO-PVS degree and PiB uptake 
found within the healthy control group alone. In other words, the significant findings in the 
merged sample do not merely reflect the higher CSO-PVS burden in the CAA subset. 
Although the mechanisms of MRI-visible CSO-PVS remain poorly understood, our 
current findings highlight a potential pathophysiologic link between amyloid burden and 
CSO-PVS. This link may reflect interstitial fluid drainage impairment within the perivascular 
spaces by progressive vascular amyloid-β deposition, causing retrograde dilation of 
perivascular spaces in the underlying white matter of the centrum semiovale.263, 279 Impaired 
perivascular drainage could then further exacerbate vascular and perivascular amyloid-β 
deposition in small cortical and leptomeningeal vessels, setting in motion a “feed-forward 
loop”, by which cumulative amyloid deposition promotes further cerebrovascular amyloid 
deposition.274, 276, 299 Consistent with this hypothesis, a post-mortem study of Alzheimer’s 
disease found that amyloid-β blocks perivascular drainage pathways in cerebrovascular 
amyloid deposition associated with Alzheimer’s disease pathology; the degree of white 
matter perivascular spaces enlargement correlated with cerebrovascular amyloid burden.132 
Moreover, a recent MRI study in spontaneous ICH patients reported that high grade CSO-
PVS were strongly associated with CAA defined according to clinical-radiological criteria.272 
Similar associations were reported among subjects from a memory clinic, in which CSO-
PVS was associated with cerebrovascular amyloid markers, whereas BG-PVS were 
indicative of hypertensive arteriopathy.274 Our findings are also consistent with the 
hypothesis of BG-PVS have different pathophysiology to CSO-PVS and deep perforating 
arteries being largely spared by amyloid-β deposition.37 
Strong points of our study include the systematic MRI evaluation for a range of imaging 
markers of cerebral small vessel disease, which allowed testing a pre-specified hypothesis, 
and the fact that MR was obtained on the same day as PET. The main limitation, intrinsic to 
amyloid imaging, is that incipient Alzheimer’s disease pathology might also be present in 
non-demented ICH patients suspected of CAA, particularly given the frequent co-
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occurrence and overlapping molecular mechanisms of these two amyloid-related 
conditions, but also in healthy elderly. Another limitation is the relatively small sample size 
limiting statistical power. For this reason our study should be considered preliminary and 
the p-values should be interpreted cautiously, particularly within the subgroups. As our 
study was cross-sectional, we were unable to determine the cause–effect relationship 
between increased PiB retention and CSO-PVS. 
Although preliminary, our results suggest that amyloid-β burden in associated with 
CSO-PVS degree, and have implications for understanding cerebrovascular amyloid 
pathophysiology. Furthermore, our work further supports the idea of CSO-PVS being a 
useful marker of vascular amyloid burden in future studies of both clinically healthy subjects 
and symptomatic CAA cohorts, as well as disease-modifying trials.300 Larger prospective 
cohorts are needed to validate our findings and clarify exactly how exactly CSO-PVS are 
related to amyloid deposition, impaired interstitial fluid drainage as well as other markers of 
small vessels disease in CAA. 
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Chapter 8 White matter perivascular 
spaces on MRI are related to cortical 
superficial siderosis in sporadic cerebral 
amyloid angiopathy 
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ABSTRACT 
Objectives: We set out to investigate whether MRI-visible centrum semiovale perivascular 
spaces (CSO-PVS) - a potential biomarker of impaired interstitial fluid drainage in sporadic 
cerebral amyloid angiopathy (CAA) - is associated with cortical superficial siderosis (cSS), 
reflecting recurrent haemorrhage from severe leptomeningeal and superficial cortical 
vascular amyloid. 
Methods: Retrospective multicentre cohort study of possible/probable CAA according to 
the Boston criteria. PVS were rated in basal ganglia (BG-PVS) and CSO (CSO-PVS) on axial 
T2-weighted sequences, using a validated 4-point visual rating scale, and were classified as 
high (score >2) or low degree (score ≤2) for pre-specified analyses. Independent risk 
factors for high CSO-PVS degree were investigated in logistic regression. 
Results: The final cohort consisted of 138 CAA patients (mean age: 71.8; 95%CI: 70.2-73.4 
years, 52.2% male). High CSO-PVS degree was present in 61.2% of cases. The prevalence of 
any cSS, and disseminated cSS (involving >3 sulci), was higher in patients with high vs. low 
CSO-PVS degree (for any cSS 45.9% vs. 13.5%; p<0.00005; for disseminated cSS 31.8% vs. 
0%; p<0.00005). In multivariable logistic regression analysis, cSS presence (OR: 4.78; 95%CI: 
1.64-13.87; p=0.004) was an independent predictors of high CSO-PVS degree. We found no 
associations between BG-PVS and cSS. 
Conclusions: High degree of CSO-PVS is highly prevalent in sporadic CAA, and is related 
to cSS. Our findings suggest that severe leptomeningeal and cortical vascular amyloid 
(causing cSS) is related to impaired interstitial fluid drainage from cerebral white matter, 
although determining the causal direction of this relationship requires prospective studies. 
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8.1 Introduction 
Sporadic cerebral amyloid angiopathy (CAA) is a common small vessel disease that results 
from progressive amyloid–β deposition within the walls of small cortical and leptomeningeal 
arteries.28, 242 CAA is most often recognised in life by symptomatic, lobar intracerebral 
haemorrhage (ICH) and cognitive impairment in elderly patients.28, 37, 242 CAA is also 
associated with characteristic magnetic resonance imaging (MRI) markers including strictly 
lobar cerebral microbleeds (CMBs) and white matter hyperintensities.28, 35 These imaging 
markers might be suggestive of CAA even in asymptomatic elderly individuals. 
Accumulating evidence suggests that cortical superficial siderosis (cSS)171, 191, 194, 195 and 
MRI-visible centrum semiovale (i.e. cerebral hemisphere white matter) perivascular spaces 
(CSO-PVS) are new imaging markers of CAA, which may reflect distinct but related aspects 
of pathophysiology. However, the precise relationship between CSO-PVS and other 
imaging manifestations of CAA, including cSS and lobar CMBs has not been explored. 
We hypothesised that progressive amyloid-β deposition in small leptomeningeal or 
superficial cortical vessels (leading to fragility, repeated haemorrhage into the subarachnoid 
space and cSS) blocks perivascular drainage pathways from white matter to the cortical 
surface, resulting in CSO-PVS. To test this hypothesis and to gain insights into potential 
mechanisms we investigated the relationship between MRI-visible CSO-PVS and cSS in 
patients with possible or probable CAA according to the Boston criteria. 
8.2 Methods 
8.2.1 Study population and data collection 
Consecutive CAA patients(according to the original Boston criteria202 – i.e. not including 
cSS as a criterion) from an ongoing multicentre cohort study at four stroke centres over 
defined time periods as previously described,
301, 302
 were evaluated. The centres were: 
University College London Hospitals NHS Foundation Trust (London) (03/2003–09/2011), 
Addenbrooke’s Hospital (Cambridge) (07/2002–03/2010), Cliniques Universitaires Saint Luc 
(Brussels) (12/2003–04/2010) and CHU Mont-Godinne UCL (Brussels) (08/2005–03/2009). 
At participating centres, MRI is a routine investigation for cases of suspected CAA, unless 
there are contra-indications. Essential inclusion criteria for the multicentre CAA cohort301, 
302 and this analysis were: (1) CAA, defined according to the Boston criteria202 – including 
lobar CMBs, but not cSS; and (2) available MRI sequences of adequate quality including T2-
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weighted, T2*-weighted gradient-recalled echo (T2*-GRE) and FLAIR MRI sequences. The 
selection process of this multicentre cohort has been previously described:10, 11 in brief, 
from a total of 358 patients with suspected CAA/spontaneous ICH screened, 144 were 
initially excluded because of MRI was not performed or was not available/interpretable. 
After reviewing available MRI and clinical data, 56 patients not fulfilling the Boston criteria 
for CAA were further excluded, leaving a total of 158 CAA patients potentially eligible for 
the current analysis:302 59 patients from University College London Hospitals, 49 from 
Addenbrooke’s Hospital, 36 from Cliniques Universitaires Saint Luc and 14 patients from 
CHU Mont-Godinne UCL. Patients with no T2 MRI (n=14), T2 MRI of insufficient quality 
(n=1) and irretrievable sequences (n=5) where further excluded from this analysis. 
Demographic and clinical information was obtained from prospective databases and by 
medical records review using standardised data collection forms, as previously described.301, 
302 Hypertension was defined as a history of hypertension, taking antihypertensive 
treatment or documented elevated blood pressure (systolic >150 or diastolic >95mmHg) 
before admission, diabetes as ongoing use of a hypoglycaemic agent and smoking as history 
of tobacco use before admission. 
The study received ethical approval by the National Hospital for Neurology and 
Neurosurgery and Institute of Neurology Joint Research Ethics Committee, the 
Commission d’Ethique Biomedicale Hospitalo Facultaire of the Faculte de Medicine 
(Université Catholique de Louvain), and the Comite d’ethique medicale of the CHU Dinant-
Godinne (Université Catholique de Louvain). 
8.2.2 Neuroimaging data and analysis 
The MRI protocols were similar in each hospital. Imaging was performed at field strength of 
1.5T for all patients and included T2-weighted (slice thickness: 4-6 mm, slice gap: 2-6 mm, 
echo time: 89-90/92 ms, relaxation time: 4408.8/6040/5610/6630/4520 ms), FLAIR, T2*-
GRE (slice thickness 5 mm, slice gap: 1.5/5/6.5 mm, repetition time 500–1,000 ms, echo 
time 40/26/15/50-70 ms) and diffusion-weighted imaging (DWI) sequences. MR images were 
reviewed by a single trained rater blinded to clinical data. 
PVS were assessed and rated on axial T2-weighted MR images, according to STandards 
for ReportIng Vascular changes on nEuroimaging (STRIVE),31 by a trained observer using a 
validated 4-point visual rating scale (0=no PVS, 1=<10 PVS, 2=11-20 PVS, 3=21-40 PVS and 
4=>40 PVS) in the basal ganglia (BG) and CSO.30, 267, 293 The numbers refer to PVS on one 
side of the brain: after reviewing all relevant slices for the anatomical area being assessed, 
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the slice and side with the highest number of PVS was recorded. The assessment of PVS 
may be influenced by the presence of confluent white matter hyperintensities; in such cases 
estimation was made of the closest PVS rating category, using the appearance of non-
involved white matter, according to the rating scale used. In cases of large lobar ICH, 
centrum semiovale PVS were assessed contralateral to the index ICH lesion; an estimation 
of the closest category ipsilateral to the lesion was made, and the highest severity was 
recorded. Intra-rater reliability testing of the PVS scale using a dataset of ICH scans (n=30) 
showed an intra-rater Cohen’s kappa of 0.91 for BG-PVS and 0.82 for CSO-PVS. 
cSS was defined as linear residues of chronic blood products in the superficial layers of 
the cerebral cortex showing a characteristic “gyriform” pattern of low signal on T2*-GRE 
images, without corresponding hyperintense signal on T1-weighted or FLAIR images.301 The 
distribution of cSS was classified as focal (restricted to ≤3 sulci) or disseminated (≥4 
sulci).195 The inter-rater agreement for the presence or absent of cSS in our group has been 
previously punished and was 89.6% (Cohen’s kappa=0.79) and for cSS categories was 89.6% 
(weighted Cohen’s kappa=0.75).302 T2-weighted MR images were assessed for PVS blinded 
to cSS status on T2*-GRE and vice versa; both markers were rated blind to the study 
hypothesis. 
White matter hyperintensities (leukoaraiosis) were assessed with the four-step 
simplified Fazekas rating scale, from 0 to 3 (0=no lesions; 1=focal lesions; 2=early confluent; 
3=confluent).239, 301 Lobar CMBs were evaluated on T2*-GRE images according to the 
Microbleeds Anatomic Rating Scale (MARS), as previously described.35, 238, 301  
8.2.3 Statistical analysis 
We pre-specified a dichotomised classification of PVS degree as high (score >2) or low 
(score ≤2). This definition is in line with the most severe category of CSO-PVS used in a 
previous study (and found to relate to vascular risk factors),270 and appears to be sensitive 
for CAA diagnosis.293 We compared demographic, clinical and imaging characteristics of 
CAA patients with high versus low CSO-PVS degree using appropriate univariable tests: chi-
square test or Fisher’s exact test for categorical variables, and Student t-test for age. 
Multivariable logistic regression analysis was used to explore the relation between high 
CSO-PVS degree and cSS adjusted for other variables based on the results of univariable 
analysis, plus other biologically plausible confounders related to PVS264, 270, 272, 274, 303 or CAA 
severity, including age, sex, hypertension, WMH, CMBs number, and previous history of 
symptomatic ICH (see Results). We further adjusted our multivariable model for possible 
or probable CAA diagnostic category. We repeated these analyses only within the probable 
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CAA Boston diagnostic category. Because CMBs number distribution in our cohort was 
not normally distributed, as a sensitivity analysis, we repeated our multivariable logistic 
regression analyses by including multiple (≥2) CMBs or CMBs categories (0, 2-4, 5-10 
and >10 CMBs) into the models, which remained consistent. Multicollinearity was assessed 
by computing variance inflation factors (VIF) for all predictors and removing all variables 
with VIF>5. None of our included predictors in multivariable models had a VIF>5. 
Significance level was set at 0.05 for all analyses. Statistical analyses were carried out using 
STATA (Version 11.2, StataCorp.). 
8.3 Results 
The final cohort consisted of 138 patients: 32 patients with possible CAA, 97 with probable 
CAA and 9 patients with supportive pathology based on the Boston criteria (Table 8.1). Of 
these, 120 (87%) patients presented with symptomatic lobar ICH at baseline, 9 with 
transient focal neurological episodes, 3 with cognitive decline, 1 with acute convexity 
subarachnoid haemorrhage and 5 with ischaemic stroke. All patients had some degree of 
MRI-visible CSO-PVS; high CSO-PVS degree was present in 61.2% (n=85) of cases. Fifteen 
(10.9%) individuals had 1-10 CSO-PVS, 38 (27.5%) had 11-20 CSO-PVS, 50 (36.2%) had 21-
40 CSO-PVS and 35 (25.4%) patients had ≥40 CSO-PVS. There was no correlation between 
BG-PVS and CSO-PVS severity (data not shown). 
cSS was detected in 46 (33.3%; 95%CI: 25.5%-41.9%) CAA patients; 19 (13.8%; 95%CI: 
8.5%-20.7%) patients had focal and 27 (19.7%; 95%CI: 13.3%-27.2%) had disseminated cSS. 
Patients with cSS more often had ≥5 CMBs than patients without siderosis (47.8% vs. 30%; 
p=0.040) and a higher (but not statistically significant at the 5% level) prevalence of small 
acute ischaemic lesions on DWI sequences (22% vs. 11.3%; p=0.117). 
Comparisons of characteristics between patients with high degree and low degree of 
CSO-PVS are summarised in Table 8.1. Representative examples of cSS and CSO-PVS are 
shown in Figure 8.1. The prevalence of any cSS was higher in patients with high CSO-PVS 
degree (45.9% vs. 13.5%; p<0.00005). Disseminated cSS was present in 31.8% of 
participants with high CSO-PVS degree but none of those with low CSO-PVS degree 
(p<0.00005). High degree of CSO-PVS was associated with lower prevalence of moderate-
to-severe leukoaraiosis and lower prevalence of hypertension (Table 8.1). cSS extent (i.e. 
no cSS, to focal and disseminated) was associated with CSO-PVS degree in ordinal logistic 
regression analysis (OR: 3.22; 95% CI: 1.99-5.21; p<0.00005). We found no association 
between BG-PVS and cSS.  
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Table 8.1 Characteristics and comparison of CAA patients with and without severe centrum 
semiovale perivascular spaces (CSO-PVS). P-values refer to differences between CAA patients with 
vs. without CSO-PVS, using chi-square tests and the Fisher’s exact test for categorical variables, and 
two-sample t-tests or Mann-Whitney U-tests depending on the distribution of continuous variables. 
Characteristics 
All CAA 
(n=138) 
High degree of 
CSO-PVS 
(n=85) 
Low degree of 
CSO-PVS 
(n=53) 
p-value 
Age, mean (95% CI:), years 71.8 (70.2-73.4) 72.6 (71-74.3) 70.5 (67.2-73.7) 0.189 
Sex, male (%) 72 (52.2) 43 (50.6) 29 (54.7) 0.637 
Hypertension (%) 80 (63) 39 (50.7) 41 (82) <0.0001 
On antithrombotics (%) 36 (27.5) 24 (29.6) 12 (24) 0.483 
History of symptomatic ICH (%) 44 (32.8) 22 (26.8) 22 (42.3) 0.063 
Acute ischaemic lesions (%) 18 (14.9) 14 (18) 4 (9.3) 0.287 
Lobar CMB presence (%) 91 (66.9) 58 (68.2) 33 (64.7) 0.672 
Lobar CMBs count, median  
(IQR range) 
2 (0-8) 2 (0-9) 2 (0-6) 0.479 
Presence ≥5 lobar CMBs (%) 49 (36) 35 (41.2) 14 (27.5) 0.107 
cSS presence (%) 46 (33.6) 39 (45.9) 7 (13.5) <0.00005 
    Focal cSS (%) 19 (13.9) 12 (14.1) 7 (13.5) 0.914 
    Disseminated cSS (%) 27 (19.7) 27 (31.8) 0 (0) <0.00005 
Moderate-to-severe white 
matter hyperintensities 
(Fazekas score 2-3) (%) 
23 (16.9) 10 (11.8) 13 (25.5) 0.039 
 
 
Figure 8.1 T2 and T2*-GRE MRI of a patient with probable cerebral amyloid angiopathy showing 
(A) High degree of CSO-PVS on MRI (small, sharply delineated structures of CSF intensity (or close 
to CSF intensity), following the course of cortical vessels), associated with (B) multifocal cortical 
superficial siderosis (cSS) especially in the right hemisphere.  
A B
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In multivariable logistic regression models, high degree of PVS in the CSO was 
independently associated with the presence of cSS (OR: 4.78; 95%CI: 1.64-13.87; p=0.004) 
after adjusting for age, sex, hypertension, CMBs number, white matter hyperintensities, 
previous history of symptomatic ICH and probable vs. possible CAA. All results were of 
similar effect size in sensitivity analyses including only patients with probable CAA (Table 
8.2). Both models remained consistent when multiple (≥2) CMBs or CMBs categories (0, 2-
4, 5-10 and >10 CMBs) were included instead of CMBs number. 
 
Table 8.2 Univariate (unadjusted) and multivariable (adjusted) logistic regression analysis of 
associations with high degree centum semiovale perivascular spaces (CSO-PVS), in the whole cohort 
of patients with cerebral amyloid angiopathy (CAA) and in patients with probable CAA. Both models 
remained consistent when multiple (≥2) CMBs or CMBs categories (0, 2-4, 5-10 and >10 CMBs) 
were included. 
 
  
Whole CAA cohort (n=138) 
Unadjusted Adjusted 
OR (95% CI) p-value OR (95% CI) p-value 
cSS presence 5.45 (2.21-13.45) <0.0001 4.78 (1.64-13.87) 0.004 
Age (per year increase) 1.03 (0.99-1.06) 0.189 1.02 (0.97-1.06) 0.501 
Hypertension 0.23 (0.10-0.53) 0.001 0.27 (0.10-0.74) 0.011 
Sex (male vs. female) 0.85 (0.43-1.69) 0.637 0.85 (0.33-2.18) 0.735 
CMBs count 1.01 (0.98-1.04) 0.449 1.15 (0.54-2.42) 0.718 
History of symptomatic ICH 0.50 (0.24-1.04) 0.065 0.65 (0.26-1.61) 0.354 
WMH (moderate-to-severe) 1.10 (0.55-2.20) 0.709 1.78 (0.66-4.73) 0.254 
Probable vs. possible CAA 1.58 (0.71-3.51) 0.263 0.69 (0.17-2.82) 0.608 
Probable CAA (n=106)     
cSS presence 5.29 (2.05-13.65) 0.001 4.05 (1.36-12.08) 0.012 
Age (per year increase) 1.04 (1.00-1.08) 0.073 1.03 (0.98-1.09) 0.235 
Hypertension 0.24 (0.09-0.63) 0.004 0.28 (0.09-0.89) 0.032 
Sex (male vs. female) 0.78 (0.35-7.74) 0.543 1.30 (0.43-4.00) 0.642 
CMBs count (0.98-1.04) 0.582 1.00 (0.97-1.04) 0.824 
History of prior symptomatic 
ICH 
0.63 (0.27-1.47) 0.288 0.83 (0.28-2.40) 0.724 
WMH (moderate-to-severe) 0.90 (0.40-2.03) 0.799 1.18 (0.39-3.59) 0.768 
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8.4 Discussion 
In this multicentre study we have shown that high degree of MRI-visible CSO-PVS are highly 
prevalent in patients with CAA and are related to the presence and severity of cSS, a 
characteristic neuroimaging marker of CAA.195, 301 This association further adds to the 
accumulating evidence that CSO-PVS (but not BG-PVS) might be another potential MRI 
marker of CAA with implications for improving the sensitivity of in vivo diagnosis.272, 274, 293 
We found neither an association between BG-PVS and any CAA-specific imaging markers 
(including cSS and lobar CMBs), nor any correlation between severe CSO-PVS and BG-PVS, 
supporting the hypothesis that MRI-visible CSO-PVS compared to BG-PVS are due to 
different pathophysiological processes.272, 274, 293 The structure of perivascular spaces in the 
basal ganglia, however, differs from those in the cerebral cortex, in that they are 
surrounded by two periarterial membranes, perhaps making them less vulnerable to 
vascular amyloid accumulation.304 Our findings also have implications for understanding 
CAA pathophysiology, and suggest that severe leptomeningeal and cortical vascular amyloid 
(causing cSS) might be related to impaired interstitial fluid drainage from cerebral white 
matter (causing severe CSO-PVS). 
The link between CSO-PVS and CAA may reflect interstitial fluid drainage impairment 
within the perivascular spaces caused by leptomeningeal and superficial cortical vascular 
amyloid-β - a major feature in sporadic CAA and Alzheimer’s disease. Perivascular spaces 
form important pathways (along the basement membranes of capillaries and arteries) for 
the drainage of interstitial fluid and solutes, including soluble amyloid-β, from the brain. 
One key hypothesis for the development of CAA is that as perivascular drainage pathways 
fail with age (particularly in association with the ApoE e4 allele), or are overloaded by 
reduced capacity of other elimination mechanisms, amyloid-β is increasingly trapped and 
deposited in the walls of small arteries.276 Amyloid-β deposition in small cortical and 
leptomeningeal arteries in CAA could disrupt drainage, leading to retrograde dilation of 
perivascular spaces in the underlying white matter of the centrum semiovale (either by 
blocking bulk flow, or by diminishing the pulsatility of small vessels required for efficient 
interstitial fluid drainage),263, 279 leading to CSO-PVS visible on MRI. Cumulative superficial 
amyloid deposition could then promote further amyloid deposition, creating a “feed-
forward loop”, further reducing drainage efficiency.274, 276, 299 
Of note, histopathological studies have shown a gradient of reducing vascular amyloid-
β severity moving from the cortical surface into the cerebral white matter: CAA is 
significantly more severe in leptomeningeal than in parenchymal vessels of the same brain 
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section,67 and superficial cortical layers have more extensive vascular amyloid-β deposition 
than deeper layers.305 Repeated episodes of haemorrhage from these brittle, severely CAA-
affected leptomeningeal or very superficial cortical vessels into the subarachnoid space are 
probably an important cause of cSS. Indeed, in CAA, cSS has a characteristic predilection 
for the cerebral convexities, reflecting linear blood residues in the superficial layers of the 
cerebral cortex or in the subarachnoid space.190, 195, 243 
Our study has several strengths including the systematic evaluation of MRI scans by 
trained raters using validated scales for a range of imaging markers of small vessel disease 
and the testing of a prespecified hypothesis. The main limitation is the potential selection 
bias due to the requirement for MRI done as part of routine clinical care; hence, our results 
can only be extrapolated to patient populations in a similar clinical context with available 
MRI and need to be validated using larger independed cohorts. Also, although the MRI 
protocols were similar in each hospital, they varied across centres, introducing another 
potential source of bias. However, our findings are unlikely to be accounted by differences 
in MRI sequence parameters. Although we did our best to blind the MRI rating of cSS from 
CSO-PVS severity and vice versa (e.g. by assessing T2-weighted MR images for PVS blinded 
to cSS status on T2*-GRE and vice versa, by rating both markers blinded to the study main 
hypothesis etc.), we do acknowledge that the blinding might not be complete. In addition, 
the retrospective cross-sectional design prevents conclusions on the causal direction of the 
reported associations. Although it is likely that cSS and severe CSO-PVS each reflect the 
overall CAA severity in the brain, severe CSO-PVS was not associated with lobar CMBs 
number, a putative marker of CAA, indicating that the two phenomena may be causally 
related to each other, independed of CAA severity. In addition, we may have had 
insufficient statistical power to confirm or refute an association between CSO-PVS and 
small acute ischaemic lesions on DWI, due to our limited sample size and the relatively low 
prevalence of these lesions in CAA. However, severe CAA is associated with numerous 
cortical microinfarcts, which are difficult to resolve on 1.5T MRI, as used in this study. It 
may be of interest to study the relation of CSO-PVS and microinfarcts on high field 
strength in the future.197 The inverse association between high CSO-PVS degree and 
presence of hypertension is also interesting and may reflect a protective effect related to 
aggressive treatment of hypertension in these patients. Finally, we did not have pathological 
confirmation of CAA, and acknowledge that the Boston criteria for CAA diagnosis have 
imperfect specificity, especially for the “possible CAA” category, which in some cases may 
include other cerebral small vessel diseases (e.g. hypertensive arteriopathy).202, 203Our study 
should be considered hypothesis-generating. Larger prospective CAA cohorts are needed 
to clarify how exactly CSO-PVS are linked to cSS (i.e. to determine the causal direction of 
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this relationship) as well as other specific MRI markers, and whether they might identify an 
imaging phenotype of CAA with more superficial disease. A key question for future work 
will be whether CSO-PVS are an early marker of a CAA-related disease process which 
ultimately leads to severe cortical and leptomeningeal amyloid deposition, with important 
implications for future haemorrhage risk.302 Both cSS and PVS have been shown to be more 
prevalent in memory clinic patients (with Alzheimer’s disease or mild cognitive impairment) 
compared to healthy controls;243, 306-308 it would be very interesting to investigate whether 
patients with cSS and CSO-PVS differ from those without these findings with regard to 
cognitive function. MRI-visible PVS are also quite common in the general population, 
especially with increased age,264, 303, 308, 309 and might be related with worse cognitive 
function267 and incident dementia.271 
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Chapter 9   Cerebral amyloid angiopathy 
with and without intracerebral 
haemorrhage: MRI-pathological evidence 
for different disease phenotypes 
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ABSTRACT 
Objective: To gain further insights into different cerebral amyloid angiopathy (CAA) 
phenotypes and mechanisms, we investigated cortical superficial siderosis (cSS) - a new 
imaging marker of the disease, and its relation with APOE genotype in patients with 
pathologically-proven CAA, who presented with and without intracerebral haemorrhage 
(ICH). 
Methods: MRI scans of 105 consecutive patients with pathological confirmation of CAA 
and MRI obtained during life were analysed for cSS (focal, ≤3 sulci; disseminates, ≥4 sulci), 
and other small vessel disease markers. We compared pathological, imaging and APOE 
genotype data between subjects with vs. without ICH, and investigated associations 
between cSS and APOE genotype. 
Results: Our cohort consisted of 54 CAA patients with symptomatic lobar ICH and 51 
without ICH. APOE genotype was available in 53 patients. More than 90% of pathology 
samples in both groups had neuritic plaques, whereas neurofibrillary tangles were more 
commonly present in the non-ICH patients (87% vs. 42%, p<0.0001). On the other hand, 
the combination of neuritic plaques and neurofibrillary tangles was more common in the 
CAA group without ICH (84.8% vs. 41.7%, p=0.001). There was a trend for CAA patients 
with ICH to more commonly have APOE ε2 (48.7% vs. 21.4%, p=0.075), whereas non-ICH 
patients were more likely to be APOE ε4 carriers (85.7% vs. 53.9%, p=0.035). Disseminated 
cSS was considerably commoner in ICH patients (33.3% vs. 5.9%, p<0.0001). In logistic 
regression, disseminated cSS was associated with APOE ε2 (but not APOE ε4) (OR: 5.83; 
95% CI: 1.49-22.82, p=0.011). 
Conclusions: This neuropathological-defined cohort of CAA patients suggests that cSS 
and APOE ε2 are related to the hemorrhagic expression of the disease. In addition, APOE 
ε4 is enriched in non-hemorrhagic CAA; plaques and tangles pathology appears to be 
different in the two groups. Our study emphasizes that different clinical presentations of 
CAA have distinct features. This may suggest divergent pathophysiological mechanisms 
underlie these different CAA phenotypes. 
  
 139 
9.1 Introduction 
Sporadic cerebral amyloid angiopathy (CAA) is a small vessel disease that preferentially 
involves small cortical and leptomeningeal arteries due to progressive amyloid-β deposition 
in their walls.28, 242 CAA occurs frequently in elderly people, and is now considered a 
common and important cause of symptomatic lobar intracerebral haemorrhage (ICH).28, 37, 
242 However, it has long been recognised that CAA might present without major lobar ICH 
but instead with cognitive impairment (either chronic or rapidly progressive), a very 
clinically salient manifestation of the disease, or transient focal neurological symptoms.167 
CAA is also almost invariably found in Alzheimer's disease, but in most cases is relatively 
mild.65 
CAA is also associated with characteristic magnetic resonance imaging (MRI) 
biomarkers including strictly lobar cerebral microbleeds (CMBs), cortical superficial 
siderosis (cSS),171, 191, 194, 195 centrum semiovale perivascular spaces (CSO-PVS) and white 
matter hyperintensities (WMH).28, 35 Lobar CMBs might be suggestive of CAA even in 
asymptomatic elderly individuals.174 These neuroimaging markers probably reflect related 
but distinct aspects of CAA pathophysiology. cSS in particular, is an interesting recently 
recognized form of CAA-related haemorrhage, which likely reflects repeated episodes of 
blood leaking into the subarachnoid space from brittle and fragile CAA-affected vessels. 
Recently, cSS has been shown to carry a high risk of future symptomatic lobar ICH.195, 246, 
302 
Genetic factors, such as apolipoprotein E (APOE) genotype, are important in the 
pathophysiology of CAA.80, 84 APOE ε4 appears to enhance vascular amyloid-β deposition in 
a dose-dependent fashion,310 whilst APOE ε2 promotes vasculopathic changes which can 
lead to vessel rupture.88 To gain further insights into different CAA phenotypes and 
potential mechanisms,311 we investigated associations between neuroimaging markers of the 
disease, APOE genotype, and pathologic findings in patients with CAA presenting with and 
without symptomatic ICH. We hypothesized that: (1) hemorrhagic markers of CAA (cSS 
and lobar CMBs) would be more strongly associated with APOE ε2 genotype; (2) 
hemorrhagic markers of disease severity in CAA (cSS and lobar CMBs) and APOE ε2 
genotype would be more common in patients presenting with symptomatic ICH than in 
those presenting without ICH; and (3) neurofibrillary tangles will be more common in the 
non-haemorrhagic compared to haemorrhagic CAA, whereas amyloid plaques might be 
invariably present in the two groups due to their close molecular pathogenesis. 
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9.2 Methods 
9.2.1 Case selection and clinical data collection 
We included all eligible patients from the Massachusetts General Hospital (MGH) identified 
retrospectively by a systematic keyword search of pathology reports and prospective 
clinical databases. Cases were defined as subjects with both pathology-proven CAA (from 
routinely collected brain biopsy, biopsy at haematoma evacuation or autopsy) and adequate 
brain MRI sequences for the study. Data search covered patients seen at the hospital 
between 1997 and 2012. An additional overlapping search through established prospective 
datasets of patients with lobar haemorrhages (ICH and/or CMB) was performed to confirm 
identification of all potential eligible cases for the study. Among more than 3200 retrieved 
cases, we initially included those having: 1) a pathology report containing explicit 
information regarding CAA assessment; and 2) available brain MRI sequences of adequate 
quality including T2-weighted, T2*-weighted gradient-recalled echo (T2*-GRE) and/or SWI 
and FLAIR sequences. After reviewing all neuroimaging, pathological and clinical data 
available, we excluded subjects with: 1) small brain biopsy samples (greater diameter <1 
cm) or samples from clot evacuations not containing any assessable vessels; 2) autopsy 
studies not grading CAA; and 3) known alternative causes for lobar ICH. A total of 192 
patients were eligible for analysis. Patients with no pathological evidence of CAA (n=54), 
clinical/imaging presentations not characteristic of CAA (3 cases with deep ICH and 9 with 
ischaemic stroke at baseline), no T2 or T2*-GRE MRI (n=18), T2/T2*-GRE MRI of 
insufficient quality (n=2) and irretrievable sequences (n=1) were further excluded. 
Demographic and clinical information was obtained from prospective databases and by 
medical records review using standardised data collection forms. Variables of interest were 
age, gender, history of hypertension, antithrombotic drug use and clinical presentation at 
baseline. Hypertension was defined as a history of hypertension, taking antihypertensive 
treatment or documented elevated blood pressure (systolic >150 or diastolic >95mmHg) 
before admission. APOE genotype was determined in a subset of patients who provided 
blood samples and consented to genetic testing as previously described,312 and without 
knowledge of clinical or neuroimaging data. 
The original clinical presentation of patients included in the study was ascertained from 
all available neuroimaging, pathological and clinical data, and was determined as either 
symptomatic lobar ICH confirmed on neuroimaging or non-haemorrhagic (including 
cognitive impairment, transient focal neurological episodes, or other neurological 
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symptoms). Cases of inflammatory CAA were also included in the analysis when an MRI 
outside the acute phase (≥1 month) was available. To investigate how stable these clinical 
phenotypes are (e.g. CAA with ICH and CAA without ICH), for the patient group 
presenting without ICH we extrapolated follow-up information from prospective databases 
and medical records on incident symptomatic ICH. 
9.2.2 Standard Protocol Approvals, Registrations, and Patient 
Consents 
The study received ethical approval by the Institutional Review Board of MGH. 
9.2.3 Pathological data collection 
Morphological assessment was performed in routine haematoxylin-eosin staining and the 
presence or absence and severity of vascular amyloid-β deposition was confirmed by 
immunohistochemical detection and/or congo red staining. CAA presence and severity was 
assessed in all available vessels. Cases were considered positive for CAA when they had at 
least one leptomeningeal or cortical vessel with amyloid-β reported, providing enough 
information to reliably classify CAA severity using the Vonsattel grading system67, 72 and 
were classified as mild (Vonsattel grade 1) or moderate to severe (Vonsattel grades 2-4). 
Where available from neuropathology reports, we also systematically extracted information 
on: 1) neuritic plaques and neurofibrillary tangles assessed in routinely immunostained 
sections for amyloid-β and phosphorylated tau and recorded as present or absent; and 2) 
the presence or absence of moderate to severe arteriolosclerosis features (including thick 
arteriolar walls, lipohyalinosis, perivascular haemosiderin-laden macrophages etc.) mainly in 
the basal ganglia and deep cerebral white matter.2 
9.2.4 Neuroimaging data and analysis 
Imaging for all patients included T2-weighted, FLAIR, T2*-GRE and or susceptibility-
weighted imaging (SWI). MR images were reviewed blinded to clinical, histopathological and 
genetic data by trained observers, according to STandards for ReportIng Vascular changes 
on nEuroimaging (STRIVE).31 
CMBs presence and number were evaluated on axial T2*-GRE or SWI images 
according to current consensus criteria35 and categorised as lobar (i.e. cortical-subcortical), 
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deep (i.e. basal ganglia, thalami, brainstem) or cerebellar. The presence and number of 
“macro” ICHs (>5 mm in diameter on T2*-GRE/SWI)198 was also noted.  
cSS was defined as linear residues of chronic blood products in the superficial layers of 
the cerebral cortex showing a characteristic “gyriform” pattern of low signal on T2*-
GRE/SWI images; T1-weighted and FLAIR images were used for anatomical confirmation of 
the gyral location of these signal hypointensities identified on blood-sensitive sequences.301 
The distribution and severity of cSS was classified as focal (restricted to ≤3 sulci) or 
disseminated (≥4 sulci).195 Areas of cSS were ≥2 unaffected sulci away from any lobar ICH, 
at multiple axial levels; cSS contiguous or potentially anatomically connected with any lobar 
ICH were not included in these categories.301 
PVS were assessed in line with STRIVE definitions31 and rated on axial T2-weighted MR 
images, using a validated 4-point visual rating scale (0=no PVS, 1=<10 PVS, 2=11-20 PVS, 
3=21-40 PVS and 4=>40 PVS) in the basal ganglia (BG) and CSO as previously described.30, 
267, 293  
Periventricular and deep WMH were visually assessed on axial FLAIR images on the 
four-point Fazekas rating scale for each adding up to a total score on 7-point scale.313 For 
deep WMH, 0 indicating absent; 1 indicating punctuate; 2 indicating early confluent; or 3 
indicating confluent. For periventricular WMH, WMH 0 indicating caps; 1 indicating pencil-
thin linings; 2 indicating smooth halos; or 3 indicating irregular appearance. Total WMH was 
dichotomized to score 0-4 vs. 5-6. 
9.2.5 Statistical analysis 
Categorical variables were analysed using Pearson’s χ2 or Fisher exact test, and continuous 
variables by the 2-sample t test (for normal distributions), and Wilcoxon rank sum (for 
non-normal distributions). We compared demographic, genetic, pathological and imaging 
characteristics of CAA patients with and without ICH using these univariate tests as 
appropriate. Variables for APOE ε2 and ε4 were each coded as the number of alleles per 
participant (0, 1, or 2). Separate logistic regression models were used to assess the 
relationship between APOE genotype and cSS (presence or burden), as well as CMB count 
(linear regression). As sensitivity analyses, these models were predetermined to adjust for 
age and clinical presentation of CAA. All tests of significance were two-tailed. Significance 
level was set at 0.05 for all analyses. Stata software (Version 11.2, StataCorp.) was used. 
The manuscript was prepared with reference to the STrengthening the Reporting of 
OBservational studies in Epidemiology (STROBE) guidelines.258 
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9.3 Results 
Our final cohort consisted of 105 patients with pathological evidence of CAA: 52 from 
autopsies, 22 from brain biopsies and 31 with pathological samples from haematoma 
evacuations. Fifty-four patients were admitted with symptomatic, spontaneous lobar ICH, 
while 51 patients without any symptomatic ICH. Patients without ICH presented either 
with cognitive impairment (n=42), transient focal neurological episodes (n=3), or a 
combination of other symptoms (n=6; including altered mental status, or seizures, with 
findings consistent with inflammatory CAA). The median Clinical Dementia Rating (CDR) 
score of patients without ICH and available data (n=27) was 1 (IQR: 0.5-2). 
Table 9.1 indicates the severity of CAA, and the presence or absence of neuritic 
plaques and neurofibrillary tangles, in the two groups. In general, mild (Vonsattel grade 1) 
or moderate to severe (Vonsattel grades 2-4) CAA were equally represented in the 
cohorts (p>0.2 for both comparisons). There was no difference in the presence of 
vasculopathic changes (vessel-within-vessel appearance and vessel wall necrosis) in the two 
groups (29.6% vs. 24%, p= 0.336). Although the prevalence of neuritic plaques was very 
similar in the two groups, neuritic plaques in isolation (i.e. with no tangles) were much 
more frequent in the ICH patients than in the non-ICH CAA patients (53% vs. 13%, 
p<0.0001). More than 90% of pathology samples in both groups had neuritic plaques, 
whereas neurofibrillary tangles were more commonly present in the non-ICH patients (87% 
vs. 42%, p<0.0001). These associations remained consistent in logistic regression models 
controlling for age. 
Comparisons of clinical and imaging characteristics between CAA patients with vs. without 
ICH are summarised in Table 2. There was a trend for CAA patients with ICH to more 
often have APOE ε2 (48.7% vs. 21.4%, p=0.075), whereas non-ICH patients were more 
likely to be carriers of APOE ε4 (85.7% vs. 53.9%, p=0.035). The two groups were very 
similar in imaging markers of small vessel disease, including WMH burden, high degree of 
CSO-PVS and BG-PVS and lobar CMBs counts ( 
 
Table 9.2). However, the prevalence of cSS was higher in patients with ICH (51.9% vs. 
19.6%, p=0.001), especially disseminated cSS (33.3% vs. 5.9%, p<0.0001). Representative MR 
images are showing in Figure 9.1. 
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Table 9.1 Cerebral amyloid angiopathy with and without intracerebral haemorrhage: severity and 
associations with neuritic plaques (NP) and tangles (NT)*. 
 
CAA severity 
(Vonsattel grade) Vasculopath
changes 
NP alone 
NT 
alone 
NP and 
NT 
No NP 
or NT 
Grade 1 Grade 2-4 
CAA with ICH 7 (13%) 47 (87%) 16 (29.6%) 19 (52.8%) 0 15 (41.7%) 3 (5.6%) 
CAA without 
ICH 
11 (21.6%) 40 (78.4%) 12 (24%) 6 (13%) 1 (2.2%) 39 (84.8%) 0 
*Data on neuritic plaques and tangles were available in 37/54 patients with ICH and 46/51 patients without ICH. 
 
 
Table 9.2 Comparison of clinical, imaging and genetic characteristics between pathologically-proven 
CAA with vs. without ICH cohorts. 
 
Whole CAA 
cohort 
(N=105) 
CAA with 
ICH 
(N=54) 
CAA without 
ICH 
(N=51) 
p-value 
Age, mean (95% CI), years 72.7 (71.1-74.2) 71.6 (69.4-73.7) 73.9 (71.5-76.2) 0.148 
Sex, female n (%) 55 (52.4) 33 (63.1) 22 (43.1) 0.065 
Hypertension, n (%) 66 (64.7) 30 (57.8) 36 (72) 0.131 
Antithrombotic drug use, n (%) 40 (44.4) 15 (36.6) 25 (51) 0.170 
*APOE ε2 present, n (%) 22 (41.5) 19 (48.7) 3 (21.4) 0.075 
*APOE ε4 present, n (%) 33 (62.3) 21 (53.9) 12 (85.7) 0.035 
Time from MRI to pathology, 
median (IQR), months 
5.3 (0.3-31.4) 1.3 (0.2-11) 23.3 (1.4-50.7) 0.0002 
Premorbid diagnosis of Alzheimer’s 
disease, n (%) 
24 (22.9) 2 (3.7) 22 (43.1) <0.0001 
Severe (Fazekas 5-6) WMH, n (%) 21 (20) 13 (24.1) 8 (15.7) 0.283 
High grade CSO-PVS (>20), n (%) 57 (54.8) 29 (54.7) 28 (54.9) 0.985 
High grade BG-PVS (>20), n (%) 25 (24) 11 (20.8) 14 (27.5) 0.424 
Lobar CMBs presence, n (%) 63 (60) 36 (66.7) 27 (52.9) 0.151 
Lobar CMBs count, median (IQR) 2 (0-27) 3 (0-23) 2 (0-31) 0.411 
Presence of cSS, n (%) 38 (39.2) 28 (51.9) 10 (19.6) 0.001 
    Focal cSS, n (%)  17 (16.2) 10 (18.5) 7 (13.7) 0.505 
    Disseminated cSS, n (%) 21 (20) 18 (33.3) 3 (5.9) <0.0001 
*APOE genotype was available in 53 CAA patients: 39 with ICH and 14 without ICH. 
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Figure 9.1 Representative MR images of patients with pathological evidence of cerebral amyloid 
angiopathy (CAA) with and without symptomatic intracerebral haemorrhage (ICH). A. 73-year-old 
woman with CAA-ICH and disseminated cortical superficial siderosis on T2*-GRE (left). Her APOE 
genotype was ε2/ε4. (B) Multiple strictly lobar cerebral microbleeds (but no siderosis) on T2*-GRE 
MRI (left) in a 73-year-old woman with cognitive impairment and ε4/ε4 APOE genotype. Note the 
comparable white matter hyperintensities burden on FLAIR MRI (middle panels) and centrum 
semiovale perivascular spaces on T2-weighted images (right panel) in the two patients. Both cases 
had severe CAA with vasculopathic changes. 
Among subjects with available genetic testing (n=53), APOE ε2 (but not ε4) allele was 
overrepresented in cases with disseminated cSS, in the whole cohort (p=0.013), and in the 
CAA subgroup with ICH (Table 9.3). In logistic regression, disseminated cSS was associated 
with APOE ε2 (OR: 5.83; 95% CI: 1.49-22.82, p=0.011). These results remained consisted 
and of similar effect size in a sensitivity analyses adjusting for age and symptomatic ICH 
clinical presentation (OR: 4.97; 95% CI: 1.11-22.21, p=0.036) and in models further 
adjusting for the presence of vasculopathic changes on pathology. There was no association 
between cSS (burden or presence) and APOE ε4. There was no association between CMBs 
counts and APOE genotype. 
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Table 9.3 APOE allele prevalences according to cortical superficial siderosis (cSS) burden in 
cerebral amyloid angiopathy (CAA) patients with or without intracerebral haemorrhage (ICH). 
 
cSS burden 
No cSS Focal cSS Disseminated cSS 
Whole CAA cohort    
APOE ε2, n (%) 7 (29.2) 3 (25) 12 (70.6) 
APOE ε4, n (%) 18 (75) 6 (50) 9 (52.9) 
CAA with ICH    
APOE ε2, n (%) 7 (46.7) 1 (11.1) 11 (73.3) 
APOE ε4, n (%) 9 (60) 4 (44.4) 8 (53.3) 
CAA without ICH    
APOE ε2, n (%) 0 (0) 2 (66.7) 1 (50) 
APOE ε4, n (%) 9 (100) 2 (66.7) 1 (50) 
Follow-up data were available in all patients presenting without ICH at baseline. 
During a median follow-up time of 3 years (IQR: 1.1–5.6 years), 2 of 51 patients (3.9%, 
95%CI: 0.5-13.5%) experienced a symptomatic lobar ICH. One of these two patients had 
focal cSS at baseline MRI. 
9.4 Discussion 
The major findings from this study show that CAA patients presenting with ICH are more 
likely to have superficial siderosis (particularly disseminated cSS) and the APOE ε2 
genotype compared to CAA patients presenting without ICH. By contrast, APOE ε4 is 
enriched in non-hemorrhagic CAA. In addition, there was an overall higher burden of 
neurofibrillary tangle pathology in the non-hemorrhagic CAA group. Interestingly, the 
severity of vascular amyloid pathology did not appear to be different between CAA patients 
with and without ICH in our cohort, although this could have been influenced by sampling 
bias. APOE genotype might partly influence these relationships: APOE ε2 was found to be 
associated with both symptomatic ICH clinical phenotype and disseminated cSS. 
Our results provide new insights into the clinical and imaging spectrum of sporadic 
CAA, as well as potential mechanims and point to different disease phenotypes.311 While 
sporadic CAA is commonly found in the elderly,58 it is currently unknown why only a 
fraction of people with CAA pathology develop symptomatic disease, and why some 
present with symptomatic ICH, while others only develop cognitive impairment or other 
clinical symptoms (but not haemorrhage). A previous comparative post-mortem 
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histopathological study found that the brain features from CAA patients that are most 
consistently related to ICH are severe degree of vascular amyloid deposition and the 
presence of fibrinoid necrosis (with or without microaneurysms).72 However, cases of CAA 
with symptomatic ICH in our study had a fairly similar vascular amyloid burden and 
prevalence of CAA-associated vasculopathic changes compared to cases without ICH. In 
addition, the two groups had a very similar profile of putative neuroimaging biomarkers of 
CAA severity, including lobar CMBs presence and number, WMH and high degree of CSO-
PVS. It thus seems likely that additional and/or distinct biological pathways from those 
involved in amyloid-β accumulation in cortical and leptomeningeal vessels play a role in 
determining clinical expression. 
The most distinctive neuroimaging feature between the two groups was the much 
higher prevalence of disseminated cSS in CAA patients with ICH. The prevalence of cSS in 
our histopathology-confirmed CAA-ICH group is in line with the reported prevalence in a 
previous imaging study of CAA-ICH.301 In addition, the presence of cSS in the group 
without ICH (10%) is more in line with recent imaging studies evaluating cSS in a memory 
clinic setting and Alzheimer’s disease,306, 307, 314 and much higher compared to cSS in the 
population-based Rotterdam Study (0.7% in 1,062 non-demented subjects ≥60 years).315 
Although the pathophysiological mechanisms underlying cSS in CAA are not yet fully 
understood, observational data suggest that cSS represents blood residues related to blood 
leaking episodes into the subarachnoid space from CAA-affected vessels.190, 195, 301 A 
‘secondary’ mechanism due to leakage or expansion of a lobar ICH into the subarachnoid 
space cannot be fully excluded; however, similar to other studies, cSS was mostly found 
distant from any ICH (and often in the opposite hemisphere), and was also detected even in 
cases without any ICH. In addition, cases in which siderosis was clearly connected to a 
lobar haematoma were not classified as cSS. Two recent cohort studies have identified cSS 
as a particular risk factor for subsequent ICH in CAA.246, 302 In a cohort on 51 patients with 
CAA-related cSS and a median follow-up of 35.3 months, new intracranial haemorrhages 
were observed in 24 patients (47.1%).246 The majority of new haemorrhages (i.e. 13/18 new 
ICH and 4/6 new acute convexity subarachnoid bleeds) were located immediately adjacent 
to pre-existing cSS.246 A European multicentre cohort of probable or possible CAA patients 
(n=118; median follow-up 24 months), found that cSS was a significant predictor of time 
until ICH.302 The ICH risk at 4 years was 25% (95%CI: 7.6-28.3%) for patients without 
siderosis, 28.9% (95%CI: 7.7-76.7%) for patients with focal siderosis and 74% (95%CI: 44.1-
95.7) for patients with disseminated cSS (log-rank test: p=0.0031).302 A small autopsy series 
of six CAA cases showed that multiple leptomeningeal arteries (and not parenchymal 
cortical vessels) can rupture into the subarachnoid space and the brain parenchyma, leading 
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to large lobar haemorrhages.248, 316 All patients had multiple haematomas in the 
subarachnoid space (mainly in cerebral sulci), as well as intracerebral haematomas, and each 
intracerebral haematoma was connected to the subarachnoid haematomas at the depth of 
cerebral sulci or through the lateral margin of the cortex.248 In this neuropathological study 
there was evidence of only few ruptured cortical arteries associated with lobar ICH. These 
observations might explain the association between disseminated cSS and CAA patients 
with ICH in the present study, as well as why patients with disseminated cSS have the 
highest risk of future ICH.302 
In addition, our study demonstrates that there might be APOE genotype-specific 
effects on the imaging and clinical expression of CAA-related disease. While APOE ε4 
seems to be more associated with CAA without ICH, APOE ε2 is linked more strongly 
with bleeding and cSS. The APOE ε2 allele was previously reported to be associated with 
CAA-related lobar ICH, possibly owing to the disease-related vasculopathic abnormalities 
seen with this allele,83, 88 and recently with cSS in a cohort of CAA defined by clinico-
radiographic criteria.317 APOE ε4 is also associated with risk of sporadic CAA and ICH, the 
severity of which depends on the number of APOE ε4 alleles.77, 318, 319 APOE ε4 might 
increase CAA severity by enhancing amyloid-β deposition within small cerebral vessels 
whilst APOE ε2 promotes the vasculopathic changes which can lead to vessel rupture.80, 88 
Our study raised the interesting possibility APOE ε2 influences pathways causing both cSS 
and ICH. Interestingly, after accounting for the presence of vasculopathic changes, the 
apparent relation of APOE ε2 to cSS was not reduced, suggesting that vascular amyloid load 
and how extensively the vessel wall architecture is disrupted is not the sole driving force 
underlying these pathways and hence, these clinical phenotypes. However, any mechanistic 
links are clearly complex and need to be treated with caution, as APOE genotype alone 
might not be necessary or sufficient to cause or drive these effects. It is important to note 
that links may differ according to the presence or absence of Alzheimer’s disease pathology, 
particularly for APOE ε2, which has been associated with a reduced risk of late-onset 
Alzheimer’s dementia.77 This observation is in line with the differential associations between 
neuritic plaques and neurofibrillary tangles data in our CAA patients with and without ICH. 
Indeed, there is significant variation in the pathological appearance of CAA and its influence 
on Alzheimer’s disease pathology,320, 321 further highlighting the concept of different 
phenotypes of CAA which can follow and influence several different pathways. It is 
important to acknowledge thought that the overrepresentation of neurofibrillary tangles 
among the non-ICH CAA patients might also partly reflect a bias issue, since by definition 
these cases presented cognitive impairment, partly driven by neurofibrillary tangle 
pathology. 
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Although the natural history of symptomatic CAA patients mainly presenting with 
cognitive impairment (i.e. without ICH at baseline) has not been fully investigated, our data 
suggest that this CAA phenotype may have a lower risk of developing ICH. It is important 
to note that CAA patients without major ICH (microbleeds- or cSS-only CAA) presenting 
to stroke services with symptoms other that cognitive impairment (e.g. transient focal 
neurological episodes), might still be at significant risk of future bleeding.244, 302 A recent 
study on patients presenting with isolated lobar microbleeds showed that they indeed have 
a hemorrhagic risk profile suggestive of severe CAA pathology.322 However, the ICH risk 
among CMB-only CAA patients was lower compared to CAA patients with past ICH. This 
topic requires further investigation in prospective studies, especially given the increased 
incidence of ICH in patients with Alzheimer’s disease and the biological association of 
Alzheimer’s disease with CAA.323, 324 Whether patients with CAA-related cognitive 
impairment/Alzheimer’s disease and cSS have a distinct clinical sub-phenotype (e.g. worse 
outcome, high APOE e2 genotype frequency, increased ICH) also requires further study.  
The main strengths of this study include the large sample of patients with 
histopathologically confirmed CAA and available MRI sequences, the systematic evaluation 
of MRI scans for a range of imaging markers of small vessel disease, and the testing of a 
prespecified hypothesis. The main limitations, inherent to any clinical-pathology series in 
CAA, include: (a) the difference in pathology sampling between autopsied brains and 
biopsies/haematomas; (b) the biases regarding which patients get biopsied or autopsied 
which might be skewed towards end stage or advanced disease; and (d) potential selection 
bias due to the requirement for both pathology and MRI and the unavailability of APOE 
genotype data in all patients. The differences in Alzheimer’s pathology between groups 
could potentially be explained by a longer duration of disease (taking time from MRI to 
pathology as a surrogate for disease duration) in CAA patients without ICH or the different 
characteristic between the two groups (including APOE ε4 prevalence). Further molecular 
imaging studies assessing amyloid and tau burden in vivo325 may help resolve this question. 
Also, the cross-sectional design of the current study did not allow us to assess potential 
causality of the reported associations. 
In summary, results from this neuropathological-defined cohort of CAA patients with 
and without ICH provide multiple lines of evidence for distinct disease phenotypes, and 
suggest that cSS and APOE ε2 are related to the haemorrhagic expression of the disease. 
Our study emphasizes the widening spectrum of CAA with clinical phenotypes reflecting 
different neuroimaging and genetic features and suggests divergent pathophysiological 
mechanisms. Although these findings require external validation in larger CAA cohorts, 
they may be relevant for future biomarkers studies and disease-modifying CAA trials.300  
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Chapter 10 Cerebral microbleeds, 
microangiopathy subtype and recurrent 
spontaneous intracerebral haemorrhage 
risk: systematic review and meta-analysis 
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ABSTRACT 
Objective: To evaluate cerebral microbleeds (CMBs) and recurrent intracerebral 
haemorrhage (ICH) and ischaemic stroke risk in spontaneous ICH survivors, stratified by 
the MRI-defined presumed underlying microangiopathy – i.e. cerebral amyloid angiopathy 
(CAA) vs. non-CAA related ICH. 
Methods: Meta-analysis of prospective cohorts with recent spontaneous ICH. We 
estimated annualised recurrent symptomatic ICH and ischaemic stroke rates for each study 
and pooled odds ratios of recurrent ICH and ischaemic stroke across CMBs groups (i.e. 1, 
2-4, 5-10 and >10 CMBs), using a random effects model. 
Results: We pooled data from 8 hospital-based studies including 981 patients: 3 CAA-
related ICH cohorts (n=248) and 6 non-CAA related ICH cohorts (n=733). The annual risk 
of recurrent ICH was higher in patients with CAA-related ICH compared with non-CAA 
related ICH cohorts (9.96%; 95%CI: 5.08-14.84 vs. 1.31%; 95%CI: 0.51-2.11 respectively, 
p=0.012). In non-CAA related ICH cohorts, only patients with >10 CMBs had an increased 
risk of recurrent ICH (OR: 5.63; 95%CI: 1.79-17.72; p=0.003); CMBs located in both deep 
and lobar regions the stronger association with recurrent ICH (OR: 4.01; 95%CI: 1.47-
10.94; p=0.007). In CAA-related ICH cohorts higher numbers of baseline CMBs strongly 
predicted an increased risk of recurrence during follow-up: the cumulative OR was 3.32 
(95%CI: 1.41-7.81; p=0.006), 4.43 (95%CI: 1.76-11.14; p=0.002) and 3.03 (95%CI: 1.19-7.74; 
p=0.02) for 2-4, 5-10 and >10 CMBs respectively. This risk of recurrent ICH was not 
significant for patients with a single CMB in any of the cohorts. CMBs were not associated 
with ischaemic stroke risk in either CAA or non-CAA related ICH cohorts. The relative 
risk for recurrent ICH vs. ischaemic stroke in non-CAA ICH patients with CMBs did not 
differ significantly. By contrast, in CAA-related ICH patients with CMBs, the relative risk of 
recurrent ICH compared to ischaemic stroke was 31.2 (95% CI: 5.9-164.6; p<0.0005). 
Conclusions: In ICH patients, multiple CMBs at baseline are associated with an increased 
ICH recurrence risk. The recurrent ICH risk in those with MRI-defined CAA-related ICH is 
about 8 times higher than for non-CAA related ICH. The balance of risk for recurrent ICH 
vs. ischaemic stroke also differs between CAA and non-CAA related ICH cohorts. Defining 
ICH subtypes using MRI is relevant for prognosis, and should be considered in designing 
future ICH clinical prevention trials. 
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10.1 Introduction 
Spontaneous intracerebral haemorrhage (ICH) presumed to be due to cerebral small vessel 
disease31 is one of the most catastrophic forms of stroke.326 It is associated with high 
morbidity and mortality,327 but also a substantial risk of recurrence for survivors.220, 253, 254 
Understanding the causes and pathophysiology of spontaneous ICH can help stratify the 
risk of recurrent ICH or ischaemic cerebrovascular events with relevance for the 
development of new treatments. Two main disease processes can cause rupture of small 
arteries of the brain leading to spontaneous ICH: hypertensive arteriopathy and sporadic 
cerebral amyloid angiopathy (CAA).2 Hypertensive arteriopathy is characterized by 
lipohyalinosis and fibrinoid necrosis of small deep perforating arteries, resulting in 
haemorrhages particularly in deep brain regions, such as the basal ganglia and thalamus.2 
CAA affects the small cortical and leptomeningeal arteries, by the progressive deposition of 
amyloid-β in the vessel walls and is an important cause of lobar (but not deep) ICH, 
especially in the elderly.28, 328 These two common small vessel pathologies that result in ICH 
seem to have intrinsically different risks of recurrent haemorrhage: a history of CAA-
related lobar ICH might carry a significantly higher risk for recurrence compared to deep 
ICH due to hypertensive arteriopathy,254, 255, 329 but these risks are currently difficult to 
predict. 
With the development of more advanced imaging techniques over the past decades, 
new neuroimaging markers of small vessel disease have been emerged. Among them, 
cerebral microbleeds (CMBs) on blood-sensitive MRI sequences, including T2*-weighted 
gradient-recalled echo (T2*-GRE) and susceptibility-weighted imaging (SWI), have become a 
relatively common finding in patients with spontaneous ICH and warfarin-related ICH.35, 212 
By contrast with other markers of small vessel disease (e.g. leukoaraiosis or lacunes), CMBs 
may provide direct evidence of blood leakage from haemorrhagic-prone 
microangiopathy.172, 330 The presence of CMBs is also regionally associated with ICH, 
making them a possible marker of more bleeding-prone areas.177 In addition, the location of 
CMB in the brain appears to reflect the type of the underlying microangiopathy: similar to 
macrobleeds, strictly lobar CMBs (cortical-subcortical) are characteristic of CAA-related 
small vessel disease (allowing the diagnosis of CAA during life using the Boston criteria202, 
203), whilst deep CMBs appear to reflect hypertensive arteriopathy.27, 35 If the risk of ICH 
recurrence is related to the underlying arteriopathy type and burden, CMBs may be of 
particular value in identifying patients at high risk of recurrence. 
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Some studies indeed show that the burden of CMBs predicts the risk of recurrent 
ICH; the relationship with the risk is stronger in patients with CAA-related lobar ICH.180, 
227, 331 However, these studies are too small to guide patient management at present; and 
more reliable estimates of the risks are urgently needed. We therefore performed a meta-
analysis of all available evidence from published prospective ICH cohorts investigated using 
MRI, to investigate the power of CMBs (including CMBs number and location) to predict 
recurrent ICH, stratified by the presumed underlying microangiopathy (CAA vs. non-CAA 
related ICH). Since CMBs could also be associated with occlusive features of 
cerebrovascular disease, as a secondary analysis we also explore their relation with incident 
ischaemic stroke in this patient population. 
10.2 Methods 
10.2.1 Search strategy, selection criteria and data 
extraction 
PubMed was searched between January 1, 1999 and November 1, 2013 using medical 
subject heading (MESH) terms and text words: [“microbleed*” OR “microh(a)emorrhage*” 
OR “h(a)emorrhagic lacune” AND [“stroke” OR “intracerebral h(a)emorrhage” OR “brain 
h(a)emorrhage”]. Reference lists from all included articles, relevant review articles and the 
authors’ own files were also searched for additional eligible reports. Studies were eligible 
for inclusion if they: included adult patients with spontaneous symptomatic ICH confirmed 
by imaging; had a prospective design, with at least three months of follow-up; assessed the 
risk of recurrent symptomatic spontaneous ICH (main outcome) during follow-up; had data 
for the presence of CMBs on baseline T2*-GRE MRI; and were published in English. In cases 
of multiple publications from the same or overlapping cohorts, only the most recent 
comprehensive results from the report with the largest sample size were generally used in 
the analysis. We excluded case-control and cross-sectional studies, case reports or case-
series, population-based studies and studies in other patient populations (e.g. CADASIL, 
thrombolysis-related ICH etc.).  
For each study, we extracted data on the country of the study, time period, clinical 
setting, population size, demographic data (including mean age and sex and vascular risk 
factors), use of antithrombotic agents, T2*-GRE MRI parameters, number of participants 
with at least one CMB at baseline, method and duration of follow-up and number of 
participants with the outcome events of interest (recurrent spontaneous symptomatic ICH 
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and symptomatic ischaemic stroke, clearly defined according to defined criteria). For 
included cohorts we sought further information from the authors (by email) on total 
person-years of follow-up and outcome events (recurrent ICH and symptomatic ischaemic 
stroke) stratified by CMBs numbers (1 CMB, 2-4, 5-10 and >10 CMBs) and location (lobar - 
in the cortex or subcortical areas of the cerebral hemispheres , deep or mixed CMBs). We 
classified each study cohorts as CAA-related ICH or non-CAA related ICH according to 
classic Boston criteria,202 based on published information of included subjects in each study 
and correspondence with authors. 
10.2.2 Statistical analysis 
We estimated annualised recurrent symptomatic ICH and ischaemic stroke rates (%/year) 
and corresponding 95% confidence intervals (CI) for each study from a poisson regression 
model and exact poisson intervals. Pooled rates were calculated using an inverse variance-
based random effects method (DerSimonian-Laird) and stratified by study population 
(presumed underlying small vessel disease cause of baseline ICH, i.e. CAA-related ICH vs. 
non-CAA ICH). The log(incidence) of recurrent ICH events where compared between 
these groups using a significance test with the appropriate degrees of freedom. 
We meta-analysed data for recurrent ICH and ischaemic stroke across studies, using a 
random effects model with DerSimonian-Laird weights,332 quantifying the strength of any 
association using odds ratios (OR) and its associated 95% CI in patients without CMBs vs. 
different CMBs groups. To maximise the power of our analyses, for comparisons with zero 
events in both groups, we added 0.5 to each group, considered OR=1 and calculated 
calculating the standard error (SE), logOR and SE logOR by using the 2-variable input 
method. We assessed heterogeneity by I-squared and x-squared statistics and also visually 
through inspection of the forest plot and checking for overlapping confidence intervals. We 
explored publication bias with funnel plots and the Harbord regression tests for funnel plot 
asymmetry. Analyses were stratified by baseline ICH presumed cause (CAA vs. non-CAA 
related ICH). As a sensitivity analysis we investigated the influence of one study on the 
overall meta-analysis estimate (using the “metaninf” command) and inspect the results 
graphically with meta-analysis estimates computed, omitting one study in each turn. We 
used meta-regression to explore whether certain confounders could have affected our 
results. 
All meta-analyses were performed using Stata 11.2 (StataCorp LP, Texas). We 
prepared this report with reference to the Preferred Reporting Items for Systematic 
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reviews and Meta-Analyses (PRISMA)333 and the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE)334 guidelines. 
10.3 Results 
Eight unique hospital-based studies with a total of 981 patients (665 with CMBs) met our 
predefined inclusion criteria,227, 302, 331, 335-339 and were pooled in meta-analyses. The studies 
comprised of three CAA-related ICH cohorts (n=248) 227, 302, 337 and six non-CAA related 
ICH cohorts (n=733)331, 335, 336, 338, 339 (i.e. one study included both cohorts227). The basic 
characteristics of included cohorts are summarised in Table 10.1. Most studies had similar 
inception points (i.e. the start of follow-up), methods of assessment and a high number of 
participants lost to follow-up. Most studies used reliable ascertainment methods for 
establishing recurrent ICH events at the follow-up. 
In these studies, the overall pooled annual risk of recurrent ICH and ischaemic 
stroke was 3.20% (95% CI: 1.52-4.88) and 0.87% (95% CI: 0.25-1.48) respectively (Figure 
10.1). Patients with CAA-related ICH had a higher annual risk of recurrent ICH compared 
with non-CAA related ICH cohorts (9.96%; 95% CI: 5.08-14.84 vs. 1.31%; 95% CI: 0.51-2.11 
per year respectively, p=0.012). The ischaemic stroke rates could not be directly compared 
in the two patient groups, because in one CAA cohort ischaemic stroke was not an 
outcome event,337 and in another study no ischaemic strokes were observed.227 However, 
individual non-CAA ICH cohorts seem to have a higher risk of ischaemic stroke at follow-
up when indirectly compared with the CAA cohorts. 
All studies used T2*-GRE MRI to detect CMBs at baseline, although imaging 
parameters, including echo time and slice thickness varied slightly (Table 10.1). Differences 
in demographic, clinical and imaging characteristics between the CMB (+) vs. CMB (-) 
groups are noted in Table 10.1. Among patients with CMBs, 79/665 (11.9%; 95% CI: 9.5-
14.6%) experienced recurrent ICH during follow-up, compared to 16/316 (5.1%; 95%CI: 
2.9-8.1%) patients without CMBs. The results of the overall analysis showed that those with 
any baseline CMBs had a higher risk of recurrent ICH at follow-up (OR: 2.81; 95% CI: 1.61-
4.93); p<0.0005) (Appendix F Figure 1). This risk was not significant for patients with a 
single CMB compared to those without CMBs. However, amongst different multiple CMBs 
groups (i.e. 2-4, 5-10 and >10 CMBs), there was a graded relationship between CMBs 
burden and higher recurrent ICH risk (Appendix F Figure 1). The results were consistent 
from study to study (test for heterogeneity p>0.10). 
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Table 10.1 Basic study design and patients characteristics of included studies. 
Study 
Country/ 
Setting 
T2*-GRE MRI parameters 
(Field strength/ET/ST) 
Patient 
number 
(% men) 
Inception point 
Mean 
age (SD) 
HTN 
Hx of 
ICH 
Antithrombotic users  Advanced 
WMC 
(grade 2 or 
3) 
CMBs 
prevalence 
Significant differences  
CMBs(+) vs. CMBs(-) 
groups Antiplatelet
s 
Oral 
anticoa
gulants 
Non-CAA related ICH cohorts 
Kang et al 
2012335 
South Korea 
Multicentre 
1.5T/30, 20,23ms/1-2mm 
97 
(60.8%) 
ICH onset 
(within 3 d) 
59.1y 
(12.1) 
84.5% 5.2% 14.4% 0% 42.2% 76.3% 
Age: 62(26-81) vs. 
53(38-77); p=0.059 
Advanced WMH: 
52.7% vs. 8.7%; 
p<0.001 
Imaizumi et al 
2012336 
Japan  
Single centre 
1.5T/26ms/7.5mm 
187 
(57.8%) 
ICH onset 
(within 7 d) 
68.4y 
(11.9) 
67.4% 9.1% 5.9% 3.2% 28.9% 71.1% No  
Biffi et al 
2010227 
USA 
Single centre 
1.5T/50ms/5-6mm 
104 
(58.5%) 
90 d after 
onset 
70.2y 
(12) 
81.7% 2.9% 40.4% 19.2% 75% 58.7% No 
Jeon et al 
2007331 
South Korea 
Single centre 
1.5T/30ms/2mm 
63 
(66.7%) 
ICH onset 
(within 10 d) 
58.3y 
(range 
38-81) 
96.8% NA 6.4% 0% NA 68.3% 
Hypocholesterolemia 
37.2% vs. 5%;  
p= 0.013 
Naka et al 
2006338 
Japan 
Single centre 
1T/26ms/5mm 
83 
(65.1%) 
Hospital 
discharge 
63 .5y  
(11 .7 )  
83.1% 18.1% 2.4% 2.4.% 28.9% 48.2% 
Advanced WMH: 45% 
vs. 14%; p=0.002 
Imaizumi et al 
2004339 
Japan 
Single centre 
1.5T/26ms/8mm 
199 
(50.8%) 
Days after 
onset 
65.9y 
(10.9) 
84.4% 9.1% 1% 0% NA 77.4% 
Age: 67.3±10.8 vs. 
61.4±11.2; p=0.0013 
CAA-related ICH cohorts 
Charidimou 
et al 2013302 
UK/Belgium 
Multicentre 
1.5T/15-70ms/5mm 
104 
(48.1%) 
MRI (median 
17 d post ICH) 
71.3y 
(9.5) 
59% 28.9% 20% 2% 44.1% 65.4% No 
Domingues-
Montanari et 
al 2011337 
Spain 
Single centre 
1.5T/29ms/?mm 40 (45%) 
1 month after 
onset 
74.7y 
(7) 
43.6% 45% NA NA 51.3% 70% 
Previous ICH: 53.6% 
vs. 16.7%; p=0.041 
Biffi et al 
2010227 
USA 
Single centre 
1.5T/50ms/5-6mm 
104 
(58.7%) 
90 d after 
onset 
72.5y 
(8.2) 
58.2% 7.7% 15.4% 10.6% 71.2% 60.6% 
HTN: 63.4% vs. 36.6 
%; p=0.007 
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Figure 10.1 Pooled risks of recurrent symptomatic intracerebral haemorrhage (top panel) and 
ischaemic stroke (lower panel) during follow-up in included studies.  
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In the non-CAA related ICH cohorts, amongst patients with CMBs, 26/506 (5.1%; 
95% CI: 3.4-7.4%) experienced recurrent ICH, compared to 3/227 (0.8%; 95% CI: 0.3-3.8%) 
patients without CMBs. The presence of CMBs was marginally related to an increased risk 
of recurrent ICH risk (OR: 2.63; 95% CI: 0.99-6.99; p=0.053) (Figure 10.2). Although there 
was a trend for higher risk across different CMBs burden groups compared to no CMBs, 
this risk was more pronounced only for patients with >10 CMBs (OR: 5.63; 95% CI: 1.79-
17.72; p=0.003) (Figure 10.2). When we meta-analysed data based on CMBs location in the 
brain (strictly lobar, strictly deep, mixed CMBs etc.), the presence of any lobar and mixed 
CMBs (but not strictly lobar or strictly deep) were associated with a risk of recurrent ICH 
(OR: 3.66; 95% CI: 1.31-10.27; p=0.014 and OR: 4.01; 95% CI: 1.47-10.94; p=0.007 
respectively) (Figure 10.3). The presence of any deep CMBs were marginally associated 
with a high risk of ICH recurrence (Figure 10.3). 
In the CAA-related ICH cohorts, 53/159 (33.3%; 95% CI: 26.1-41.2%) patients with 
CMBs and 13/89 (14.6%; 95% CI: 8-23.7%) patients without CMBs suffered recurrent lobar 
ICH during follow-up. The pooled OR for CMBs presence and recurrent ICH risk was 2.91 
(95% CI: 1.47-5.77; p=0.002) (Figure 10.4). The presence of a single CMB was not 
associated with a higher risk of recurrence compared to CAA patients without any CMBs 
(OR: 1.71; 95% CI: 0.63-4.66; p=0.294). However, the cumulative OR for recurrent ICH 
during follow-up was 3.32 (95% CI: 1.41-7.81; p=0.006) for subjects with 2-4 CMBs, 4.43 
(95% CI: 1.76-11.14; p=0.002) for 5-10 CMBs and 3.03 (95% CI: 1.19-7.74; p=0.02) for 
more than 10 CMBs (Figure 10.4). Further analyses within these groups revealed no 
differences in the risk for each increase in category and for 2-4 CMBs vs. ≥5 CMBs groups 
(RR: 1.035; 95% CI: 0.66-1.62; p=0.879) (data not shown). 
In a secondary analysis, CMBs (including presence and different number groups) were 
not associated with ischaemic stroke risk in either CAA or non-CAA related ICH cohorts. 
In a direct comparison, the relative risk for recurrent ICH vs. ischaemic stroke in patient 
with CMBs, was not significant for non-CAA related ICH cohorts across different CMBs 
groups. In patients with CAA-related ICH and any CMBs, the relative risk of recurrent ICH 
compared to ischaemic stroke was 31.2 (95% CI: 5.9-164.6; p<0.0005). Even though no 
heterogeneity was detected overall we used meta-regression to see whether certain 
confounders could have affected our results. No significant heterogeneity was noted 
according to age, gender, hypertension at baseline, history of previous ICH or white matter 
changes for the main outcomes. Sensitivity analyses involving sequential removal of each 
individual study in turn yielded very similar results for all comparisons. Estimation of 
publication bias via the Egger test and the Begg test returned non-significant results (all 
p>0.20).  
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Figure 10.2 Meta-analysis of effect of cerebral microbleeds (CMBs) presence and burden on the 
risk of recurrent spontaneous ICH in non-CAA ICH cohorts. 
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Figure 10.3 Meta-analysis of effect of cerebral microbleeds (CMBs) location on the risk of 
recurrent spontaneous ICH in non-CAA ICH cohorts. 
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Figure 10.4 Meta-analysis of effect of cerebral microbleeds (CMBs) presence and burden on the 
risk of recurrent spontaneous ICH in CAA ICH cohorts. 
10.4 Discussion 
In this systematic review and meta-analysis of eight cohorts involving 981 survivors with 
symptomatic spontaneous ICH, the pooled estimates demonstrated a consistent association 
between CMBs presence at baseline and future ICH recurrence. However, the strength of 
the association and the magnitude of recurrent ICH risk, especially in relation to CMBs 
burden and location, were considerably different depending on the nature and severity of 
the underlying microangiopathy – i.e. CAA-related and non-CAA related (presumably 
hypertension-related). 
Based on data from included cohorts the aggregate rates of recurrent ICH was about 
8-fold higher in patients with presumed CAA-related lobar ICH, compared to non-CAA 
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ICH. This is in line with most previous studies149, 340, 341 and a systematic review254 that have 
found ICH recurrence is more common following lobar ICH than non-lobar ICH (i.e. deep 
ICH) (4.4% vs. 2.1% per year respectively; p=0.002). In the cited review, the risk of 
ischaemic stroke (1.1% per year) was lower than the overall risk of recurrent ICH.254 A 
more recent meta-analysis also confirmed that ICH survivors seem to be at considerable 
risk of serious vascular events, with recurrent ICH being more frequent after lobar ICH.327 
In contrast with the previous systematic review, ischaemic stroke appeared to be at least as 
common as recurrent ICH over 3 years in four studies with appropriate data.327 
However, the included studies in these meta-analyses254, 327 did not have the benefit of 
MRI to systematically phenotype the likely underlying arteriopathy. The causal small vessel 
disease might have implications for prognosis and treatment, for example, the potential 
benefits and hazards of antithrombotic drugs (including antiplatelets and oral 
anticoagulant).342, 343 In our meta-analysis, the risk of ischaemic stroke was negligible for 
CAA patients; but nearly as high as the risk of recurrent ICH in the non-CAA cohorts. The 
prominent rate of recurrent CAA-related ICH and the different rates of subsequent 
ischaemic stroke compared to non-CAA related ICH, suggest that vascular mechanisms 
(and relative risk of bleeding vs. ischaemia) are fundamentally different between these two 
subtypes of small vessel disease.2 It is important to remember that hypertensive small vessel 
disease resulting in haemorrhages in deep brain areas, and hypertension in general (which 
was more prevalent in non-CAA compared to CAA cohorts; see Table 1), is also a major 
risk factor for ischaemic cerebrovascular events. By contrast, CAA is not accounted by 
conventional vascular risk factors (such as hypertension) and seems to be a more active 
haemorrhage-prone microangiopathy compared to hypertensive arteriopathy: the 
progressive accumulation of vascular amyloid-β causes weakening and cracking of cortical 
and leptomeningeal vessel walls, resulting in haemorrhage.28 History of previous ICH was 
more common in CAA compared to non-CAA cohorts in our meta-analysis. While CAA is 
associated with presumed asymptomatic cerebral microinfarcts, symptomatic ischaemic 
strokes are rare.197, 328 These characteristics, as well as variation in the use of 
antihypertensive therapy might partly account for the different stroke risks in the two 
groups. 
The differential stroke risks in ICH survivors have implications for prognosis and 
secondary prevention decision-making, especially regarding whether to prescribe 
antithrombotic treatments in individuals with a history of ICH, an increasingly common 
clinical dilemma.342, 344 The key question is whether CMBs are linked to an increased risk of 
“macrobleeding”, but available data for this hypothesis are limited.345 The high prevalence of 
CMBs in patients with ICH and the relatively low recurrence rates of ICH we found, 
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suggest that there might be only specific sub-group of patients with CMBs that are at 
particularly high risk for further haemorrhagic events. Our meta-analysis of ICH cohorts 
provides new and stronger evidence for this assumption. 
Perhaps unsurprisingly, we did not find a significant association between the presence 
of only one CMB and future recurrent ICH risk in the whole ICH population and also in 
neither CAA-related, nor non-CAA-related ICH cohorts. However, the pathophysiological 
significance of a single CMB is unclear: it might indicate a less severe or less active 
microangiopathy, or it might be just the tip of the iceberg of small vessel damage. This issue 
is further complicated because the classification of patients into those having single vs. 
multiple microbleeds may vary with MRI characteristics used: e.g. higher field strengths, 
thinner slices, or susceptibility-weighted imaging seem to increase sensitivity to CMBs 
detection.346 All of the included studies have relied on “conventional” T2*-GRE MRI 
performed under standard imaging parameters, commonly used in clinical practice. Also, in 
one microbleed rating scale validation study, patients with only one potential CMB 
accounted for most cases of disagreement and inter-rater variability.238 
We have confirmed that CAA-related lobar CMBs are a strong predictor of recurrent 
ICH on clinical follow-up, making them good prognostic biomarkers in CAA. Despite this 
overall association, the occurrence of CAA-related recurrent lobar ICH was considerably 
lower than the overall prevalence of lobar CMBs at baseline. This observation indicates that 
particular properties of the CAA-affected vessels as well as additional factors may 
determine whether a vessel rupture will result in a CMB or a larger macrobleed.198 
However, underscoring a connection between microbleeding and macrobleeding, the 
dynamic development of new CMBs on serial T2*-GRE MRI over time also predicts 
subsequent recurrent ICH in CAA.180 Recent studies have shown most of these new CAA-
related haemorrhages arise at sites of high baseline amyloid-β deposition, detected in vivo 
using PiB PET imaging.176, 285 It is thus possible that in certain circumstances (e.g. with the 
use of antithrombotic drugs) CAA-related CMBs, rather than being sealed off by normal 
hemostatic mechanisms and surrounding tissue, may enlarge into a symptomatic lobar ICH, 
underlying the strong association between CAA and anticoagulant-related ICH.152, 347, 348 
Within this context, a decision analysis based on a 69-year-old survivor of a lobar CAA-
related ICH and newly diagnosed non-valvular atrial fibrillation suggested that should not be 
anticoagulated with warfarin across the spectrum of thromboembolic and haemorrhagic 
risks.349 The strong association of lobar CMBs burden and CAA-related recurrent ICH we 
demonstrated, as well as the association with anticoagulation-related ICH152 makes them an 
important feature for haemorrhagic risk assessment in older patients at high risk of CAA 
pathology. However, it remains unclear whether the presence of strictly lobar CMBs in the 
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absence of symptomatic lobar ICH (i.e. microbleeds-only CAA) which are highly prevalent 
in the elderly,174 confers sufficient risk of future ICH. A recent study indicates that this 
incident ICH risk is not trivial and warfarin might be a significant predictor of ICH 
occurrence in this population (p<0.05) but definitive data are lacking.350 
In the non-CAA related ICH cohorts, our results indicate that a certain CMBs load, 
specifically the presence of more than ten CMBs, and a mixed distribution in the brain, are 
a strong marker of recurrent ICH risk. Since hypertensive small vessel damage primarily 
affects deep brain regions, the presence of both deep and lobar CMBs is an indication of 
advanced and widespread disease. In all the other CMBs groups the risk of recurrent ICH 
might be at least as important as the risk for future ischaemic stroke (and probably all vaso-
occlusive events).327 Consistent with this notion, the relative risks for recurrent ICH 
compared to future ischaemic stroke where not different within each CMBs subgroup - 
although the patient numbers and the magnitude of the effect sizes were quite low. One 
could assume that these relative effects of CMB burden on recurrent ICH and ischaemic 
stroke risk might tip the risk-benefit balance in favour of antithrombotic treatment use in 
non-CAA ICH patients with less than ten CMBs. 
Our meta-analysis has limitations. Some studies had a small sample size, variable 
follow-up, and few outcome events, leading to wide confidence intervals around risk 
estimates. In these studies, inception points (i.e. the start of follow-up), and methods of 
outcome assessment varied. Studies used different imaging parameters, for example echo 
time, potentially affecting the detection of CMBs,27 although the prevalence of CMBs was 
fairly consistent across studies. Furthermore, studies are subject to selection bias since not 
all ICH patients undergo T2*-GRE, thus probably excluding more severe cases of ICH. 
However, our findings represent the most up-to-data summary of available data on the 
topic and can be generalised in ICH survivors who undergo clinical T2*-GRE MRI. Finally, a 
potentially important limitation is possible confounding due to lack of adjustment for other 
baseline variables related to future recurrent ICH risk (e.g. antithrombotic drug use, 
hypertension treatment, ApoE genotype etc.). Nevertheless, all studies showed a consistent 
direction of association between CMBs and recurrent ICH, even when adjusted for these 
potential confounders. Furthermore, we did not have pathological confirmation of the small 
vessel pathology underlying ICH in each cohort and we acknowledge that the Boston 
criteria for CAA classification have imperfect specificity.195, 202 Of note, the type of included 
cohorts and the presumed underlying causes of ICH are in line with the higher prevalence 
of hypertensive arteriopathy rather than CAA in Asia compared to the United States or 
Europe.32 For this reason only one study had concurrent groups of patients with both 
CAA-related and non-CAA related ICH.227 
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Spontaneous ICH originates from different cerebral small vessel pathologies which 
have intrinsically distinct prognostic significance for future stroke (including recurrent ICH 
and ischaemic stroke). Our findings suggest that CMBs on blood-sensitive MRI sequences 
are helpful in stratifying the risk of recurrent bleeding in ICH survivors. Furthermore, the 
use of MRI is critical for phenotyping the presumed underlying aetiology of spontaneous 
ICH, to inform patients and carers, plan clinical services and design clinical trials. The 
current data support routine neuroimaging in survivors of spontaneous ICH to define the 
microangiopathy subtype and CMBs burden to inform prognosis and relative risk of future 
ICH and ischaemic stroke, which could add to risk–benefit analyses for antiplatelet or 
anticoagulant use. Whether the risk of recurrent ICH and ischaemic stroke after ICH 
change over time and the specific influence of antithrombotic drugs on outcome, are 
important questions which remain unanswered. However, in light of the very high risk of 
recurrence, in the absence of a compelling indication (e.g. recent coronary stenting, non-
valvular atrial fibrillation) antithrombotics should not be routinely used in survivors of 
CAA-related lobar ICH, especially in the presence of lobar CMBs. For non-CAA related 
ICH survivors, given that the risk of future ischaemic stroke being almost as high as the risk 
of recurrent ICH, the distribution and burden of CMBs may need to be taken into account 
in starting antithrombotics. More research is needed to incorporate these data into a more 
comprehensive bleeding risk model. 
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Chapter 11 General discussion, future 
perspectives and challenges 
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The CAA story is remarkable in that unlike most neurological disorders, the understanding 
of the underlying pathology preceded by many years the association with clinical syndromes 
and disease. Part of this long delay might be explained by a much lower prevalence of CAA 
in the early 20th century,351 because most of the population at the time did not live long 
enough to be at risk for developing this age-related disease. As life expectancy increased 
significantly and effective control of hypertension has been achieved in the current era, 
CAA has become an increasingly prominent cause of lobar intracerebral haemorrhage and 
dementia.34 Despite the tremendous contributions from neuropathology (including modern 
molecular pathology) towards understating of CAA, there are now compelling reasons for 
exploring the disease also from a clinical-radiological perspective. First and foremost, the 
advent of advanced MRI has increased our ability to detect and define the consequences of 
CAA in routine clinical practise, including more dynamic features of the disease (i.e. 
evolution of imaging features over time, incidence of new lesions, clinical recurrence etc.) 
which are in a way “frozen” (like a “snapshot”) in neuropathological examination. 
Furthermore, the growing knowledge of the underlying pathology, biology, genetics, as well 
as of the neuroimaging and neurological correlates of CAA can be translated into better 
techniques for diagnosing and ultimately modifying its natural history. 
The main objective of this PhD thesis was to gain novel insights into aspects of 
potential new CAA biomarkers on applied clinical neuroimaging, which are likely to have 
increasing relevance in the field. This was accomplished by (a) investigating the clinical and 
radiological spectrum of transient neurological episodes in CAA; (b) exploring the 
prevalence, associations and prognostic significance of cSS, a new haemorrhagic marker of 
the disease; (c) examining MRI-visible PVS in the centrum semiovale as a new CAA marker 
(including pathophysiological features); (d) identifying pathological, neuroimaging and genetic 
characteristics in haemorrhagic and non-haemorrhagic CAA with the potential to point 
towards different phenotypes of the disease; and (e) summarising the evidence on how 
cerebral microbleeds burden, an established imaging marker of cerebral small vessel 
disease, relates to recurrent symptomatic ICH according to the presumed MRI-defined 
underlying arteriopathy (CAA vs. non-CAA). 
In this chapter, I would like first to focus the discussion on the potential clinical aspects 
of CAA-related transient focal neurological episodes in the field of cerebrovascular disease 
in general. Next, I discuss themes related to the other main thesis findings, namely CAA 
imaging biomarkers. These are discussed both as meaningful markers to measure the 
disease’s consequences in routine clinical practice, but also in the context of current 
knowledge and recently published consensus papers on outcome markers for clinical trials 
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in CAA300 and cerebral small vessels disease imaging standards.31 Finally, suggestions for 
future research are given. 
11.1 Transient focal neurological episodes in cerebral 
amyloid angiopathy: looking beyond TIAs 
When vascular neurologists or stroke physicians encounter patients with transient focal 
neurological symptoms, they usually consider at least five diagnoses: transient ischaemic 
attacks (TIAs), migraine auras, seizures, peripheral nerve compression, or psychogenic 
disorders.352 Surveys show that the diagnosis and management of patients with suspected 
TIAs, especially by primary care physicians and non-neurologists, remains challenging.353, 354 
As recently as 2008, a report suggested that some general practitioners may not refer 
patients with transient focal neurological symptoms, while others have a much lower 
threshold for referral to minimise any risk.355 It is thus clear that the differential diagnosis of 
TIAs is not straightforward,356 despite the simple descriptions given in textbooks. Even for 
experienced vascular neurologists, it is sometimes impossible to be sure if a transient 
symptom was truly neurological, and even more difficult to be certain if it was of vascular 
origin. There is no test to prove a diagnosis of TIA in all cases, although longer attacks are 
associated with diffusion-weighted imaging (DWI)-positive lesions,357 which are also 
associated with an increased risk of future ischaemic stroke.357 However if the symptoms 
are very brief, brain imaging, including DWI can be normal; moreover, taking the history 
can be extremely difficult and the inter-observer agreement for the diagnosis of TIA even 
amongst experienced neurologists is only modest, with kappa values ranging between 0.65 
and 0.78.358-360 
In our study (Chapter 2) we have highlighted this common diagnostic dilemma with 
reference to the transient focal neurological episodes (TFNE) which are increasingly 
recognized in the context of CAA; these attacks can resemble TIAs, migraine auras or 
seizures (although they are often not quite typical of any of them), but are probably more 
often related to bleeding in the brain (especially cortical superficial siderosis and acute 
convexity subarachnoid haemorrhage) rather than ischaemia.361 It is important to note that 
TNFEs are not always associated with cSS; there have been reports of transient 
neurological symptoms in the presence of acute subcortical cerebral microbleeds alone.362 
Since the completion of the study presented here there have been further reports from 
small cases series on the topic,363-365 which accord with our data. This is a practical point 
with potentially important implications for patient care, because: (a) appropriate blood-
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sensitive MRI scans can detect small areas of intraparenchymal or subarachnoid bleeding to 
establish the diagnosis of CAA and likely origin of the episodes; and (b) giving 
antithrombotic drugs in these patients could increase the risk of serious future 
intracerebral haemorrhage. 
There are similarities between the clinical phenomenology of amyloid spells in our 
study and those of some of Miller Fisher’s famous “late-life migraine accompaniments” 
(especially the non-visual phenomena):366, 367 “Typical of migrainous accompaniments are the 
build-up and migration of visual scintillations, the march of paresthesia, and progression from one 
accompaniment to another, characteristics that do not occur in thrombosis and embolism”.366 
Some of Miller Fisher’s cases could have been CAA-related, but at that time there was no 
access to advanced MRI, and cerebral angiograms were used to "exclude" a vascular cause. 
In our multicentre study, blood-sensitive MRI sequences, including T2*-weighted gradient-
recalled echo (T2*-GRE) and susceptibility-weighted imaging (SWI) revealed that TFNE may 
be caused by haemorrhagic neuroimaging manifestations of CAA, including superficial 
cortical siderosis, convexity subarachnoid haemorrhage or lobar cerebral microbleeds.361 
Importantly, and in contrast to Miller Fisher’s migraine accompaniments, CAA-related 
TFNE did not have a benign course, but were associated with a high early risk of 
symptomatic lobar ICH (about 50% at 2-3 months).361 It is difficult to speculate as to why 
Miller Fisher’s patients with migraine accompaniments had such a benign course compared 
to “amyloid spells”; perhaps the follow-up available was not very systematic, or some of his 
patients had a mild underlying disease process not associated with a high risk of bleeding. 
The correct recognition of TFNE in CAA has clinical implications which can be 
considered according to two scenarios: first, a patient with suspected or probable CAA 
(e.g. a previous lobar intracerebral haemorrhage) who develops a TFNE; and second, a 
patient who presents with TFNE but without any previous suspicion of CAA. In both of 
these settings, our recent findings clearly suggest a key role for T2*-GRE MRI (or other 
blood-sensitive sequences). In the first scenario, where the suspicion of CAA is high 
appropriate imaging may identify the possible cause of the TFNE, for example focal 
superficial cortical siderosis or acute convexity subarachnoid haemorrhage (depending on 
the timing of the MRI),28, 171, 191, 195, 361, 368 but also possibly small cortical DWI lesions.73 The 
identification of these potential mechanisms of TNFE should mandate aggressive treatment 
of known risk factors for recurrent ICH, with particular attention to blood pressure 
control and avoidance of antithrombotics. Anticonvulsant medications may also be helpful if 
the underlying mechanism is suspected to be related to seizure activity or cortical 
spreading depression.170 In the second scenario, the use of T2*-GRE or SWI may reveal 
previously unsuspected CAA by detecting multiple lobar cerebral microbleeds,35 old silent 
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lobar ICHs, cortical superficial siderosis or acute convexity subarachnoid haemorrhage.28, 
195, 202 Since in our study TFNE were observed in patients without a history of symptomatic 
ICH,361 they may also prove to be a useful diagnostic marker of CAA, potentially allowing 
diagnosis earlier in its disease course, before symptomatic ICH occurs. A recent 
neuropathological study identified TIA–like episodes as being significant clinical predictors 
of severe CAA in persons with pathologically confirmed Alzheimer’s disease.369 As noted by 
the authors, the prevalence of a history of TIA-like events in their participants with both 
Alzheimer’s disease and advanced CAA on pathology was striking similar to the reported 
prevalence of the CAA cohort presented in Chapter 2, at 12.5%.369 We therefore suggest 
that the performance of MRI, including not only DWI but also blood-sensitive sequences is 
essential in the investigation of older patients with unexplained TFNE, especially if they are 
atypical for TIA, recurrent and stereotyped or occur without known risk factors for typical 
TIAs. 
The magnitude of the problem – i.e. how many patients with TFNE associated with 
CAA are missed, is currently unknown. Some indirect estimates can be extrapolated from 
studies including patients with relevant clinical and neuroimaging features. A study by 
Lovelock et al using data from a population-based cohort (Oxford Vascular Study) scanned 
early with CT and a hospital-based stroke clinic cohort scanned with MRI, found that 
approximately 5% of consecutive patients presenting with minor stroke have ICH.370 In the 
Rotterdam Study population-based cohort, nonspecific transient focal neurological episodes 
(not typical of TIAs, including visual symptoms and spreading sensory symptoms) were 
found in 1%, 1.8%, 2%, and 2.9%, of patients aged 55-64 years, 65-74 years, 75-84 years, and 
85 years or older respectively.371 In the population-based Rotterdam Scan Study cortical 
superficial siderosis was found in 0.7% of elderly individuals (mean age 69.6 years), all of 
whom had cerebral microbleeds in lobar locations and in close vicinity to the cortical 
superficial siderosis.243 
Further large prospective studies with systematic enquiry about TFNE and appropriate 
brain and detailed standardized vascular imaging are needed, and should ideally be 
conducted: (a) in stroke services treating patients with CAA (to get detailed clinical 
descriptions of TFNEs before ICH and assess their association with CAA compared with 
other types of ICH); and (b) in services assessing suspected TIAs. Although TFNE 
diagnosed as TIAs are established as a critical predictor of a high early risk of an ischaemic 
stroke,372 some TFNE, in conjunction with appropriate neuroimaging signs, may in the 
future provide an early warning sign and window for prevention of symptomatic ICH. With 
this rationale in mind, we are further investigating the prevalence, phenomenology and 
significance of transient focal neurological symptoms before intracerebral haemorrhage 
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within the context of CROMIS-2 Study II. This is a large UK-based observational case-
control study originally designed to investigate genetic associations with spontaneous and 
oral anticoagulation-related intracerebral haemorrhage. Adult (>18y) patients treated at 
participating centres with confirmed intracerebral haemorrhage (confirmed on CT or MRI 
scans) in the past 1 month, with or without a history of anticoagulant use at the time of the 
haemorrhage are eligible for the study. We have specifically designed a questionnaire to 
systematically capture any transient focal neurological symptoms before intracerebral 
haemorrhage and will further investigate their associations with detailed clinical and imaging 
data, as well as 6-month outcome. 
11.2 Developing biomarkers for cerebral amyloid 
angiopathy (including outcome markers for trials) 
As mentioned throughout this thesis, neuroimaging markers have a central role in defining 
CAA (and cerebral small vessel disease in general), which falls into at least two basic 
categories: to make accurate diagnosis of CAA (or identify individuals “at risk” of 
developing the disease) and predict underlying biological and clinical progression (e.g. 
bleeding risk stratification). Additionally, neuroimaging or other biomarkers can potentially 
measure treatment efficacy and effects (sometimes termed “outcome markers” or 
“surrogate markers”). To address all of these requirements in CAA, a combination of 
different biomarkers will be needed. Emerging data continue to increase the range of CAA 
markers which currently include clinical events (e.g. symptomatic intracerebral 
haemorrhage or cognitive impairment), structural neuroimaging brain lesions (both 
haemorrhagic and non-haemorrhagic, e.g. cerebral microbleeds, cSS, white matter 
hyperintensities, cerebral microinfarcts or CSO-PVS), alterations of vascular physiology, and 
direct visualisation of cerebrovascular amyloid using PET-based radioligands.300  
There are now grounds for optimism that amyloid-modulating therapies, including 
immune-based therapies (amyloid-β immunisation), may soon be possible in CAA. There 
are several potential treatment approaches to modify the progression or prevent CAA, 
including reducing amyloid-β production, enhancing amyloid-β clearance or protecting small 
vessels from its toxic effects. A candidate agent which might delay or inhibit the 
progression of CAA is tramiprosate, an ionic compound which binds soluble amyloid-β, and 
interferes with the amyloid cascade.373 Tramiprosate has been shown to be a safe treatment 
option for patients with suspected CAA in a phase 2 study, supporting future efficacy 
trials.374 Emerging data from the use of secretases inhibitors or immunization against 
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amyloid-β in Alzheimer’s disease will be invaluable in guiding further efforts for disease 
modification in CAA. A phase 2 randomized controlled trial is currently ongoing at 
specialist centres worldwide, in patients with probable CAA, evaluating the safety and 
efficacy of Ponezumab, a humanized anti-amyloid monoclonal antibody designed to bind and 
remove the vascular amyloid-β (ClinicalTrials.gov Identifier: NCT01821118). Other 
potential disease-modifying mechanisms may also be on the horizon: for example in a 
transgenic mouse model of CAA, researchers found less severe vascular amyloid 
deposition, and improved neurological function, associated with knockout of function of the 
CD36 receptor (found on immune and endothelial cells), with preservation of an important 
amyloid-β clearing mechanism involving another receptor, LRP-1.375 Thus, blocking the 
binding of amyloid-β to CD36 receptor could be a new human therapeutic target in CAA. 
Deciding which disease-modifying treatments are the most promising requires: (a) 
early-phase trials to show safety, feasibility and efficacy, and (b) late-phase pivotal large scale 
clinical trials to establish those treatments suitable for medical use.300 The evaluation and 
implementation of such treatments for CAA increases the urgency with which biomarkers 
of the disease are needed. By definition, for therapeutic trials, a perfect CAA biomarker 
should have some additional desirable features: be representative of an established step in 
disease pathogenesis, correlate well with the underlying pathology or disease severity, and 
clinical consequences, be efficient for detecting changes in response to treatment, reliably 
and reproducibly measurable across many trial sites and cost-effective.300 376 Since there is 
currently no ideal CAA biomarker with all these desired features, different surrogates 
should be utilised based on the aim, nature or stage of the trial. 
For early-phase proof-of-concept studies aimed at identification of promising 
candidate treatments, markers with high statistical efficiency for small or short studies 
should be utilised. These are unlikely to include clinical events or most of the structural 
neuroimaging CAA markers, as they seem to be more prevalent in only selected patients 
with advanced disease and might not accumulate at high enough rates to be sensitive 
enough and practical to capture disease progression over short time periods.300 For 
example, symptomatic intracerebral haemorrhage is somewhat more common in individuals 
with multiple cerebral microbleeds as indicated by our findings in Chapter 10 and is likely a 
more relevant outcome marker as a recurrent event in the subgroup of patients surviving 
one or more lobar intracerebral haemorrhage (9.96%; 95% CI: 5.08-14.84 per year in the 
meta-analysis presented here). In addition, symptomatic lobar intracerebral haemorrhage 
and most CAA MRI markers probably represent only the “tip of the iceberg” of CAA-
related brain structural damage, as they come very late in the postulated CAA 
pathophysiological pathways, from vascular dysfunction to vascular-mediated brain 
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parenchyma injury and clinical dysfunction. Hence, quantitative measures of CAA-related 
abnormalities on the vessels themselves or their function might have a clearer potential to 
directly detect more subtle (and potentially reversible) effects of the disease in early-phase 
studies, although there are big challenges to overcome in running these across multiple 
sites.300 Findings from recent studies suggest that a physiological biomarker for direct CAA-
related vascular injury can be altered cerebrovascular reactivity,377 measured by the 
functional MRI (fMRI) blood oxygen level-dependent (BOLD) response to visual 
stimulation.378-380 These cross-sectional studies have shown that patients with CAA have 
reduced and delayed vascular reactivity (lower peak amplitude, longer time to peak and 
longer time to return to baseline) compared with age-matched healthy controls,378, 379 and 
correlate with established markers of disease severity in CAA.246, 247 Based on these results 
highlighting the validity of fMRI as a physiologic biomarker of vascular dysfunction,380 change 
in cerebrovascular reactivity as measured by the slope (amplitude over time to peak) from 
visual task-evoked BOLD fMRI was recently adopted as a surrogate endpoint measure in 
the phase 2 monoclonal antibody study mentioned above (NCT01821118). 
Notwithstanding their limitations, compared to physiological biomarkers, clinical 
events and haemorrhagic or non-haemorrhagic structural neuroimaging biomarkers of CAA 
are probably more clinically meaningful for use in everyday clinical practise, and alone or in 
combination are better suited to serve as surrogate markers in late-phase large scale 
clinical trials. In addition to disease-modifying trials, imaging markers of CAA can be useful 
as surrogate markers in other interventions, e.g. trials of acute blood pressure lowering in 
patients with symptomatic ICH. Alternatively, they can be markers affecting prognosis in 
specific treatment settings, e.g. intravenous thrombolysis for acute ischaemic stroke in the 
presence of microbleeds.381 
11.2.1 Cerebral microbleeds, macrobleeds and their inter-
relation 
Histopathological correlation studies suggest that radiologically-defined microbleeds 
generally correlate with small collections of blood-breakdown products, which have 
presumably leaked from fragile small vessels into the brain parenchyma.172, 330 Hence, 
cerebral microbleeds differ from other MRI markers of small vessel disease (e.g. lacunes 
and white matter hyperintensities), in that they seem to provide more direct evidence of 
microvascular leakiness.27 As such, cerebral microbleeds in some populations and disease 
settings might have clinical value as markers of increased future risk of symptomatic ICH 
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(“macrobleeding”), potentially raising clinical dilemmas27, 382-384 especially regarding the 
safety of antithrombotic drugs, a cornerstone of stroke prevention treatment. 
The two sporadic small vessel pathologies which give rise to both microbleeds and 
macrobleeds, namely CAA and hypertensive arteriopathy, have distinct natural history and 
prognosis. As outlined in Chapter 10, the risk of recurrent bleeding after symptomatic 
intracerebral haemorrhage seems to be significantly higher for CAA-related lobar 
intracerebral haemorrhage.37, 149 Lobar cerebral microbleeds, suggesting CAA may thus be a 
stronger risk factor for future intracerebral haemorrhage than deep cerebral microbleeds. 
Furthermore, there is still a controversy about the origin of deep (basal ganglia) cerebral 
microbleeds, with a recent pathological study suggesting an association with ischaemia 
rather than small haemorrhages.385 It is of course important to bear in mind that CAA and 
hypertensive arteriopathy can co-exist and interact, particularly in older populations, and 
the interpretation of a “mixed” lobar and deep distribution of cerebral microbleeds 
presents a challenge. 
In a cross-sectional case-case analysis, cerebral microbleeds were more commonly 
found in patients with warfarin-related intracerebral haemorrhage compared to 
anticoagulated patients without intracerebral haemorrhage and patients with non-
anticoagulant related spontaneous intracerebral haemorrhage.386 These data suggest that 
both deep perforating arteries in the basal ganglia and cerebral white matter (affected by 
hypertensive arteriopathy) and CAA-laden leptomeningeal or cortical small vessels 
weakened by amyloid-β deposition give rise to ongoing minor self-limiting leaks (i.e. 
cerebral microbleeds). It seems plausible that, under certain circumstances (e.g. minor head 
trauma, antithrombotic drugs, increased blood pressure, etc.), cerebral microbleeds might 
not be effectively “sealed off” and instead expand into a life-threatening intracerebral 
haemorrhage.387 Taken together, the associations of cerebral microbleeds with age, specific 
small vessel pathologies (particularly CAA) and warfarin-related intracerebral haemorrhage, 
and the dynamic evolution of microbleeds over time, suggest an important link between 
cerebral microbleeds and future macrobleeding. 
Are cerebral microbleeds a prognostic biomarker useful for future ICH risk 
assessment? Currently, there is no simple “yes” or “no” answer to this question; rather, 
the answer critically depends on the specific patient population under consideration, as well 
as cerebral microbleeds location and burden. So, which factors predict the small subgroup 
of those with cerebral microbleeds at risk of future macrobleeding? In patients with CAA-
related lobar ICH, longitudinal studies included in the meta-analysis presented here, show 
that higher number of lobar microbleeds (especially ≥5 cerebral microbleeds) increases the 
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risk of future recurrent intracerebral haemorrhage,227 making cerebral microbleeds a 
powerful risk predictor in this context. It remains unclear whether the presence of cerebral 
microbleeds might confer a similar increased risk of recurrence in patients with non-CAA 
related intracerebral haemorrhage. The small sample sizes and lower stroke recurrence 
rate among non-CAA intracerebral haemorrhage cohorts limit statistical power for 
detecting an effect. In ischaemic stroke/TIA patients recent estimates based on all pooled 
prospective studies showed that cerebral microbleeds presence was consistently associated 
with an increased risk of symptomatic intracerebral haemorrhage (OR: 8.52; 95%CI: 4.23-
17.18).388 This intracerebral haemorrhage risk associated with cerebral microbleeds was 
higher among Asian patients compared to Caucasians (OR: 10.4 vs. OR: 3.9 respectively).388 
The presence of cerebral microbleeds is also related with an increased risk of future 
ischaemic stroke in these populations in whom antithrombotic therapy is commonly used. 
Another key question is whether microbleeds indicate an increased risk of ICH in 
persons free of clinical stroke. Two prospective population-based studies found that 
cerebral microbleeds are associated with both future intracerebral haemorrhage and 
ischaemic stroke, even in healthy elderly individuals.389, 390 The number of outcome events 
was low in these studies, resulting in wide confidence intervals, and the populations were 
Asian, where the predominant microangiopathy is probably hypertension rather than CAA-
related, by contrast with Western populations. Longitudinal data from the Rotterdam scan 
study are keenly awaited to shed further light on this topic. 
A recent study compared the risk of future symptomatic intracerebral haemorrhage in 
patients who presented with strictly lobar microbleeds without a history of intracerebral 
haemorrhage (cerebral microbleeds-only CAA) to patients who presented with CAA-
related lobar intracerebral haemorrhage.322 These patients presenting with just lobar 
cerebral microbleeds on MRI had a clinical, genetic, and neuroimaging profile suggestive of 
severe underlying CAA pathology. In survival analysis the cerebral microbleeds-only group 
had a considerable risk of incident intracerebral haemorrhage, although lower compared to 
the lobar intracerebral haemorrhage cohort. The use of warfarin in a small subgroup of 
cerebral microbleeds-only CAA patients was associated with a significantly increased risk of 
future intracerebral haemorrhage after adjusting for other confounders.322 
A key question is whether cerebral microbleeds are a useful tool for stratifying the risk 
of ICH prior to deciding on antithrombotic or thrombolytic treatments in these patients. 
Unfortunately, good quality prospective data in large cohorts are not yet available, 
particularly regarding thrombolysis.348 Two meta-analyses391, 392 highlighted a trend of 
increased hazard of post-thrombolysis symptomatic intracerebral haemorrhage in ischaemic 
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stroke patients with cerebral microbleeds (RR: 1.90; 95% CI: 0.92 to 3.93; p=0.082).269 
CAA may be a particular risk factor for post-thrombolysis intracerebral haemorrhages, 
which are often lobar, multiple and occur remote from the infarct in around 20% of 
patients.393 Pathological studies also support a role of pre-existing CAA: one study reported 
that 70% of patients with thrombolysis-related intracerebral haemorrhage had autopsy-
proven CAA compared to 22% of unselected ICH patients of similar age.394 Finally, an 
increased risk of ICH was associated with intravenous thrombolysis in CAA transgenic 
mice.392, 395, 396 However, more robust data from large well-designed and adequately 
powered prospective studies are clearly needed, especially to investigate the role of lobar 
cerebral microbleeds as a marker of CAA in this context.381 An update meta-analysis on 
this topic is underway. 
Although lobar cerebral microbleeds have great value as a diagnostic biomarker of 
CAA and can identify patients with established disease (as part of the Boston criteria), many 
key questions remain unanswered. The current data support the notion that the nature and 
severity of the underlying arteriopathies, which carry intrinsically different bleeding risks 
(i.e. CAA vs. hypertensive arteriopathy), may modify the relationship between cerebral 
microbleeds and macrobleeds. More well-designed large scale prospective studies are 
needed to draw solid conclusions across different populations (e.g. the CROMIS-2 study in 
patients anticoagulated after cardioembolic stroke; www.ucl.ac.uk/cromis-2). Studies should 
ideally take into account not only cerebral microbleeds presence, but also their number, 
location and progression as well as other markers of small vessel brain injury.397 For now, 
the available evidence suggests that in patients with probable CAA the risk of future 
intracerebral haemorrhage seems to be substantial, and might aggravated by 
anticoagulation. 
Several studies have shown that cerebral microbleeds dynamically accumulate over 
time, with the burden (presence and number) of baseline cerebral microbleeds predicting 
the development of new cerebral microbleeds in both deep and lobar regions.398-400 In the 
Rotterdam study, appearance of new lobar cerebral microbleeds was reported in 6.1% of 
831 healthy elderly individuals in the general population, rescanned after a mean of 3.4 
years from their baseline MRI.399 In the subset with one or more strictly lobar microbleeds 
at baseline, possibly reflecting clinically silent CAA, 17.5% developed new lobar 
microbleeds.399 In a small study of probable CAA patients with intracerebral haemorrhage 
(n=34), 50% demonstrated new incident lobar cerebral microbleeds, after a mean of 15.8 
months.180 Although larger systematic studies are need for more accurate estimates, the 
apparent substantially higher prevalence and incidence of lobar cerebral microbleeds 
compared to symptomatic intracerebral haemorrhage in CAA, makes them an appealing 
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outcome marker to track disease progression and show a relative reduction in incident 
events for trials.300 One of the main downsides of cerebral microbleeds as an outcome 
marker is their uncertain relevance as a clinically meaningful outcome in patients that will 
not go on to develop an intracerebral haemorrhage, or populations with underlying CAA in 
whom the risk of bleeding is low (e.g. Alzheimer’s disease). Although strictly lobar cerebral 
microbleeds have been independently linked to cognitive impairment in the in the general 
elderly population401 as well as in patients with ischaemic stroke,402 their role in 
neurological dysfunction is still an area under investigation. 
11.2.2 Cortical superficial siderosis 
Studies presented in this thesis (Chapter 3 and 4) add to the accumulating evidence that cSS 
is a central component of the haemorrhagic manifestations of CAA, expanding its clinical-
imaging spectrum,167, 403 with the potential to identify new mechanisms and subtypes of the 
disease. cSS is very common in CAA being found cSS in 60.5% of patients with 
histopathologically-proven CAA (n=38; mean age 70 ± 6.4 years) but in none of the 
controls with histopathologically-proven non-CAA-related ICH (n=22; mean age 54 ± 18 
years).195 The clinical-radiological cohort presented in Chapter 3 further investigated the 
strength of this association and found cSS in 40% of probable CAA patients, but less than 
5% of patients with a ‘strictly deep’ pattern of ICH;301 cSS was also detected in 15% of 
patients with a single lobar ICH or mixed (lobar and deep) haemorrhages but in most of 
these cases the presence of lobar CMBs was suggesting some degree of CAA pathology.301 
In addition, similar to the previous pathological study,195 cSS was often distant from sites of 
lobar haemorrhage and occasionally can occur in the absence of intracerebral 
haemorrhage.182, 277 196, 303 These and other observations,203, 404 reinforce the idea that cSS is 
a separate bleeding event related to CAA, offering equal evidence to lobar cerebral 
microbleeds or intracerebral haemorrhage for its presence. One study included cSS in 
modified Boston criteria for CAA diagnosis, showing a potential improvement in 
sensitivity,195 but further validation studies are needed to determine whether disseminated 
cSS increases the specificity for CAA. In the retrospective imaging study presented here, 
disseminated cSS (affecting at least 4 sulci) appeared to be more specific than focal cSS for 
CAA.301 Interestingly, cSS was not associated with lobar CMBs burden raising the possibility 
that cSS and CMBs may result from different haemorrhagic mechanisms. The population-
based Rotterdam Study in 1,062 non-demented subjects ≥60 years, reported cSS in 7 
persons (0.7% prevalence),315 compared to a much higher prevalence of lobar microbleeds 
(nearly 14%175). 
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In addition to being a trigger of transient focal neurological symptoms, cSS might have 
another clinically meaningful role in CAA, as a marker of vulnerability to future lobar 
intracerebral haemorrhage. This has been suggested by case reports and small case 
series191, 237, 260, 405 and more recently in a retrospective cohort of patients with CAA-
related cSS.246 The multicentre cohort study of probable or possible CAA presented in 
Chapter 3, including those patients without cSS at baseline,302 provides systematic evidence 
that cSS is a strong and independed predictor of intracerebral haemorrhage risk in these 
patients. It remains unclear whether isolated cSS without other features of CAA confers an 
equality high risk of incident intracerebral haemorrhage, e.g. sufficient enough to avoid 
antithrombotic treatment. Future studies should explore if cSS is a clinically important 
feature for haemorrhagic risk assessment in older patients without symptoms, in the 
context of anticoagulants, including recently approved newer direct oral anticoagulants 
(dabigatran, rivaroxaban, apixaban, edoxaban).406-409 
Why a particular CAA-related bleeding event results in cSS, lobar ICH or CMBs 
remains uncertain. A neuropathological series of six autopsy cases of lobar haematomas 
caused by CAA showed that multiple leptomeningeal arteries can rupture into the 
subarachnoid space and the brain parenchyma:248, 316 all cases had multiple haematomas in 
the subarachnoid space (mainly in the cerebral sulci), as well as intracerebral haematomas. 
Each intracerebral haematoma was connected to the subarachnoid haematomas at the 
depth of cerebral sulci or through the lateral margin of the cortex.248 These observations 
might explain why patients with disseminated cSS have the highest risk of ICH;302 
disseminated cSS may reflect numerous and widespread leptomeningeal blood vessels 
damaged by advanced CAA, providing multiple initiation sites for future ICH.248, 316 
Since lobar cerebral microbleeds and CAA are associated with Alzheimer’s 
disease,183 some Alzheimer’s disease patients may also be expected to have cSS. cSS, CAA 
and Alzheimer’s disease were described on autopsy in two patients with dementia.410 Two 
recent imaging studies evaluated cSS in a memory clinic setting.306, 307 Patients with mild 
cognitive impairment (MCI) or dementia had prevalence rates of cSS between 2.1% (in 
MCI) and 7.1% (any dementia according to ICD-10). 72, 73 Patients fulfilling the criteria for 
Alzheimer’s disease showed a prevalence of 4.8%.31, 32 cSS was associated with lower MMSE 
score, APOE e4 genotype, higher number of cerebral microbleeds, and white matter 
hyperintensities burden. The majority of cSS-affected patients did not have a history of ICH. 
Moreover, not all patients with cSS had cerebral microbleeds, so cSS might be the only 
diagnostic clue to CAA in these patients. The available data thus support the hypothesis 
that cSS is a manifestation of CAA in memory clinic cohorts. Although cSS has been related 
to lower MMSE scores, a direct effect of cSS on cognition has currently not been 
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convincingly shown. The exact relation of cSS, CAA and Alzheimer’s disease requires 
further study. An interesting hypothesis is that patients with Alzheimer’s disease and cSS 
might have a distinct clinical phenotype (e.g. worse cognitive outcome, high ApoE e4 or e2 
genotype frequency, increased ICH risk etc.). cSS could have implications for disease-
modifying immunotherapy treatments in Alzheimer’s disease for which there are concerns 
regarding inflammatory and haemorrhagic complications (collectively referred to as 
amyloid-related imaging abnormalities: ARIA) attributed to rapid amyloid–β shifts from 
brain parenchyma to the perivascular spaces surrounding the small vessels.261, 411-413 
cSS holds promise and should be investigated as a potential biomarker (including a 
marker for ICH risk) in future disease-modification trials in CAA. Similar to lobar cerebral 
microbleeds, it is tempting to think that the progression of cSS, representing a new bleeding 
event, can thus be an attractive candidate CAA biomarker, especially if new lesions 
accumulate at a higher rate compared to cerebral microbleeds or intracerebral 
haemorrhage (Figure 11.1). However, this topic has not yet been systematically studied.  
 
Figure 11.1 Incident and progression 
of cSS in healthy elderly individuals. A. 
Baseline (left) and 3-year follow up 
(right) T2*-GRE scans of the same 
participant, showing incident cSS 
(arrow) on the follow up scan. B. 
Baseline (left) and 3-year follow-up 
(right) T2*-GRE images of community 
dwelling subject showing right frontal 
lobe cSS on baseline not changing at 
follow up (yellow arrows) as well as 
new left parietal cSS at follow-up (white 
arrow). Note the presence of multiple 
microbleeds in close vicinity to the area 
cSS (Panel B, white arrowhead). Images 
provided by Dr Meike W Vernooij. 
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Table 11.1 Recommended criteria for identification of CAA-related cortical superficial siderosis and 
acute convexity subarachnoid haemorrhage (acute cSAH) 
 Well-defined, homogeneous hypointense curvilinear signal intensity (black) on T2*-GRE or SWI 
MRI in the superficial layers of the cerebral cortex, within the subarachnoid space, or both 
 Blooming effect on T2*-GRE and SWI compared to T1- or T2-weighted sequences 
 If there is corresponding signal hyperintensity in the subarachnoid space on proton density-
weighted or FLAIR sequences (or hyperdense on CT if available) we recommend the term 
“acute cSAH” 
 Axial T1-weighted or FLAIR images should be used for anatomical confirmation of the gyral 
location of the signal hypointensities identified on T2*-GRE or SWI sequences 
 Absence of infratentorial (brainstem, cerebellum, spinal cord) siderosis 
 Ensure exclusion of potential haemorrhagic and non-haemorrhagic mimics (e.g. vessels flow 
voids, thrombosed vessels, petechial haemorrhagic transformation of infarcts, calcium deposits) 
 Consider all potential non-CAA secondary aetiologies of cSS and acute cSAH 
 
Table 11.2 Advised standards for evaluating cortical superficial siderosis (cSS) in research studies of 
small vessel disease and cerebral amyloid angiopathy 
 cSS and acute cSAH should be clearly defined according to the criteria in Panel 1 
 cSS should be categorised as focal or disseminated (e.g. in line with modified Boston criteria) 
 In each patient the location (cerebral lobes etc.) of cSS and number of cerebral sulci affected 
should be recorded 
 cSS and acute cSAH should be evaluated separately as they convey information on the 
chronicity of bleeding events 
 cSS or acute cSAH clearly connected with any lobar intracerebral haemorrhage should be 
rated separately as they may not provide clear evidence of individual bleeding events distinct 
from the ICH 
 Other relevant vascular neuroimaging lesions both remote from and in close proximity (e.g. 
up to 1 cm) to cSS should be evaluated using established standards, e.g. cerebral microbleeds, 
acute small DWI lesions etc. 
Another drawback of cSS as a trial outcome is the lack of standardised rating 
methods. Since this is a topic not covered in the STRIVE position paper31 we suggest 
standards for cSS definition, detection and evaluation as a starting point for future research 
studies on the topic that will help facilitate cross-study comparisons and pooling of data in 
collaborative efforts (Table 11.1 and Table 11.2). Interest is increasing in the clinical 
relevance of cSS and acute convexity subarachnoid haemorrhage: their influence on clinical 
decision making, future haemorrhage risk and how this is modulated by antithrombotic 
drug use, their relation with other signs of small-vessel disease, and their independent 
contribution to cognitive impairment and neurological dysfunction are future research 
goals. The on-going SuSPect-CAA trial (Superficial Siderosis in Patients with suspected 
Cerebral Amyloid Angiopathy; clinical trials identifier: NCT01856699) is a multi-centre 
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study, which aims to prospectively evaluate acute cSAHs and cSS as independent predictors 
for future stroke and mortality in patients with possible or probable CAA, as well as to 
better define their clinical presentation and outcome. Data from the SuSPect-CAA study 
may help define the role of cSS as a neuroimaging biomarker in future CAA treatment 
trials.300 Further promising areas of research include correlations of cSS with non-invasive 
amyloid-β molecular imaging with PET agents such as Pittsburgh compound B (PiB) to 
determine its relationship to amyloid deposition,285, 289 assessment of associations with 
ApoE genotype,319 and systematic radiological-pathological correlation studies. These 
studies should shed further light on whether cSS identifies distinct phenotypes of CAA or 
Alzheimer’s disease. 
11.2.3 Non-haemorrhagic CAA markers 
MRI-visible perivascular spaces 
Perivascular spaces (also termed Virchow-Robin spaces) visible on MRI represent one of 
the most recent, and perhaps less well known, candidate non-haemorrhagic biomarkers of 
CAA. One of the most important advances in the field was the inclusion of perivascular 
spaces as a neuroimaging feature of small vessel disease in the STRIVE consensus paper,31 
based on recent data. Here, using a portfolio of hypothesis-driven studies (Chapters 5-8) 
direct and robust evidence is provided that the topography of perivascular spaces may 
differ according to the underlying arteriopathy, with CAA being preferentially associated 
with high numbers of visible perivascular spaces in the centrum semiovale. In summary, the 
main new findings presented are that: (a) perivascular spaces are very common in 
spontaneous intracerebral haemorrhage; and (b) different mechanisms may account for 
perivascular spaces according to their anatomical distribution in intracerebral haemorrhage, 
consistent with the known localisation of the underlying pathology. Severe centrum 
semiovale perivascular spaces are more prevalent in patients with lobar intracerebral 
haemorrhage (probable or possible CAA) and are associated with age, supporting the idea 
of being a promising new imaging marker of CAA. By contrast, the severity of basal ganglia 
perivascular spaces is associated with markers of hypertensive arteriopathy suggesting 
common pathophysiological mechanisms. (c) Severe centrum semiovale perivascular spaces 
on MRI are present in 85.7% of patients with pathologically proven CAA but in none of the 
control subjects with intracerebral haemorrhage but no pathological evidence of CAA. 
Adding centrum semiovale perivascular spaces to current diagnostic criteria might increase 
the sensitivity, without reducing specificity hence contribute to improving the in vivo 
diagnosis of CAA. (d) MRI-visible perivascular spaces in the centrum semiovale are 
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associated with PET-based cerebrovascular amyloid-β burden, providing important 
pathophysiological clues, and further highlighting their possible utility as a surrogate for 
vascular amyloid burden. 
Looking back in light of these findings, previous studies across different populations 
have highlighted strong associations between basal ganglia perivascular spaces severity 
(more consistently than centrum semiovale perivascular spaces) and hypertension, white 
matter hyperintensities and lacunes, which are all typical neuroimaging features of 
hypertensive arteriopathy.30, 270, 275 By contrast, centrum semiovale perivascular spaces were 
not associated with conventional vascular risk factors, but only with increasing age,30, 272 so 
may relate to a different underlying small vessel arteriopathy. This is supported by a recent 
study among memory clinic patients, showing an association between centrum semiovale 
perivascular spaces and lobar cerebral microbleeds count and basal ganglia perivascular 
spaces and hypertension.274 The new observations presented in this thesis are in line with 
these previous studies, but provide more direct evidence pertinent to CAA. 
The link between centrum semiovale perivascular spaces on MRI and CAA is 
particularly attractive as it may specifically reflect a central and probably early event in the 
pathophysiology of the disease: interstitial fluid drainage impairment within the perivascular 
spaces, caused by cumulative leptomeningeal and superficial cortical vascular amyloid-β 
deposition.274, 276, 299 Data from molecular pathology studies and animal models support the 
hypothesis that in CAA, amyloid-β could reach the vessel walls through perivascular spaces, 
eventually aggregating within them and causing retrograde perivascular spaces due to 
interstitial fluid blockage, setting in motion a vicious cycle which promotes further amyloid 
deposition.276, 282 However, the exact mechanisms of perivascular space enlargement and 
their appearance on MRI remain poorly understood. The very close anatomical relationship 
of this perivascular compartment to the perforating small vessels (as recently demonstrated 
in a 7-Tesla study414) suggests that potentially any small vessel pathology could lead to 
dysfunction and morphological changes of the perivascular compartment (e.g. 
enlargement),263 making them visible on conventional neuroimaging. 
From the perspective of a pathologist, evidence from autopsy studies to indicate that 
the signal changes seen on imaging are actually expansion of the perivascular spaces is still 
very limited.268, 273 More direct correlation studies between MRI-visible perivascular spaces 
and underlying pathology-morphology in the setting of CAA are needed if they are to be 
assessed as a potential biomarker. In addition, as discussed in the relevant Chapters, 
perivascular spaces will need analysis for their spatial and temporal relation to other 
markers of CAA, incident appearance over time, and improved protocols for detecting and 
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quantifying them, ideally using volumetric semi-automated methods.415 Whether the 
presence of several visible perivascular spaces is clinically significant also remains 
controversial, although some studies have associated enlarged perivascular spaces with 
worse cognitive function.267 
 
White matter hyperintensities 
White matter hyperintensities of presumed vascular origin are another very common non-
haemorrhagic manifestation of CAA on MRI. To date, voxel-based analyses have not 
definitely shown different patterns of white matter hyperintensities between patients with 
CAA and hypertensive arteriopathy.158, 179, 186 Based on the almost inverse topography of 
CAA and hypertensive arteriopathy in the brain, one would expect striking differences in 
the regional distribution of white matter hyperintensities (similar to lobar vs. deep cerebral 
microbleeds, or perivascular spaces) between these small vessel diseases.186 Surprisingly, 
some studies suggest no major differences in overall white matter hyperintensities 
topography in CAA compared to hypertensive arteriopathy.158, 179 This relatively preserved 
anatomic distribution despite the specific topography across small vessel diseases, with 
greatest periventricular lesion burden around the frontal and occipital horns, indicates that 
white matter injury might occur through chronic microvascular ischaemia in the most 
vulnerable regions.186 Despite the lack of pathological specificity for white matter 
hyperintensities,24 amyloid-related alterations in vascular reactivity observed in CAA, are 
consistent with this hypothesis.377, 378 A more recent study using a semi-quantitative visual 
scale suggested that, compared to normal elderly controls, patients with CAA-related lobar 
intracerebral haemorrhage may have a higher prevalence of occipital-predominant (rather 
than anterior) white matter hyperintensities.187 Although this finding is interesting and 
consistent with the relative predilection of CAA vascular pathology for posterior cortical 
regions,109 it requires further investigation. A recent study developed a quantitative method 
to measure the antero-posterior distribution of white matter hyperintensities and provided 
further lines of evidence that their distribution may indeed represent a promising 
neuroimaging marker of CAA, at least in specific populations without ICH.416 In a cohort of 
patients without intracerebral haemorrhage (n=59) and with pathological evaluation, more 
posterior white matter hyperintensities distribution was an independent predictor of 
pathology evidence of CAA, even in cases without lobar microbleeds.416 Also, in a separate 
memory clinical cohort (n=259) it was shown that strictly lobar cerebral microbleeds were 
associated with more posterior white matter hyperintensities distribution after adjusting 
for other confounders.416 
 184 
An easy and clinically meaningful visual assessment tool of the frontal-to-occipital 
white matter hyperintensities distribution in patients with different microangiopathies has 
not yet been established, and a quantitative method might not be practical or sufficient for 
routine clinical use as a diagnostic biomarker. However, patients with advanced CAA have a 
larger overall load (i.e. volume) of chronic microvascular white matter hyperintensities 
compared to healthy elderly people158 or patients with Alzheimer’s disease alone.284, 417 
PET-based cerebrovascular amyloid load is also strongly correlated with ischaemic white 
matter hyperintensities in CAA.284 Although data are limited, CAA patients seem to have a 
high pace of white matter hyperintensities progression189 Furthermore, damage to white 
matter in CAA is associated with cognitive impairment independent of the effects of 
haemorrhage in the brain,188, 418 making white matter hyperintensities progression a 
reasonable biomarker to measure a clinically meaningful aspect of CAA-related brain 
injury.300 In various other studies (including randomised trials) in the field of small vessel 
disease, this model has been successfully implemented.2, 419 Whether a reduction in white 
matter hyperintensities progression burden is associated with a decrease in the incidence of 
cognitive and functional decline in CAA needs to be further tested. 
 
Cerebral microinfarcts 
Another non-haemorrhagic manifestation of advanced CAA that likely has an important 
cumulative effect on cognitive function, are cerebral microinfarcts.197 These have been 
defined histopathologically as tiny areas of infarction (generally up to a maximum of 1-2 
mm), only visible on microscopic tissue examination. Because of their small size, they are 
typically “invisible” in clinical-radiological studies that rely on conventional structural MRI. 
Recently, two approaches have detected microinfarcts in vivo (likely at the large end their 
size spectrum). The first approach is the detection of clinically silent small areas of 
restricted diffusion on DWI MRI, thought to represent acute microinfarcts, typically 
described in CAA-related intracerebral haemorrhage cohorts at a frequency of about 
20%.46, 73, 199, 420 The transient appearance of DWI lesions, and their occurrence even in the 
chronic post-intracerebral haemorrhage time window,199 suggests they may be part of an 
ongoing active process, they must accumulate frequently (around 8-10 large microinfarcts 
lesions per person per year – much higher compare to incident lobar microbleeds) and that 
the lifetime burden of ischaemia in patients with CAA may therefore be substantial. 
Nevertheless, this very transience nature of DWI lesions makes them hard to be used as 
meaningful biomarkers. In addition, there is no neuropathological confirmation that these 
lesions truly represent cerebral microinfarcts; some may represent ‘healed or healing’ 
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microbleeds.421 The second approach for detecting microinfarcts in vivo, utilized ultra-high-
field MRI to reveal small permanent, FLAIR hyperintense and T1 hypointense, structural 
lesions which have been correlated with microinfarcts at post-mortem.422 A cross-
validation of microinfarcts found on 7T MRI with 3T MRI will open the way for more 
routine detection of these lesions as a biomarker of ongoing damage in CAA. Of course, a 
key limitation of both approaches is that with current neuroimaging most burden of 
cerebral microinfarcts is left undetectable.423 
11.3 The concept of potential cerebral amyloid 
angiopathy phenotypes: rational and promise for clinically 
meaningful biomarkers 
As we have seen, during the past decades, progress has been made in understanding the 
pathophysiology and imaging-clinical expression of CAA and cerebral small vessel disease in 
general, with trials of disease-modifying drugs being the ultimate goal. What has also 
become evident is that CAA in not a uniform, but rather a very heterogeneous entity. 
While sporadic CAA is commonly found in the elderly, it is usually mild and clinically silent. 
Only a fraction of patients with CAA will go on to develop symptomatic intracerebral 
haemorrhage, despite the fact that many more might have evidence of haemorrhagic 
manifestations on neuroimaging, such as multiple lobar cerebral microbleeds or cortical 
superficial siderosis.28, 37 In other patients, CAA might cause only white matter 
hyperintensities and cognitive impairment.416 In a distinct minority of patients, CAA may be 
revealed by a striking acute inflammatory encephalopathy and nil else (inflammatory 
CAA).162 CAA is also very often present in cases of Alzheimer's syndrome. From these and 
other observations a picture arises where CAA might have a spectrum of distinct 
phenotypes of neuropathology and neuroimaging manifestations, comorbid conditions and 
ultimately clinical expression.167, 403 
Currently, at least two pathological subtypes of CAA have been identified: CAA-type 
1, characterised by amyloid in cortical capillaries (with or without involvement of other 
vessels), and CAA-type 2, where amyloid deposits are restricted to leptomeningeal and 
cortical arteries, but not capillaries.38 The APOE ε4 allele is most strongly associated with 
CAA-type 1, while APOE ε2 is more associated with CAA-type 2.107 In addition, it is 
generally accepted that APOE ε4 promotes vascular amyloid deposition, while APOE ε2 
promotes structural vasculopathic changes in amyloid-laden vessels, making them prone to 
rupture and intracerebral bleeding. CAA-type 1 (especially capillary, more than arteriolar 
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CAA) appears to be more closely associated with parenchymal amyloid deposition in 
Alzheimer’s disease108 and may cause luminal obstruction in the most severe stages, 
potentially explaining the low incidence of microbleeds and intracerebral haemorrhage in 
patients with Alzheimer’s disease and the association between microinfarcts, ischaemic 
white matter hyperintensities and cognitive impairment in CAA. 
Thus, APOE genotype probably influences CAA phenotype, but it is likely that this is 
not the whole story. Although multiple lobar microbleeds are a marker of increased risk of 
intracerebral haemorrhage, an interesting study in a cohort of consecutive CAA patients 
(n=46) suggests that cerebral microbleeds arising from CAA-related pathology might be in 
some respects distinct from macrohaemorrhages, since they have a bimodal, rather than 
continuous, size distribution on MRI.198 In a subset of patients who underwent autopsy, 
those with high microbleeds counts (“microbleeders”) had increased wall thickness of 
amyloid-positive vessels compared to those with relatively low microbleeds counts 
(“macrobleeders”).198 Surprisingly, cortical superficial siderosis, another CAA haemorrhagic 
marker associated with high risk of haemorrhage, is not associated with lobar microbleeds 
as shown in Chapter 3.301 It is possible that the topography and severity of CAA may affect 
the relative likelihood of the small vessel pathology resulting in cerebral microbleeds versus 
macrobleeds or cortical superficial siderosis and convexity subarachnoid haemorrhage. For 
example, heavy vascular amyloid might actually make cerebral microbleeds more likely than 
macrobleeding, and leptomeningeal versus deeper cortical CAA might make siderosis more 
likely than cerebral microbleeds. It is also important to bear in mind that ICH may result 
from mechanisms not related to the presence of cerebral microbleeds or siderosis. 
It is tempting to speculate that multiple different (endo-)phenotypes of CAA exist. This 
assumption touches onto the very basic question of what pathophysiological mechanisms 
determine whether CAA causes intracerebral haemorrhage or other haemorrhagic 
manifestations versus non-haemorrhagic manifestations, or cognitive decline. This question 
was partly addressed in the study presented in Chapter 9, and although literature to 
support firm conclusions is not yet available, it suggests that a “phenotype approach” in 
CAA provides a conceptual model which might allow greater reliance on the clusters of 
different surrogate biomarkers in future CAA trials.300 This approach could also strengthen 
the links between imaging biomarkers and neurological function. CAA is a dynamic, 
chronically progressive disease and future longitudinal studies should determine whether 
the described CAA phenotypes represent really distinct entities adhering to their 
characteristic imaging feature over time. Maybe one interesting study to perform would be 
to gather large numbers of possible and probable CAA cases as part of an international 
network and do principal component and cluster analysis, a statistical procedure that 
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converts a set of observations of possibly correlated variables into a set of values of linearly 
uncorrelated variables called principal components. This method can potentially allow 
determining clusters of clinical-radiological manifestations that could be used to determine 
prospectively if these phenotypes are really distinct. 
Another key requirement is the identification of the exact role of CAA in the context 
of Alzheimer’s disease:320 is amyloid vascular degeneration a silent partner or a key player in 
the natural history of neurodegeneration? What are the differences and similarities with 
sporadic CAA and what lessons can we learn from immunotherapeutic trials of Alzheimer’s 
disease that can be applied to the design of CAA trials? For example, CAA is associated 
with cerebral microinfarcts and given the common association between CAA and 
Alzheimer pathology, one mechanism contributing to cognitive impairment in Alzheimer’s 
disease patients may thus be widespread microinfarcts, at least in a subgroup of subjects 
with especially advanced CAA.157, 305 In turn, the pattern of cognitive impairment seen in 
advanced sporadic CAA could represent the cumulative effects of the various haemorrhagic 
and non-haemorrhagic tissue injuries discussed earlier, in combination with coexistent mild 
Alzheimer’s disease pathology. In addition, as shown in Chapter 9, CAA patients with 
cognitive impairment and Alzheimer’s disease pathology with an APOE e2 genotype might 
be at increased risk of certain haemorrhagic manifestations of small vessel disease, including 
intracerebral haemorrhage.83, 424 
11.4 Final conclusions and future perspectives 
Although the use of the clinical and MRI biomarkers presented here should play a key role, 
future studies should aim to provide stronger support and further insights from 
pathological-imaging correlations, improved imaging modalities and larger study populations 
as part of multicentre collaborations and international networks. Obviously an urgent need 
is to improve the sensitivity and specificity of diagnostic criteria for CAA; a large 
collaborative effort in underway to explore the value of a range of structural imaging 
makers presented in this thesis as part of modified Boston diagnostic criteria. Another key 
area of need is the identification of neuroimaging biomarker dynamic progression over time 
and whether these also capture clinically relevant changes, which may also contribute in 
identifying patients at an earlier stage of the disease, ideally before the serious 
complications of symptomatic intracerebral haemorrhage or cognitive impairment has 
developed. Early identification will clearly provide the best chance of efficacy for future 
disease-modifying treatments; however, a big challenge is that not all people with CAA will 
 188 
go on to develop problems. Advanced imaging methods together with improved 
pathophysiological understanding of CAA-related or in general small vessel disease related 
degeneration, will validate new promising biomarkers reflecting different steps in CAA 
pathogenesis in addition to the known haemorrhagic and non-haemorrhagic structural 
damage and their clinical consequences. New promising biomarkers in CAA include 
molecular imaging of amyloid in the brain (e.g. using amyloid radioligands, including 11C 
Pittsburgh Compound B - PiB),200 quantitative measures of brain structural integrity and 
cerebral blood flow, such as diffusion tensor imaging and arterial spin labelling respectively, 
fMRI as well as cerebrospinal fluid measures of amyloid and markers of neurodegeneration 
or retinal abnormalities. Studies in the near future should systematically investigate how 
strongly and specifically each of these biomarkers are related to putative CAA and its 
severely as assessed by known structural brain imaging findings (e.g. cerebral microbleeds, 
white matter hyperintensities), and to clinical consequences (e.g. cognitive function). The 
work described in this thesis has begun to increase the range of potential clinical and MRI 
biomarkers for CAA, and should contribute to the ultimate aims of early diagnosis and 
disease modification to slow the progression of this common, yet enigmatic and devastating 
disease. 
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Appendix A: Supplementary material for Chapter 2 
 
Table 1. Electronic database search strategies 
No Search history Results 
Pubmed search strategy 
1 
(amyloid angiopathy OR cerebral amyloid angiopathy) AND (seizure OR 
seizures OR episode OR episodes OR transient OR attack OR attacks OR 
aura OR TIA OR subarachnoid OR sub-arachnoid OR SAH OR cSAH OR 
fSAH OR siderosis OR hemosiderosis OR haemosiderosis OR spells) 
202 
2 Limit to: Publication Date from 1970/01/01 202 
Embase search strategy 
1 (amyloid angiopathy or cerebral amyloid angiopathy).tw. 1911 
2 Limit 1 to (human and yr="1970 -Current") 1472 
3 
(seizure or seizures or episode or epidodes or transient or attack or attacks 
or aura or TIA or subarachnoid or sub-arachnoid or SAH or cSAH or fSAH 
or siderosis or h?emosiderosis or spells).tw. 
522882 
4 Limit 3 to (human and yr="1970 -Current") 270996 
5 2 and 4 175 
 
Search software used: OvidSP_UI03.04.02.112, SourceID 54875 
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Figure 1. Flow chart of study selection for the systematic review. Twenty-one studies were 
included in our systematic review.43, 167-171, 191, 194, 237, 241, 405, 425-434 Three studies had no extractable 
individual patient data.43, 191, 194 Fifteen studies (six case series and nine case reports; n=43) had 
follow-up data.43, 167, 170, 171, 237, 241, 405, 425, 426, 429-434 
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Figure 1. Flow chart of patient selection in our study at four stroke centres over defined time 
periods. The hospitals were: University College London Hospitals NHS Foundation Trust (London) 
(03/2003–09/2011), Addenbrooke’s Hospital (Cambridge) (07/2002–03/2010), Cliniques 
Universitaires Saint Luc (Brussels) (12/2003–04/2010) and CHU Mont-Godinne UCL (08/2005–
03/2009). Patients excluded from the study were not significantly different from included analysed 
individuals in median age (71.7 years; IQR: 57.5-76.4 vs. 71.8; IQR: 63.6-77.5, p=0.205), sex (38.4% 
vs. 39.7% male; p=0.805), and measures of ICH severity including: median (IQR range) ICH volume 
(10.25 cm3; 3.2–19.1 cm3 versus 12.6 cm3; 3.99–22 cm3; p=0.621), and median (IQR range) Glasgow 
Coma Score on admission (15; 12–15 versus 14; 13–15; p=0.987) in patients excluded versus 
patients included respectively. 
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Table 1. Frequency of cortical superficial siderosis (cSS) in specific subgroups within the single lobar 
ICH and mixed haemorrhages comparison group. 
Subgroups within the comparison group of 
patients with single lobar ICH and mixed 
haemorrhages (n=67) 
Number of cases cSS, n (%) 
Single lobar ICH with no CMBs  
(i.e. possible CAA by original Boston criteria) 
33 2 (6.1%) 
Lobar ICH with deep or mixed CMBs 11 2 (18.2%) 
    Lobar ICH with deep CMBs 2 0 (0) 
    Lobar ICH with mixed CMBs (lobar and deep) 9 2 (22.2%) 
Deep ICH with lobar or mixed CMBs 17 3 (17.7%) 
    Deep ICH with lobar CMBs 6 1 (16.7%) 
    Deep ICH with mixed CMBs (lobar and deep) 11 2 (18.2%) 
Both lobar and deep ICH, and CMBs 6 3 (50%) 
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Table 2. Distribution of cerebral microbleeds (CMBs) and intracerebral haemorrhage (ICH) in 
control patients with single lobar ICH and mixed haemorrhages, and cortical superficial siderosis. 
Subject 
no. 
Lobar CMBs Deep CMBs Location of ICH 
1 7 2 Lobar (2) 
2 0 0 Lobar (2); deep (1) 
3 23 4 Deep (1) 
4 6 1 Lobar (1) 
5 16 1 Lobar (2) 
6 28 3 Deep (1) 
7 1 0 Deep (2) Lobar (1) 
8 2 0 Deep (1) 
9 0 0 Lobar (1) 
10 0 0 Lobar (1) 
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Table 3. Univariable binary regression analysis testing the factors associated with cortical superficial 
siderosis in patients with probable cerebral amyloid angiopathy. 
 
OR (95% CI) p-value 
Age (years) 1.06 (1.02-1.11) 0.007 
Sex (male) 0.78 (0.37-1.62) 0.500 
Hypertension* 0.28 (0.13-0.64) 0.002 
On antithrombotics* 0.89 (0.36-2.25) 0.811 
History of prior symptomatic ICH 
(%)* 
1.08 (0.50-2.34) 0.845 
History of TFNE 6.08 (2.30-16.06) <0.001 
Evidence of chronic lobar ICH 2.49 (1.17-5.31) 0.018 
Evidence of acute lobar ICH 1.49 (0.71-3.11) 0.292 
Acute ischaemic lesions 1.64 (0.62-4.35) 0.324 
Lobar CMBs number 0.97 (0.94-1.01) 0.093 
Lobar CMBs 
(for each category increase) 
0.79 (0.55-1.13) 0.201 
Leukoaraiosis 0.82 (0.56-1.20) 0.307 
Acute cSAH 2.53 (0.84-7.67) 0.099 
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Appendix C: Supplementary material for Chapter 4 
 
Table 1. Characteristics and comparison of cerebral amyloid angiopathy (CAA) patients with vs. 
without cortical superficial siderosis (cSS). The p-values refer to differences between patients with vs. 
without cSS, using chi-square tests and the Fisher’s exact test for categorical variables, and two-
sample t-tests or Mann-Whitney U-tests depending on the distribution of continuous variables. 
Characteristics 
cSS (+) 
(n=41) 
cSS (-) 
(n=77) 
p-value 
Age, mean (95% CI), years 73.2 (70.4-76) 70.4 (68.2-72.5) 0.116 
Median follow-up time (months) 
(IQR range) 
24.4 (9.5-39.3) 25 (9.2-52.3) 0.527 
Sex, male (%) 21 (52.2) 40 (52) 0.940 
Hypertension (%) 16 (42.1) 50 (71.4) 0.003** 
On antithrombotics at baseline (%) 10 (25) 19 (25.7) 0.937 
Previous symptomatic ICH (%) 
(other than index event) 
11 (26.8) 19 (24.7) 0.798 
History of TFNE (%) 20 (48.8) 6 (7.8) <0.001** 
Presence of CMBs (%) 31 (75.6) 49 (63.6) 0.185 
Number of CMBs, median  
(IQR range) 
4 (1-10) 2 (0-6) 0.110 
≥2 CMBs (%) 27 (65.9) 42 (54.6) 0.235 
≥5 CMBs (%) 20 (48.8) 21 (27.3) 0.019* 
Moderate-to-severe white matter 
changes (Fazekas score 2 or 3) (%) 
16 (40) 36 (47.4) 0.448 
Symptomatic lobar ICH at follow-up (%) 14 (34.2) 9 (11.7) 0.003** 
*Statistically significant difference at P<0.05; **Statistically significant difference at P<0.01. 
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Table 2. Different multivariate analysis models of predictors of symptomatic lobar intracerebral 
haemorrhage (ICH) during follow-up in patients with cerebral amyloid angiopathy. cSS: cortical 
superficial siderosis; CMBs: cerebral microbleeds. 
 
Model 1: Presence of cSS 
Model 1A HR (95%CI) p-value 
Presence of cSS 2.27 (0.95-5.44) 0.065 
CMBs number 1.02 (0.99-1.05) 0.245 
Previous symptomatic ICH 2.01 (0.78-5.17) 0.148 
Age (for every year increase) 1.07 (1.02-1.13) 0.011 
 
Model 1B HR (95%CI) p-value 
Presence of cSS 2.37 (0.98-5.75) 0.057 
Presence of ≥2 CMBs 1.09 (0.44-2.67) 0.857 
Previous symptomatic ICH 2.04 (0.80-5.23) 0.138 
Age (for every year increase) 1.07 (1.01-1.13) 0.016 
 
Model 1C HR (95%CI) p-value 
Presence of cSS 2.50 (1.00-6.18) 0.049 
Presence of ≥5 CMBs 0.90 (0.37-2.20) 0.815 
Previous symptomatic ICH 2.03 (0.79-5.23) 0.141 
Age (for every year increase) 1.07 (1.01-1.13) 0.014 
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Model 2: Increasing cSS category (from no, to focal and disseminated cSS) 
Model 2A HR (95%CI) p-value 
Increasing cSS category 
(from no, to focal and disseminated cSS) 
1.72 (1.07-2.75) 0.025 
CMBs number 1.02 (0.98-1.05) 0.369 
Previous symptomatic ICH 1.96 (0.77-5.04) 0.160 
Age (for every year increase) 1.08 (1.02-1.14) 0.010 
 
Model 2B HR (95%CI) p-value 
Increasing cSS category 
(from no, to focal and disseminated cSS) 
1.78 (1.11-2.87) 0.018 
Presence of ≥2 CMBs 1.03 (0.42-2.53) 0.950 
Previous symptomatic ICH 1.97 (0.77-5.05) 0.156 
Age (for every year increase) 1.07 (1.01-1.13) 0.015 
 
Model 2C HR (95%CI) p-value 
Increasing cSS category 
(from no, to focal and disseminated cSS) 
1.87 (1.14-3.08) 0.014 
Presence of ≥5CMBs 0.79 (0.32-1.97) 0.612 
Previous symptomatic ICH 1.96 (0.77-5.04) 0.161 
Age (for every year increase) 1.07 (1.02-1.13) 0.012 
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Model 3: Disseminated cSS (vs. all other patients: no and focal cSS) 
Model 3A HR (95%CI) p-value 
Disseminated cSS  
(vs. all other patients: no and focal cSS) 
2.78 (1.17-6.58) 0.020 
CMBs number 1.01 (0.98-1.05) 0.404 
Previous symptomatic ICH 1.98 (0.77-5.06) 0.155 
Age (for every year increase) 1.08 (1.02-1.15) 0.007 
 
Model 3B HR (95%CI) p-value 
Disseminated cSS  
(vs. all other patients: no and focal cSS) 
2.97 (1.26-7.01) 0.013 
Presence of ≥2 CMBs 1.05 (0.43-2.58) 0.914 
Previous symptomatic ICH 1.99 (0.78-5.07) 0.151 
Age (for every year increase) 1.08 (1.02-1.14) 0.010 
 
Model 3C HR (95%CI) p-value 
Disseminated cSS  
(vs. all other patients: no and focal cSS) 
3.26 (1.32-8.01) 0.010 
Presence of ≥5CMBs 0.79 (0.32-1.98) 0.618 
Previous symptomatic ICH 1.99 (0.78-5.10) 0.149 
Age (for every year increase) 1.08 (1.02-1.14) 0.008 
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Figure 1. Kaplan-Meier estimates of progression to recurrent symptomatic intracerebral 
haemorrhage (ICH) in patients with probable or possible cerebral amyloid angiopathy (CAA) and 
symptomatic lobar ICH at baseline (n=104), in the presence of: (A) cortical superficial siderosis (cSS) 
(HR: 2.71; 95%CI: 1.12-6.60; p=0.027); (B) focal cortical superficial siderosis (HR: 2.00; 95%CI: 0.53-
7.56 p=0.305); and (C) disseminated (>3 sulci) cortical superficial siderosis (HR: 3.18 ; 95%CI: 1.20-
8.40; p=0.020). Testing of significance is by the log-rank test. 
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Table 1. Details of basic MR imaging parameters. 
 
University College London Hospitals NHS Foundation Trust, UK 
MRIs were carried at 1.5T field strength. T2-weighted sequences were acquired in the 
axial plane with parameters as follows: slice thickness 5 mm, slice gap 1-2 mm, echo time 
100–106 ms, repetition time 4763/6000. Axial T2*-GRE images were obtained at: 
repetition time 300/800 ms, echo time 40/26 ms, slice thickness 5 mm, slice gap 1.5 mm. 
Cliniques Universitaires Saint Luc, Brussels, Belgium 
MRIs were carried at 1.5T field strength. T2-weighted sequences were acquired in the 
axial plane with parameters as follows: slice thickness 4-5 mm, slice gap 1 mm, echo time 
89–90 ms, repetition time 4768/6040. Axial T2*-GRE sequences were acquired, with 
parameters as follows: repetition time 230–240 ms, echo time 50–70 ms, slice thickness 
5 mm, gap 1 mm. 
Addenbrooke’s Hospital, Cambridge, UK 
MRIs were carried out at 1.5T field strength. T2-weighted sequences were acquired in 
the axial plane with parameters as follows: slice thickness 4-5 mm, slice gap 1-3 mm, 
echo time 80–100 ms. T2*-GRE sequences were obtained in the axial plane using the 
following parameters: repetition time 460–660 ms, echo time 15 ms, field of view 22 cm, 
slice thickness 6 mm, slice gap 7 mm. 
CHU Mont-Godinne UCL, Belgium 
MRIs were carried at 1.5T field strength. T2-weighted sequences were acquired in the 
axial plane with parameters as follows: slice thickness 5 mm, slice gap 1-2 mm, echo time 
85–100 ms, repetition time 6000. T2*-GRE sequences were obtained in the axial plane: 
repetition time 921 ms, echo time 22 ms, slice thickness 4 mm, slice gap 10%. 
 
 
Table 2. Associations between the severity of centrum semiovale and basal ganglia EPVS. A 
comparison using chi square test across categories, showed no significant relationship between EPVS 
severity in the two anatomical areas (p=0.100 for trend). 
N (%) Centrum semiovale EPVS  
Basal ganglia 
EPVS 
Mild: 1-10 Moderate: 11-20 Frequent: 21-40 Severe: >40 Total 
No EPVS 1 (14.29) 0 (0) 1 (2.33) 0 (0) 2 (1.65) 
Mild: 1-10 2 (28.57) 23 (63.89) 21 (48.84) 24 (68.57) 70 (57.85) 
Moderate: 11-20 2 (28.57) 11 (30.56) 16 (37.21) 8 (22.86) 37 (30.58) 
Frequent: 21-40 2 (28.57) 2 (5.56) 5 (11.63) 2 (5.71) 11 (9.09) 
Severe: >40 0 (0) 0 (0) 0 (0) 1 (2.86) 1 (0.83) 
Total 7 (100) 36 (100) 43 (100) 35 (100) 121 (100) 
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Figure 1. Flow chart: identification of patients with histopathologically confirmed cerebral amyloid 
angiopathy (CAA) and control patients with non-CAA related spontaneous ICH (ICH). Patients 
were identified retrospectively through an electronic keyword search of the Neuropathology 
database in the Division of Neuropathology, Queen Square (2006-2012) and Department of 
Neuropathology, Hospital Sainte-Anne, Paris, (1999-2005). The electronic keyword searches were 
performed in the “Microscopic finding”, “Diagnosis” and “Comments” database fields of the 
Neuropathology databases. We also systematically searched prospective clinical databases of 
consecutive patients with suspected CAA referred to two specialist stroke centres (Cliniques 
Universitaires Saint Luc-Brussels: 12/2004–04/2008; and Addenbrooke’s Hospital-Cambridge: 
07/2002–12/2009) to identify additional patients with histopathologically proven CAA (Figure 1). Ten 
of the CAA patients were admitted for spontaneous lobar ICH, one because of ischaemic stroke, 
one with transient focal neurological episodes, and four due to cognitive decline. All of the control 
patients were admitted with spontaneous ICH. 
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Figure 1. Meta-analysis of effect of cerebral microbleeds (CMBs) presence and burden on 
the risk of recurrent spontaneous ICH in all the ICH cohorts (CAA and non-CAA). 
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